var title_f21_25_21904="Culprit lesion wall motion";
var content_f21_25_21904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relationship of two-dimensional views and coronary artery perfusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21904=[""].join("\n");
var outline_f21_25_21904=null;
var title_f21_25_21905="Nose external anatomy";
var content_f21_25_21905=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    External anatomy of the nose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomical structures of the nose. Bony components are shown in tan; cartilage is shown in blue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21905=[""].join("\n");
var outline_f21_25_21905=null;
var title_f21_25_21906="Patient information: Genital herpes (The Basics)";
var content_f21_25_21906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/13/16594\">",
"         Patient information: Genital warts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/57/1940\">",
"         Patient information: Screening for sexually transmitted diseases (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/62/8162\">",
"         Patient information: Trichomoniasis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/3/36916\">",
"         Patient information: Genital herpes (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Genital herpes (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/genital-herpes-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H472670097\">",
"      <span class=\"h1\">",
"       What is herpes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Herpes is a disease that can cause blisters and open sores on the genital area. Herpes is caused by a virus that is passed from person to person during vaginal, oral, or anal sex. Sometimes, people do not know they have herpes because they do not have any symptoms.",
"     </p>",
"     <p>",
"      Herpes cannot be cured. But the disease usually causes problems only during the first few years. After that, the virus is still there, but it causes few to no symptoms. Even when the virus is active, people with herpes can take medicines to reduce and help prevent symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472670104\">",
"      <span class=\"h1\">",
"       What are the symptoms of herpes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people with herpes never have any symptoms. But other people can develop symptoms within a few weeks of being infected with the herpes virus.",
"     </p>",
"     <p>",
"      Symptoms usually include blisters in the genital area. In women, this area includes the vagina, butt, anus, or thighs. In men, this area includes the penis, scrotum, anus, butt, or thighs. The blisters can become painful open sores which then crust over as they heal.",
"     </p>",
"     <p>",
"      Sometimes, people can have other symptoms that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blisters on the mouth or lips",
"       </li>",
"       <li>",
"        Fever, headache, or pain in the joints",
"       </li>",
"       <li>",
"        Trouble urinating",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In people with herpes, symptoms usually go away and come back. A return of symptoms is called an &ldquo;outbreak&rdquo;. Outbreaks usually include blisters and open sores in the genital area. In most people, the first outbreak is the worst and can last as long as 2 to 3 weeks. Outbreaks that happen later are usually not as severe and do not last as long.",
"     </p>",
"     <p>",
"      Outbreaks might occur every month or more often, or just once or twice a year. Sometimes, people can tell when an outbreak will occur, because they feel itching or pain beforehand in the legs, hips, or butt. Sometimes they do not know that an outbreak is coming because they have no symptoms. Whatever your pattern is, keep in mind that herpes outbreaks usually become less frequent over time as you get older.",
"     </p>",
"     <p>",
"      Certain things, called &ldquo;triggers&rdquo;, can make outbreaks more likely to occur. These include stress, sunlight, menstrual periods, or getting sick.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472670111\">",
"      <span class=\"h1\">",
"       Is there a test for herpes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have blisters or ulcers when your doctor or nurse examines you, he or she can order a &ldquo;culture&rdquo; test for herpes. For a culture test, the doctor or nurse takes a sample of cells or fluid from a sore and sends it to the lab.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472670118\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse the first time you have symptoms, or if your symptoms are severe.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472670125\">",
"      <span class=\"h1\">",
"       How is herpes treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor can prescribe different medicines to help reduce symptoms and speed up the healing of an outbreak. These medicines work best when people start them soon after an outbreak starts. You and your doctor should work together to decide which medicine is right for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472670132\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To reduce the pain during an outbreak, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Use a portable bath (such as a &ldquo;Sitz bath&rdquo;) where you can sit in warm water for about 20 minutes. Your bathtub could also work. Avoid bubble baths.",
"       </li>",
"       <li>",
"        Keep the genital area clean and dry, and avoid tight clothes",
"       </li>",
"       <li>",
"        Take over-the-counter pain medicine such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sold as Tylenol&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sold as Advil or Motrin&reg;). But avoid",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also let your doctor or nurse know if you are worried or upset about your herpes. He or she can talk with you about your feelings. Plus, you might want to join a support group for people with herpes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472670139\">",
"      <span class=\"h1\">",
"       What if I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant, talk with your doctor. It is possible for a baby to get herpes from its mother during birth if the mother&rsquo;s first outbreak starts near the time of delivery. Talk with your doctor or nurse about things you can do to help prevent this.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472670146\">",
"      <span class=\"h1\">",
"       Can future outbreaks of symptoms be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people with herpes take a medicine every day to help prevent future outbreaks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472670153\">",
"      <span class=\"h1\">",
"       What can I do to prevent spreading herpes to my sex partner?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People can spread herpes to a sex partner when they have blisters and open sores on their body. But people can also spread herpes to their sex partner when they do not have any symptoms. That is because herpes can be present on the body without causing any symptoms, like blisters or pain. You can decrease the risk of spreading herpes to your partner by taking an antiviral medicine every day.",
"     </p>",
"     <p>",
"      You can also reduce the chance of your sex partner getting herpes by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Telling your sex partner that you have herpes",
"       </li>",
"       <li>",
"        Using a condom every time you have sex",
"       </li>",
"       <li>",
"        Not having sex when you have symptoms",
"       </li>",
"       <li>",
"        Not having oral sex if you have blisters or open sores around your mouth",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H472670160\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"       Patient information: Screening for sexually transmitted diseases (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=see_link\">",
"       Patient information: Genital warts (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8162?source=see_link\">",
"       Patient information: Trichomoniasis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=see_link\">",
"       Patient information: Genital herpes (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/25/21906?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15442 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21906=[""].join("\n");
var outline_f21_25_21906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472670097\">",
"      What is herpes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472670104\">",
"      What are the symptoms of herpes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472670111\">",
"      Is there a test for herpes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472670118\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472670125\">",
"      How is herpes treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472670132\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472670139\">",
"      What if I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472670146\">",
"      Can future outbreaks of symptoms be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472670153\">",
"      What can I do to prevent spreading herpes to my sex partner?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H472670160\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=related_link\">",
"      Patient information: Genital herpes (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=related_link\">",
"      Patient information: Genital warts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=related_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8162?source=related_link\">",
"      Patient information: Trichomoniasis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_25_21907="Patient information: HIV/AIDS (The Basics)";
var content_f21_25_21907=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21906\">",
"         Patient information: Genital herpes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/13/16594\">",
"         Patient information: Genital warts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"./kaposi-sarcoma-the-basics\">",
"         Patient information: Kaposi sarcoma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/24/7554\">",
"         Patient information: Pneumocystis pneumonia (PCP) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/35/31282\">",
"         Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/57/1940\">",
"         Patient information: Screening for sexually transmitted diseases (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/44/22210\">",
"         Patient information: Starting treatment for HIV (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/62/8162\">",
"         Patient information: Trichomoniasis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/41/36498\">",
"         Patient information: Vaccines for people with HIV (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/29/7635\">",
"         Patient information: HIV and pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/31/15861\">",
"         Patient information: Initial treatment of HIV (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/39/44658\">",
"         Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/0/7170\">",
"         Patient information: Symptoms of HIV infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/60/1986\">",
"         Patient information: Testing for HIV (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/56/2946\">",
"         Patient information: Tips for taking HIV medications (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: HIV/AIDS (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hiv-aids-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H476112540\">",
"      <span class=\"h1\">",
"       What is HIV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;HIV is the name of a virus that can affect the body&rsquo;s &ldquo;immune system,&rdquo; which is responsible for fighting infections. When people have an untreated HIV infection, they can become sick easily. That&rsquo;s because their immune system cannot work as well to fight off infections or cancer. Even so, people with HIV can take medicines to control the virus, keep their immune system strong, and stay healthy for many years.",
"     </p>",
"     <p>",
"      People can become infected with HIV if blood or body fluid (such as semen) from a person with HIV enters their body. For example, a person can get HIV if he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Has sex without using a condom with someone who has HIV",
"       </li>",
"       <li>",
"        Shares needles or syringes with someone who has HIV",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H476112547\">",
"      <span class=\"h1\">",
"       What is AIDS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;AIDS is the term doctors use to describe the last stage of HIV infection when the immune system is very weak.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H476112554\">",
"      <span class=\"h1\">",
"       What are the symptoms of HIV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Early symptoms of HIV infection can occur within weeks or months of being infected with the virus. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fever, sore throat, headache, muscle pain, and joint pain (these symptoms usually last about 2 weeks)",
"       </li>",
"       <li>",
"        Swelling of bean-shaped organs under the skin called lymph nodes, usually in the neck or armpit (this symptom can also happen in people who have HIV for a long time)",
"       </li>",
"       <li>",
"        A rash that is usually on the face, neck and upper chest",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who have had HIV for many years might have other problems, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fever, stomach pain, nausea, vomiting, diarrhea, and weight loss",
"       </li>",
"       <li>",
"        Other infections, including:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Lung infections",
"       </li>",
"       <li>",
"        Brain infections",
"       </li>",
"       <li>",
"        Eye infections that cause trouble seeing",
"       </li>",
"       <li>",
"        Yeast infections in the mouth that can cause soreness and raised, white patches",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H476112561\">",
"      <span class=\"h1\">",
"       Is there a test for HIV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can have HIV testing done in your doctor&rsquo;s office or clinic using a sample of blood or sometimes saliva (spit). Results from some tests take a few days to come back. But results from rapid HIV tests can be ready within minutes.",
"     </p>",
"     <p>",
"      Most pharmacies also sell test kits that you can use at home. For 1 type of home test, you prick your finger, blot the blood on a test strip, and mail the strip to a lab. Then the lab calls you with the results. The test is totally private, and the results are not reported to anyone but you. A different type of home test, called OraQuick, works a lot like a home pregnancy test. It comes with a special test strip that you wipe along your gums. After 20 to 40 minutes the test strip can tell you if you might have HIV. If you take a home test that says you are HIV positive, see your doctor and ask for a follow-up test to make sure.",
"     </p>",
"     <p>",
"      Sometimes, it can take up to 6 months after being infected for the HIV virus to show up in your body. If your test does not show that you have HIV now, you might need to repeat the test in a few months to make sure you are not infected.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H476112568\">",
"      <span class=\"h1\">",
"       How is HIV treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can prescribe different combinations of medicines to treat HIV. These medicines are called &ldquo;antiretroviral medicines.&rdquo; You and your doctor should work together to decide when you should start treatment and which medicines are right for you.",
"     </p>",
"     <p>",
"      Your treatment will depend a lot on:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        How your immune system is working &ndash; Doctors use a blood test called a T-cell count to see how HIV is affecting your immune system. If your T-cell count is low, it is especially important to start treatment. Even if your T-cell count is high, your doctor might suggest treatment.",
"       </li>",
"       <li>",
"        Your age",
"       </li>",
"       <li>",
"        Any other medical problems you might have",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most people with HIV need to take pills at set times each day. It is important to follow all of your doctor&rsquo;s instructions about treatment. This is because your HIV can get worse if you skip or stop taking your medicines. Let your doctor know if you have any side effects or problems with your medicines.",
"     </p>",
"     <p>",
"      Some people with HIV also take other types of medicines every day to prevent HIV-related infections. For example, most doctors recommend that people with a low T-cell count take an antibiotic every day to keep from getting a lung infection called PCP.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H476112575\">",
"      <span class=\"h1\">",
"       What if I am pregnant or want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have HIV, your baby can become infected with HIV during pregnancy, birth, or through breastfeeding. If you are pregnant or want to get pregnant, talk with your doctor about ways to reduce the chance of passing HIV to your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H476112582\">",
"      <span class=\"h1\">",
"       What can I do to prevent spreading HIV to other people?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To reduce the chance of spreading HIV to other people:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get tested for HIV and start treatment as early as possible",
"       </li>",
"       <li>",
"        Tell anyone you have sex with that you have HIV",
"       </li>",
"       <li>",
"        Use a condom every time you have vaginal, anal, or oral sex",
"       </li>",
"       <li>",
"        Do not share razors or toothbrushes",
"       </li>",
"       <li>",
"        Do not share drug needles or syringes",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H476112589\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=see_link\">",
"       Patient information: Starting treatment for HIV (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36498?source=see_link\">",
"       Patient information: Vaccines for people with HIV (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/35/31282?source=see_link\">",
"       Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"       Patient information: Screening for sexually transmitted diseases (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=see_link\">",
"       Patient information: Genital herpes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=see_link\">",
"       Patient information: Genital warts (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8162?source=see_link\">",
"       Patient information: Trichomoniasis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/24/7554?source=see_link\">",
"       Patient information: Pneumocystis pneumonia (PCP) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"./kaposi-sarcoma-the-basics?source=see_link\">",
"       Patient information: Kaposi sarcoma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=see_link\">",
"       Patient information: Symptoms of HIV infection (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=see_link\">",
"       Patient information: Testing for HIV (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=see_link\">",
"       Patient information: Initial treatment of HIV (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/56/2946?source=see_link\">",
"       Patient information: Tips for taking HIV medications (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/39/44658?source=see_link\">",
"       Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"       Patient information: HIV and pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/25/21907?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15448 Version 13.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21907=[""].join("\n");
var outline_f21_25_21907=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H476112540\">",
"      What is HIV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H476112547\">",
"      What is AIDS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H476112554\">",
"      What are the symptoms of HIV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H476112561\">",
"      Is there a test for HIV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H476112568\">",
"      How is HIV treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H476112575\">",
"      What if I am pregnant or want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H476112582\">",
"      What can I do to prevent spreading HIV to other people?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H476112589\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=related_link\">",
"      Patient information: Genital herpes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=related_link\">",
"      Patient information: Genital warts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=related_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=related_link\">",
"      Patient information: Initial treatment of HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"./kaposi-sarcoma-the-basics?source=related_link\">",
"      Patient information: Kaposi sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/24/7554?source=related_link\">",
"      Patient information: Pneumocystis pneumonia (PCP) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/35/31282?source=related_link\">",
"      Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/39/44658?source=related_link\">",
"      Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=related_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=related_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=related_link\">",
"      Patient information: Symptoms of HIV infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=related_link\">",
"      Patient information: Testing for HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/56/2946?source=related_link\">",
"      Patient information: Tips for taking HIV medications (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8162?source=related_link\">",
"      Patient information: Trichomoniasis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36498?source=related_link\">",
"      Patient information: Vaccines for people with HIV (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_25_21908="Normal human promyelocyte";
var content_f21_25_21908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal human promyelocyte",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 255px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD/AYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCXWYk0O2KBiZyMZUjjv9Oufp+ZGJp12XfBIbHzHJHA/L/9dQ+PJZI9alVx8vysoPP0/Dr/AJ6czpupSLMFAZVHXHLHHf8ALP8AnNeJCm+S/c+gitD1Bbq3CrLKNrIGG8MRgsRu+mQM/wAsc5hurpZoXIAZWGAQePw4+v8A9fmvMfGd3cT6IUh37y4+6T3Iz0+pH+Fblhcvb6RawSMzMI+SxGc/pz1/zxU+wtFSIS96xPKzLOxZgMjADHPuPy4/D0rqfhz+98SRFAAY1ZjgcdO/t/X864tZXc8Fjwc5HTn9ew5/TivUvh1pbWsL3s6KZJQMKzHcF6/mTjr298VNd2g09x1p2gzv5JFXnuCThjnp2Pqfp2/CnBgyHZx1wc9D6kegyB/hVLzginDFucEZ56jHP4/5PNPE/wAsZ3cdiegH0x/nGK85I800EYE7R1IyvA4BPp9Ouf8AGkkmKI8pA2qOnU8dcfkT7/rVcSOAMqNmCB9ccjryBkfnVbUnY6dcFQ5/dnJXvgEcjueM/wCPGaUbsVtTyjW7+XVdbuJJHJQnAHYDuf0+taVpbMFdw3znIO3ue/P+f8eZAmMztDhmySMLkPz7c46f567FtdzR220OvIAzkHHvn6/rXo1I9EemtEkhdVc7ymQTjdwduD2/yO9c/lvtBjYkkkkbV+7xz27j1q/cyySyBV3fOcjA5GO+fXt/k11PgHwr9tuTf3sJFsjEojLyx5zxjkDFJ2pxuxyqKnG7N34aeHvKQarfDO0YiX8fvHPX8fxr0GWNZhIs6LIn3SGQce449OP/ANdVISoRViTlR8ueMZ7Y9COnr35pzzRxRNJMUWGNWdi3GFxyRz19e2a8+Tc5XZ5VSbqS5jO1XTtJs4XuJrZEwMkAjsOf8/oa8/1jxA9xJ5FpFHFGgbcB1I46j35/X2rn/FHiq913U7iMEpp8b7YkBHbo2R756/hkVmQzylh87ZX5lZTzjPTB684/D8BXdCg4q8tWd9Gi0ryN5nlkwsqjkbjswOhHT2/THp2hDbhuGQwOD83IzySMc4PA9foM1Fa3vyBZFUKTkHsCBwQOnQZ4+nPFPlZFkR4flcgHHbv0yecYPuKpJo2sd94E8UywXS6ZqUrzxSE+TM5yUPZTxjoOvrXpRI4wcZ6fX2/MV84PNISnzOFCBtrfeGPu+xAHPPf8z7p4ev3vdF0+SVsTvEu4H6fz6H1rDEU7Wkup5uKpKL5l1Nv5SBkYA4Pp/n6Um8dc42nkDuPf8u/pVWOTfg8n+np+o/H9A8liAD9T7d+PxAP8q5UcpYWQbgSCPTjr3H+f/wBdIW3Fc8MDng9fUe/UcVCCu3OQFx368nPX6857+1GNqrwM9Bxj8Dz35P51VuoEyNtXqWJyc8dyTjIHTtz/AImmyFSmBnB7D2x/9b/JqEvjCj5gc53HJz7/AFPp/LilDFlO3JJPQc5P1P1/z3FqBIzHkhicAnr16459DilRsEt6HGR+uBntz/8AXqszhAGkYCNc4LEc+xz7fT3rJHiLSIblYG1C38wH5WD7uPc+oBGc/wCOLjBvYai3sb+d3DBccduBg8Y9wR/nigSYA6gE9jnHP+elVo2RlVoXDooyChBz26+uO4/TilLD5cg7AensO344+v06UWt/X9f18hWLKt0bqgyc+x6c/wBKxfE+hWfiCyENygE/Plv3HTI46jtn/wCtmT7M4cSzMlw+4ssjMyt144ztyAe39eLrY3AMSAerZ+gHbr1+lNXTuileLTizwrWfC2qaRcOghadDlgR1deBkf56elR6fpd1PIPMiYxlvmJBH5fh/9evdJS7xlRjaSAdwyNvfHPoSOf160gSPflYgRjdg9TyO3t3rdV3bY61jJW1R49quk3VrCZDAfL5yVG3B6nA6DtkVn/aQkZeYBAMlwMbh36e2R1/Xv7izrHE5k+ZFByGAIx68j+XHtXmsllpmo6lK6MYIQS0agD5ehGP0PPOcfSrhU5t0aUsRzJ3RX8LRy3GrwQYX5n3tjPCg5/lj/OK9feVVIGPuqQB044FcHpEkWkKRaxFQT8zkc4z09u5/zitOx8SwSvsdNjA4LDuenA78ZrOqnPVbHPXTqO6Rqa5Zx6ppkttIqk4yjHnn1A64/X09vF7tBbSTQKEiMbNkAHGe4xx3x1/nmvSvEfi2z0uSK3gzLcuC3B+6Dz09Sf17cnHnWp2Y1CQXVq27cc7R7Ad/QAkZH61VCLjq9jbCqUVrsYV485fa64Hbrxk9O3611/wysDcakbySMeTbJhCfU9R045x17/jVTQNDaaeJLyYwQOQp/vEE8f0r0q3tbfTrVba0GxEO09tx4zz74/8A11tUqKMeVdS69XTlRaeUkBsc5z689P064/pVTzQAoZScZzjr1xj8CPw9yMUpZfN+6Q5bPXnPb88nr2H5ReZ8w46dcHAH457jt+Wa40tDkSInlKoDnleCwPA54z6jge5qB3JBAwFJIAPUgc9B2/z64kkbYBkY2naPUE+nfpj2/M1VlJAJwp3ZA+baM5/HqSMf0qki0V55Uzklc9sty2SeBnqepwOeD9aq+YxJ8st7/XHbn8KklJ2jG8YPy7lwenUc8ZGceo9Mmq5ZyzYPQ4PUj8DWiRaRj+LPDEHiCBSGEd6qbVkx1A7EfUd68ju9D1HSbjyr6Bh8xCnAKt759Se3/wBcV77KiBWaUkBPm64PBBGfYcdevfOSDwmu+Mreedre0hhuIkGCzqCpPov+eaeGq1LcqV0dNKTvZHCWtuJdqsjnkjleOuefqf8APQ1tWehyzqquSqNnczen+f8AIrXsdb0eFg8mmQh/9k8egG3Pv3654qjr/ig3e9bWMR2xGNp54HqBx+HX6dtbzk7JWN25X0R1OieHtGhkjIvEuG6NyBu46Y9Oucf4V2vKFV3MBjjb39fyzXgEOqiObMsgibrkn+nr15P+Neg+GPF01u6Q3rGaLO08fMvpj1rCrh5PVO5hVpSet7noijcifMOf4gehzx9Oo4PNSRMTj5SrHJ68Dk4OfpyP8c4htJoLqATWsweJjwScY9z7H8/rmp9uFQpkdev6/T/P0rkORroPjYjooX0A5PHrnvjHT9KraxN9n0i6ljwMIT75P4cAZH+etkLjnOADgbeenb/P9aoeJUlbQLrC5fYcc9cdMHpxz+R9auDvJXBLVHnVn5eSpUksTlQc5x6f5/KprgBlby13MTk4OQeRnj34/wDrds2CKSRgqI7u2SqqOWIweOe2e9eh+GPDy20IuNQjUzMAyIzZ2d+mOv8A9f2rrqy5NWds5KGpS8J+Fwxa51SD5Sd6xOo/8e+nHX+fXuIwqoip8sWOB2x27ep4/wDr1GQDhXUNt/vdv19f1p4Dkndz83OWzljx+p/LiuKcnN3kcU5ubuyQKWbsWOV/kcdepwK4b4s601jp8VhC2xrpSJDkdB0A7/l1/Ou3XBG7dkAEA44A9M+x7d68t+MlnKdRguRwhjwGByevP5cVthop1VcqhFOaucfpUnmEogO1hwxx/wDq65/zmta7gCCRoWLF/ukY57jnueev+Nc7ZfJsygDHIPrnpnH4fWtT7W0wC8htpOScgdP8e3X65rskm2em0TTfdJDYJOR6YHUfp+f5U0uBAPMA6AsvqP09vcGq6Id6eSdils88bfXH5/TNW9oYqW2ruPUrkfU+mPyyPwpIGi/pNpLfTRwQpuJ4GBn69O+Mfj6d/btOs4rK0tYQoDwRhQBzyAP5c57/AJ1yPws01rfT7i8aNdsjCOEnkkd+vTkH8f17c8ykBwNxOOD1xxx68j/OK5a8uZ8q6f1/X9W8vE1OaXKug8Hp8xPbPXqeMn2yf0/FY2KqGJBOdx59OuT9R9eajJYHKcErnp+QHtxj1/KnBlZgofAxwoGPTnGOuQPp+dc9mtjmsP8AlYYzxk/NjHI6nGOnXrS8hVBJDfnz0zj8unvzQG2sBkDOMnb37c59hSqq7NoVcew6cc8fQnr1FGrEIpJc4GMnbgHp2x9M460qAsRkkHkHvxnv+P8A9bgcqflySAcdc/XpnPc46dfamXEy20MkzEARqXY54GBn8u3NNIN9Dx3xtrd5q2r3FtudbOI+WIl43EHB3e45Nc0LdcSBFZiB90jGcY646Y4H4e9XZLhby6mlyQZGMhB6E5O3OPX/AD61JDaB03qScEAgnv0/qTz39RxXqx9xcq2PYjFRVkdP8Ptaks9TjtZpQLJ1CsGb5UOe3pk9u/scCvVpFxIcZBwfm79uB9Mf/rrwEbrdy43DBAD5xt55I98Ec/lXq3gDVZdS014pWBmiwME43Dv/APX/AKVz14O3OjixVK3vo6fbliRkhsjA9Pfn+X+FR7Q4ABx3IxnHOentk/1qUAHbgkgHJ3ck9+nbpUasHUfK6hSVG4Yzx1H97OByP15rlRxWGBPlIBG4jcRz0J7e2f8AORSYUA5ckdSemDnOfTJyPYe5pHt4nu4bkgtNCrojDIwGxkEdMZA+mPwLlYOiMpyMZQ4zkH+hx+P40WKMHxrO8GhzqBglQvyLkgk89sfn3rgtGtrqaZTbeYJWJHJB3ZPXjtyP688V6F4rs/tWly4UbuGx3bHH6DufUYrC8GXNlavN5rpHKcBS3GR1PXvk100naDtudVOXLTujVXw95kJW4upWkIPKn09+3Ufh9cVz4tFsNUkgk+6w6jrx1OenAx/Tmu6kmhSHzAybfvAg9/r68Z/Lk1514i1OGXVpXhO3bjvxxzz78jr+nOVScpNomi5SujhPEwk/tyRwfvckZzx2/QfXnnpipNIvPs7qsrsUHPzNwefT/PFaur2Y1GIyIiZ7ngkHOckfkfSudWGQxGMkDB+YfT1H0xx7/XHZFpxsz0FqrGpqXiDzbhlsmMeDwQScnIyR3GcA/lXqPhW5a+0O3MsyPOq5bGMnH8uCBk//AFq8eW0S3hDOVzgEksMfp25xk1Jaate2ErSWk5iYsMlk3Kcew9Oevf8AVTpKcOVGVWlzKyPbpI8McoBnqVPTBHbn5ev+TVcoVKsuQccbT1OOvX0/Hp3JxleEfE0OvReTcApdqM4Y9e3J/D/JznblUZbIODnOejcf1z9K4nBwfLI4tYuzKToSpcqMbSm5fTtzjgYx+BFQXKtuyuST8oJ785x+H5/yq2flJQEsvOTzwf8ADkdO/p0qtL/y0IbJyQSfXsM+/HuPSktCkUJgOecLyNwzwM8g/of/ANdVWR8/Lgnvznmrs3VyN5wfu9e/p2GSfz+pqoF8t5Gg+TzHLuV53t0LE9+n8qvoWjB+JGotDoAiiL7p327lXOABk7jnjpj6kV4/LKIiFQjBOQvYHgcfXA6cZ/EV71rWnRarZvavxuyVJxuDDofTA4/z18K1yxuNL1Fra4G3ysjp97/OK2wcouHKtzroSVrDYXLnIZyTgnBxnHPUdO3156VLDYGOErbuYotm7aTlc5JJ555ye/P6VThkYHCfxDuc5/ya17a9AfyynB+VieT1/r/n0reV+h0srJZ+S0kkqgqVGRj/AD0yKuWNxiUl43jYE7kckenJ/wDrc/Tii4ZmgGMk9M4z04GD6+w71XthIzsygEZ4APbpn8jj+VLdagejeDdW+xahGobMMvLA8YJ457fXHQflXphAX1J3E4Y/eyTx+Wf07kGvF/CFvNe6tCkKj5CGZ9pAA78+gHb/ACPZwwcHJZQMqQ3bHXrwefX8K8/EJKZ5+ISUgAIUByzN1yeWByByPxHX8BSqoIbcCQc5UgEHp+vTP+TSqNxzjBzznoPfkenr0zSIxYqPmJAPPPA44/UfjXPfTUwK9pptnayb7O3jVwfp3IyD2J5571bzkFlwCMsfTOBnt7jp+lGcg/KAOevOBnGPx5Jz3+nCttLBWbI6jLdSDgenPXr/AI02+rC7e4A7gmCcHhXzjAxxjn05xT0YFRzjI5APQ4GMc9CDkZ/qQEXDEcHc+ST6n8e3PT0FKnzAMdxzzjqTnqfXrmpAeCQ4bcQB82FPXHHp0ySP8mqev6fBqulNb3DBXKnDBgCBkcgfl/niq3ijU20rRWuoVzKWwGxu2g/j1B6V5QusXkkhLTys7EKfQ/h69+P0rpo0XL3r2NaVGU/eWgXfhe4t5G4Dk8naOv19M5H86E0qcOyIrlzjOVzkjv8Al1xx9OSEhvplO1ZJASGU4bgc9vcgceuO9aul+Ibu1uI7hyCq/NsIGO2SMdAfy+nSup8x3PmsbGj+BNSlxNd7bWPkgSHLE/T2/lWyfDWn6GEn1CTzmQ/u0ZQxJyOcZzwc5z/9cn/CwEuLZoktiLkjyy27IJ4/l2//AFVx2oXlxcXC3FzKZGzlWzgAgj5fceoP9awXtZy9/Q54xqz+LRHsdk8ElpE9qUNvj93tHQHGce/B6/zxVlQQAmMbs8MOo64wPbuK5n4bzeboUkCsQ0MjLxwcHkd++D0rp1zuJGHz8wwSBzjk9eD+X8655q0rHBOPLJxCNeI9zhiAPvDnHqSPcnp/PNOClUBOdwz8oz9OOOvP+eKTrlsg7ffpz1P455p4+820j5huHPX3+nP5/WpXkQKAMAkkHJHTjnHQ+vOMf/roAPXhAOSGPTv27df6ZxSLzu25PXIJ6DnOf8T19xS8FV2qAB0A+vP4dfpTAQYIXIByMj2/+uR/Ko76A3FjcwKMF42A+Xg8f4f5NSA5KjODnjrkknGfXOB/nmhGACuASOCMen19RyeOPTrRFhtqfPbRTRz+S5CyIzAhvk65BHP+f51raaQwjO9WBAUHoCOmR7Yx1/Wu68Y+Fnu5Hv8ASwvmY3yRgZ+YcAgf5P6kecr5lszxFWBQFQvQ47dTxwe/H616EaiqK6PXhUVSOhs3VlGYMAhRkK4A5GMZH16/5zXQ/C/dBqEkLNw8RyoORkYx27Af561yMl2xVs8DIHzDgL/T+Z75q/oOpSW2pQmLaZD3LZySOeOwHIAP4d6HF8rRFWDlBo9mlDNjcWGOo6Hr/P8Ax9DUTMkeckFm5yOQCD347cfgBXm+s69fvc+VC+FcAHBOQR2z+Hb147ms5LzUAyfvnO1g5yOGxyQQfbHPXvXOqDte5xrCu12z1jIZVbcSpXIz1+mPT2qtc/aDBJ9lkh8/I2mbcVPIyW2kEYGcY747ZzzWgeKvNlS1vh85yBOpAz9QAAO5OOtdXwOS3y8kEdAOOPfv7D07VnKLi7MxlB03Zoc6h1dWYspJyD/dz3/l/wDrrj/EXhaSST7RpxBXlnT/AD0GT+uTmuvzyVHBGflB6HORjnuOeKTJXJAG7JI5x6kEHjjk59ee3AcZOLughUlB3R5PeNfxExPv2NuwuOcHHT8h9Kz106eRkD+XEc/xHj1wT6dOvOa7/wCIuqf2Voe6EL9pmbYpYDAxzz78kY/xryNrma7bdJNuG4hioIU89s89+v8ALpXXSbkr2PRotzjzWseqeB/D8AWWS4eKUEEeScHOcfoOOvI+tUfiPbWelabGul2qw3DZPyjOOh54Pr9fTvXBR309kqSQzNAxBO5T0H/6vX17d4pNZvdQJjvZN8j8sxOc/NnH5j8/fin7KTlz3J9lLn5m9DOg8yUup3Ekdc8jp3P4fT3NT3NnstifMBcZwP7p9T9M/XHvVd38hiyr8g5zyBnjj889KJNQCRnCgf7xwcDuPYdM/wA+K6Nd0bst+HNQax1FJkYoyMVOMfMO5HPUAHHtXtyyi4t45gR84J6DAxyeeOP89K+eYbjMmEO0MPvDuP8ADoBmvYdBvrr/AIQiS7EJ8yLdsBPUA4BP0/rWWKj7qn8jlrw1RvsNwbhQW/hJ6E/j+I/wIxWmG0t0CsOBjBYA846DOR/nFeTNrWoTXDyrK4dugyCB0z35yMe5PtXT6L4rlZRDqi5JwDIowfbJJ6j9fzNYuhJK6JlRlHU6WVcucKpwcA+49T2+oqoEQjLsjEk/f4xz0GOo96uSLG7LLESUPICcDB6ZHsORn8Kz8OgARVIxz++I5/Dr9aiLtsSiyXyTjBUZJ3d27fgOef55Ncn458Mtqqpc2kYNzECrx5+8APX2APtiuuLFpSQSSM4J59z9Rn/PpQu9Ut7NyqEFvY8gfn/nntmualOUJc0DSN09DxOTT9kjJ910OCc5wfU/X0H6Z4uWWmtPIqxqWYsVbaMn3BPv7f4V3WoXtnNOrTwQEJuwy44zjIJGM8Duf6it3w/d2E7iG3jt45VXHykZ9c/55rrniGlex0uq0r2Of0zwZPcRA3jm2Q44HJ+oHv1571t2/grRUXkzOxGcsep46DHTBPHTHrXRlT8ygYbrlc9OM9+hHH161ORnOF4xgjjB/l0Bxg+tckq031OZ1ZPqVNL06z0lCNPhSJT1JPzNg8c/TPTj6VoZKrlsvnsBj6fQZIx/+s1TkmmEyqihlPU/e9M8/X8P5VdQEPlgu7PPbP8Ann2H5Vm7vVmb11YqnJWPcWB3Dd2b36dCc9fengAlQApfBODnA568f5/OlGQnAx3IX1+vA5Hcf/WpSF+fGSvIIXgD6Duf8ikSOBCuOGJ9W9Pr24I9vzpU4CkcD/aHcHvnryB/9Y0w/MQm/wC9xwcA44HHv/h+Cjg5yNo43dQOwz7fX/61GoxQQUAUMcMAdoGV5GTz6ZJ+mepOKejEfMnGeAV+vr64P+TTASMAsSevIyefTPpz1pxIHTHfgcY9AT6dfqfxwlohEGsabDq+lz2NyTGsq4DoSpUjnIORjHHTp+deN3thPp9+9vcDY/mMApPDdAOPyGT/AI17NcieW3EVrc/ZWMibpPLVyiBgXVVPy5IG0E8DcTyQAc7xToEesRyTQBUvY1JUnkMCDgH8Bge/Xjp00KvJo9jajV5NHseSWyDIJJGDgkgHqR9e/wDnvU7RkxFCAQfvqG7Djt/Oku4ZbW4kRwUZOqtkHjGfx5zz1+nNQq+No3ZK/KAMD0OB2HHHv+VdR6Cd9SRWaIhmIRhkZGMHvzgfn6/Xir6uHiGC29MHJ5PPTH14/wDrHFUDICSM525+XIHHc+nb+ftie2kARV5AC/dc4wcn8j6ds+1DuJnffDs3DS3EEMmNqbzkdB9PqAOO/wBOPQhggFs4z8xPOCO59+e/9a89+GjJFqFwpIB8jcoyTjpwfQYI688/hXoDEFto3bmHB7nGOh46cVx1vj/rseViPjJFDEYKjvzjpnrz7+/9KBkKCu4Hd+OAe5Oe4HT2pmU3DDZK54A59uc+mB/hwKUlM5685JGeRn+nT3/SsTAewyh3qQAMc4wOeh9jgfl9KXIDHcAFB55xu6Y+nf6+/WosoD8yjIAH0GfX3xn1/SgtgsORt4U98f8A6s89fxFMLDl6HDEsOM49x29eT1/rSS7SnTdjrz0554Pf685z1pvDScEKecFjyg57/n+P1zTRkcAFGJ2gYzz1xjP+cfWnYY4NjDDAPY+uOwI/zxXM+KPDC35ku7Hy47o/fQgYc8ZI/I/jXSK5IVlYEjHXJ49M+xxUcYG6RlOCeADnk+p46cnpWkJOLumVCTg7o8bvrJ7eQxzqUZCRvkzjgA8nPXHU9frV3w3p8kl2s0o2DAJIPKqeQSfTOP6Zr1p0gnx9pgSRQTyyhmzwOvrgj8/rjzDxdLd6feSWdhb4B3MqRLtGOemPUdcevvmumFRz91bnZTrur7uxZ8xLnWR8zFEJGQOc9x9f8jvXVzaTC8DoE3FwArDgjuOcnr78H68159ZRXsc3mkF5GAJZeR26fljn0rrl1/8A0JIZEYsTjzCeCRzwffHH/wBeipF6cpNSMrrlMDWIDY3cgLZAywJ/iP09Bx/nNeg+GtSa906PzPvr8j4B5I6H9T/nFea6vctdzl1OAW4LNjHHX8On16e/oXhO2e00KIPuLTEyDJzjI68j2pVV7ivuTiF7ivubjE85U8BlB6/XjuBjoPT2zTWXapHRc4A7HngdemMnj/61MJ7gcegP3h259uT+tIXQ5J+7+nY4/LH5c9BXPY4jz74tvi0sdyjYhdeeemBn68H3x+VeZpcNuBUjyjlRz+PA9O3Feq/F2yefRLN0En7qQ5we2B/T+uc15P5QBJOcZ+8eTn8uuMV3UF7n9dz1cM700S4Z2RC5dimcEeuMDHucZ9KIwfNDKsZRDjzMg/OOMAdwAMZ9eBnGQx3keURxSNGkPE0i5B9doPUHBGW7DgZOCJh5hISOMoMBVQcYx/CB7HH/ANbNb62NSyzK6nyhGZFVsblDKOCOQeMgEn1B6YrBukbytgjONvOcEj6k98ZH885NazztbxbV2vkbsq38WegB9OOfX34NGe6a4Rk+XccMoHJHPzYHpzxTjdPQTILKHfdiAAM24IEXg5OOOe5PFe8WlkbPwu1rKqg+S3Ufj39MY/H6VxHwt8ORvcy6reLhIGxEhX5Sw7/0/wAeldX8RdT/ALO8KXjZ2zSgRKCfmJzk4GOnJ5rnxVTmapo5KkueaijzbfbLNKGkBXdtCjnIz7dccdPT8pdWn01Ij9mkXOceoHHfjp7fzHFcM8kj/OGbJYk56kfX8uO/vUEVxIzqshcODtDgkjjuR/L/ACK6OR6WZ18mp6r4M1mR2+w3UhkVjiJiOncIemcADk5/GuhlVGc7xGmOB5o5I7EdeCOn8q8m0G+MWoQs2WWN+UBOT+P1HNevRXdvdr5qSMyn+72PcdetY1oWaa6nLUjZ6HK3+t3F6zJakCPPDDuPX2IOP85NVYNCu5nEgy7Eg7gNpH1Oeenb/wDVL4Vt4nAJ2jC53Z9P19f88V1ygkbVVW7cZ47nHPQgn+ftXFKfJ7sTSUuTRHk+sadeQShJQyAFlKgHrn6eo/xrGtbqXTp45LdzG0Z+Ug549c/49a9I8UzQOZN2N6jG/j5Tn+vU5/SvOLlMzMxG5dxJAGc8859+n5+nI7KcueOpvTfMtT3XRb3+0tNtLvaDvUuccjd3B46cd+/6XkG1B8pbjjng89c4+n9eawPA8csPh+1SRMSMM4JPTP8AhXQ7TgsuATzlj1Pcn8hXltcrsjhnpJoVTv55CHlhjkc9/wAe449aepZgQvB5zk4H0PHI6Hj+lR5O5VUt9043egH9QR04496kGRjHGOMHjrwPzx39D0oJFLsRhVyrZ5IwAM9Tz1zn2p4YsWyHQjIKsOcDrg+pyOeh780m/eOMYxnIGc/54z/+qmhwy5AH3cj36dQe4yfp2x2bt1ESZwxxwuCMAZzz/iR/KlXbuXKjO3AIPPTkZx1x68etHJYPwS2Rg9xnH8s/55pq5yAMHGACensCP85/GgCQYC/N8oI64wQODnH1yRjp/Ixnr8hxjaR0ycDjOeSe/f8AKogRHtTIif74TOTgcbsZ6Ekf5NOyqgooC7f4Sfw5/HP9aWlx2Jl+624HaM5x29AePT8qUhscsNwPr936e+e/T88VGON2FB5wcds+vtn/ACOgajDPO37zEZ6D6+pyaEKxU13Q7HWopBcRql3kEXC8HGPunt+f4dsec6t4XvdMkYyqZIAflkwD9foOe/XvXqoJRuCgzghs5IHHX9etKCrBo2AaMjADDIx9PXkdf15rWnWlHQ0p1ZQ9DxDymjZi5KkHGDwSR3/D1NSoC7DAG7jOB1+gz04r1fUNA0q8JaS2WF2PLxkrjn0+v8/rVey8MadZMjrEWZOods9+QD2GB2rf28dzp+sxa2I/h5YvBDNcSDqNoVuOpJIPr35HX2zXYh8IyoMj2IHXGPxJx7VTjKRKEj+VB8oXGMDrjPpj0p5kJ3b2w2eDjkHkc/l/+rNc0nzSucM25y5mWyxxzwME8HHHHI/L8KVTk5yp4OSOnuP688dfpVZmIJb+6Tx055Gf5fl70qkbhtGMNtGeuO3I9f8A9XcVNjPlLBYENkrjOduRj15/Dp7U0tjHcg44wB1yMfkajD7uEOP4ecgqeOM54yfzpHbjOB83OSBxyDz+Xfn69aa2CxJvwuY/vBiRxnnnHHcdf/rUMR8vXPI9+eO3HUD8emDUOWwURsO/C5+bke468cjHp71ICpwegydqnvjJH8j/AJxQkOw1iZeQWQL12/hn8ev6VMpJUjrt6c9+uM/X171EMqpK525KHA7+mfy6dT601fnI4zgHHp7kYP0//VVIVhNiv88rkqOhbjgEd/fkccc1wfjTW7M3yfY3S5nRSGZRlQTwAcdT16Vk/EPXZ7vVJbGGY/ZIW2NuJAc55zxycnt68ccVyiB9qsAxTO3dtwBnqOfbt0rspUVpKR20aFrSZu2WunziHRVGcAFug4yCfoMcda6iysf7XgR7WMFyOig7en8+v1x9AfO5Duwx3uzZKkYyMc4A9ensfbgV3Hw11by9Qa0IU286FlA5wy9NvfnAx+vHFXOFk5RNKycY8yOp0jw3DbBZb4LPKDuKHn25P8RyB/8AqxjpM72wrZU9WXoOmP5fn1wDUbsA4C4wc/Nz6fz4Hvx0NNAYkdyBgLjGM/h0I9P/AK1cbk5bs8+TctWPZtoXedvBPXvnpnB5470u3aRyd3I6Z9Mg+3+ApmAHUqyg9ue2OnXp/wDrpoOVC4ZgQMluAM/xY/iOcDj/AOsUnoTYW5jivIHtp086OXGVIyT6Z9xzXJXfw/06QZtbqSBFXO2QZAAPXPbr/wDqrrCznBwWB4O05A9c5/h6cevPrSlWI5XO3nLjJB/mcenp9aqM3HVMuMpQ+Fnl954EurO2k+zh7giZypB5KlyRn3ORXIXbTQSlHiCSKxJLZ4HTn3/ma98Ehc5BJYcEFsk+w46dPT+VY2ueHLPVfml/dyZ+92PA6kDqfX8/WuinXd/eOiGIe0zw90lkYKFwTxkjOe2f5fhXQ+DvDLarch/L2WpY+ZIRlQM4ABPp/wDq7mu3tPBFnbtCROzAMdzIDkN0B6djnrxiul060h0+zW1tIvLgjyUVQFAPPAHQAZ/wrWeISVo7lVMRdWiPgt4rO2FvZoI41ACjjHpjr6c/SvOPjIJRFZli5hKnBwfmPToe3Xk16U/KYzyScHoPfnPv+dc94ysre80SdZiFZCWjbdjDY6H8Sf8A69csJWkpMxoPlmmzwEIxdXCE57g8en+PocmonDFFY8KeAexI4x+HT/8AUam1FprW9AjiDKeGIJxgccjPb/OakkyqEuhUsCcnkDn/AB/z1r0r7M9LcoS3BjLrHkju2fvD/DOPxx0qCPULhF2xzOoHUKxxn8Pyqe7tm2YVMonRvU89D2OM5/w4qjFDhTvZiSc5QAA+4rSD0FJHpwt9QsZwDBMrKflCrncR+nr9O1X4b/V2HlxLMR1GV6+h+n+emK67T9W0/UMLb3CKwTOx+Avb8AMDp0H0q2o3DIUuAAOGOFOcnI9eQOf/AK1eK6t3rHU53Pujg28NaleBi6KN/OWbHP1+mPw/OtDSvBKxXKyXMsbgAfu9ny5Pr6gfrmusXcXwQwX1Jwfw9++f8h6qu4qFIYjrngDP3ce+f/10nXm1a5Lqy6EiBQq7flRVwAM8Y7H8Rx+FOBAI3YPHLDoQOnPuR2698U3jflpARyB1OAfx6fWpY1ywYKM5Pf8Az6VijEVApCjKlT/s4B7jt6Ht6c4zipAAu3IIBJzxuBzzyfy6dfrULE7Aqly2T77j3H05/wAeKkLhV4OQflOO4PY89Dg/zoFYkHHEoJxjPOSf8BkHp3NA56tuI5PAGTjA/L17+1MGAAdpyR970z6n/Oe1PYcEkgnht2cE8/z+n40MLASvbODx3yeuCR3wAcY6il+6of7gP3jnI7ZP0+n4dwGyIJcjJDDjgY+oH0wPx607cNhOPmA6np9c56DHT+tGqGCsAoRCo5IO08ADPX8adxg7Gfls4yfQYwPwH5du7CcspyCMj7uDgZ9PYE/j0x1pS4VhGWXBHc/eORnt6fr+IotZagOO3BIA28n2AJ7/AJD9ePR43NwCDnBYk+/H1/8ArUnLLyG+8fY5zz+Bwf6VIev3ieSc4x35x+ZH+cUCG5VJAAWAwWJUcY+vqDj/AD1cgG1YyVA6gdcn3+lHy8jLbgCMAltvc5xx0A//AFZpwbNx5TgKpG5O+QCM8eoyD6c00IBg4298kHHp0/Hj8OOtOQYXOSR67eo7dv8APfrTlUYBJBU8Hng+5/M49KAcH5sDaRkMfm56j9Op5/E0CGAneQwA28knuO+T+Jx6H8ql4yPmzjj2x647cj8MetOVVGA4ITONw6jnjt9Dk1zXiLx74e0CSKG+ummuWcxhLYB9rZ4BfomT69evrVxpym7QV2CTk7I6dQz5G05P90dMde3of17VIIJBgbSMg9DnjOSf58dfxzXkPirxprt1DFCNPm0+G6RpE+zSea6gYwJHBwvJA49e/bi7pdbsfsOp6xqUB0+Zka4+z3TsxkY4ULjoCf5c8c1308unJe80vxKUF1dvxPo/yW3HcG4P3SPxx06YIPr170PyeCTngng7jnkn8j+FePN4vvdK1VbJ21aWSIMtpbxqZWnZRu+Y54zz16jp6DotN+Ikx0zTze2Ueo3cof7TJaP5YtyMEIY2+ZuCOR1/QZSwNWNmle/9f19wvZyO7jE27M23YFAAVTuBH3tzZxjG3AAzkHr0Eqsdxx8ozuJz0zgj8Bn+XTNZfhjxHpPiayS50qdC33TE2UZSp5G09Rnv39K1whb7rNxnd3JJIyfx/wA5rlcHF2krMzfmQGGNpPOKDz8CLd1YLnO0c+pJ9e/pWTrviKy0eOUKwkulUuqRnoeASx7Dkcnp+ODJ4y1g6HoU1zGS1zJuWFdpIycYPTpn/J5NeFrO9xN58rsZZDzIxyck9+vP6fhXRSpKesjpw9D2nvS2LBmme6mkdvnZi+Qeue4H4n3z9eNKztdyKSoz90biOcf4ZHXnn3rKdAXOAmQOULdj3579/XHXFSxXRjWQswYqcse2OOPxPr3rrd2tDvt0H3iupUqUxlvxOf8AHt/jxo+FboWuuWUo2ZWUIGYZAz2474x/+useSVpCeCATggZ5PqCfrjPqO/FWNNjVHRyCWXnBzjGcYA9+P69KaWlmKcbxaPoKVV3b15/2h/j9CM/pUe0RB9znG4NgncFx1x7dCcf1pbVxJYWrLnDRAsSe2OR/M1Jk/KFABPRR0OOgH5/5xXmW6HjeRACfJfAD5BKhnxzxhc49+vv+FPYFo2+XccEhR6nuPfOev9eHLH8zYJIz/FyD7/57896R/mGNwA6EM2SPUnnpj056n1oGRxkHnOVJIA55/wDrfTpntzTwgJAGCCMDHJ9Bj6j/AD0FCqgJVc5ORu6Y45z/AJH9aduyCMn0IHUcjORj6fWmIay4bOO/Q9B9ffJFRqmEBKnGOHUgAA9f6HHf2zw8hULMQeB8uB/n1/yc01ivmAHluuCcEepz600MiJJyMEKxI3Hkk/T0wO3H0pGzvBzgnPy8EDHXn1wRQ7fKx3ckZ+XuM9vfpmo2GDjGR0A55HfPHv789aaGgkkWNHeXhADlmOMD6Y7ZI+v515P468XteMbWx3JbqSd/dh7ceg/z39I1+3ku9Iuokcxu3Vt2TxgYz2/z614xdaWLaUo5Bf5uI2z07knjt/LHc1vQgpPXodeGjH4nuYkmoSnlx8wGckdMe3p05P8AjTZtSbGI41JBPPXp9eAf8itdtGlaPiI4PJ4GR6Z/Xg/yqjLZNGw3RMQ3OAQcdOnoeRXZ7p2XTMK7nnmbdxxnjJPpkf8A6/1xitTRPB2raxZfa7WMeUzEBnO3eR1Iz2/wrQ0h1gmUzQJOu7JWT7vBB44+nv8Anz6xZ6hBc20bwtGgxgqHKAH6Dtz+VW6ns0uVXMKtSS2PK7e5mtrlntWxIrYGBx9Mev14Br0zSdQjureENGUnIwcjIGPr2wRjNZng7w1DaQG81FQ9w/3FYcRjt+Ppn/69cn4l8TyzajLDp7eTZq7IBF0J6dfrnp0HTvnznFV5NR6dSpWqPlR6rlQQxeMZ5Xj19/cY/H8KcGWPaVkRSQMce/8A+v8A+tmvEZZLmcb5Z5CTkcsf88/rUTTXKSEm6mYZOSHPX3Hft05+vSl9U8yfq/me7yI7I0kMrJ0ClUyOfUfn9fahAz4Dr5TcjIfIPTleDzkg89wOvWvINJ8QajYvmO6kAUchjleuf5gdK9R8M63HrdszEeXNH8roOCeOv6/5NYVKThr0MqlKUFc0kXhQOoxnfwPx9Mc/r65qWNcg8E8fw8jnoMfl/OlRR0IDYzwOn0Htj15prDemwkruUruI+pPPcEnHufes9DG4gC4yCBk8gd+5Hv1/z0p5UAqXHGTw3HJ/DPQH2/IUYwoUlS33MkZyTjj6jnr9eeRSrgc8L1z6cnp/Xj8cU0AhHmD/AG8469TwQAc9evX0/ClC5DMACSTn6kjGT6k/l+tOUFVyVznux7fl0/z60i/Px8hySowemcZ44wen+TSAbGmE4d2BOSzjcQM9sDp1xnt0zUyjnLKQRuJVcnHTnHr09s8+mK6yxNKYxIPNZicEAZORnJ/P69qmwW5KsCpPQZJ9cj16nj+WKfoNkg4wWGW5x78cfjjH/wCupFB6EFscHBHzew989Mf41EApLADOQQMcAZPHP+cVIOSCHYD6A59c4zwevFImw4jEZ2hmwMjHH4/T+dNADyQEKpxuLA8jGD1B+g/I0pGQQwLsM4AOc/h65I/Pnrin7i24swKtnaSSRj1J/Lnv2oTYh6jLYBPqSxzyTgnp3/T8aeQFVydqIBktnGAOh5Htj6+lN/4AxPJIIIyfy7kgZ9/SvM/jL4qgstIn0KJoWmvEaGRDIS5bbkKQDxnBGfoBWtGjKtNQQRi5OyMrx38S5p54bTw9BcW+mu0ttNfSptYsAMGEAnOcHtz6d68E1DU7nWdR2QvJp7zKS1vI7GOSXONx3dCcdex6c11Wg3Dwwaat5Y3GoW1u7T2caOYwAAA6sp5B5O31ql4/XRbefSrySEvYXMbNFbW04byweWyD0cMTnOAcdBX1OHpQw/uxXz/r+vkbziuWy0S/r1/A7XwrpmoR311aXwEGmyEb7F5z5qjA+7J6E5PPXB9RnP8AEkmlXIfT7K6v7Q2sij7DZxh5IOSBhjgFcnJ9P0rC0P4krpUVjLbWD3FxbkRLvbh9vQluu7B/zmtt/GPh+WK+1PS72PR/EUzi5lQoWimLYDRgkEAYP5jsM1XJUUua33d/x+/cxlVjJ2vYhj0zxJpsc12uvSRTiUi5vHmG7rhir4JzjA56ZOe1dP4hk8vWfDrWmnpM9zCUa5eYJI8YHMhUHaTnHPr+GOdjlbxJ4d1vU9Oe3stOtsQRWaxjc8f3nVlJydxPBXkflW3psVrqOlWN9f2c8UWmFltLcykBUKgEjPOM8AHp0qZdJSW11/kDb6PQ5661i58N/EPTrmCb7DHKhzOsheFME9gPmyBz9e9e7fDD4h2njKOWwuW8jV7QYYSKV+0AHaXUdjkYI6jt6DxzVbEah4Wvn0SV4UmcQi0nHCbDyQW5BJ446g81jWC3MmoaYNHaC1vrSJ7czWsu6BGB3b3AHBJzng8DnORSxGFp4qnrpJaX7W7+W/fujF35rfP72e9fGSBn0ezKsQFZgQD8wxjgEHg5xyO/ua8iiGwb36LlSQT8p4xgjoOf89K9f8F+IU+JPh3V9N1W3jtdV06f7FdrE25PM6BwcZ2kgj6j05rznVdJn0q7uLe4T96jbTgcNgnr26E14tOLp3pS3R6WEqLl5GR28ykbCWBVQuFXceRgj3PGPf2PJZNDbHaURQqjbvJzzyevToRwOR7HFU5dyCJAwyCRtyeCADgDvwOe2aVBI5OGKpjBBHX6eg9v5jitOXqddiyPLWRFAwQ3IIyR65H5/wD662/D+ny6lqFvbwB9zsQ+4BsgHlvbjP8A9eqNnYT3NzDFHC8krZCoF4x9f59cH68er+F/D83h+zWQKj30wxKQMhAOQo78EDgcH8KipNQV+pzV6qhGy3Z0jKsaJCp4RQAV6dsevXH4/hik3glmwWyMDPcDrk568D347c1GirFAsCyHbGm3kk9COc59SeTxTmOSztwTg5Pr7n6gcj0rzjzLDiVznGV+7xz0Pb35JqJImBk82dplMhZAyKoiHHyDAGRyeTz+uXZJXgAljgZOfw/DJ6/1oOWGVYHKnkfX29OOnf61QCu42kEnGcYz7gYPt/n0NCuAcLn0wDkf5wP89KY3TJzuYY57j0/D+XrzQ+cFT0Ax1z6dR60WCwjnC5wByCozj3z+WOf/AK1NkcE9R3HHX279M5/zxTJGw/lhQGOCT19DnHtx/nBpz4VuchRk43Z9wQfpTQ7ELShFQTgIQF3dSq5Hbjtx1xn2OKbITtwEYggZHXvwB7j/ABp5kAQBmMeMjrwOnb0HB/nUTYVtu8HPG1ecnuc9xj8Pxq0Mp6gTHZXG0gOqZyo4P4Z79PXj2NeOvdebeM7gkkgsR8uM9gD6fn/X2qRFlUodpiIYyBT2OOcZ9vxxXkXizRpNL1EtkGGT5lJbgk9vr2/yDXRh371n1OrDtWa6mnp7rNEFZRuIJwOvTv17j/8AVxU0umJcxu6gAZ5Yn5f/ANX9Kw9Kv2iUBckLyMdT3xjHTjvz/KuntdTtyUj8+NpWySCensfrnOP6VtNNPQuV1sY13oEVtb5Qh3b5ic8D0P0x+P4Vzi6jc2xdISwXOcI+PzHHNdvrF7FHAwU5LZ+UnqeP17enpnt5tPE00hkU4z1IAOT3Oc1VJuT1KhqtT1rxbdvY+HryeFwjhSobr09Ofc9PXnua8PtdrNHxggkfXPH4jH+RXufiS0/tDR7i1wGd14AOOckD0yc9B1/p4Q8MkU7QyCRHBIbjpjrj3/zxyKwwaTptLuVh+p0VsoEYVuGH8WOD+v8A9envZFhiMukm7J389B2HQD6cfrUdjeLGA7oHA5HXHTn6Yz1qb+0Jbi4AVQoJAHcn15/Ae3PPerbdzdpkM1sISCobI6knGewz7iuh8C3UlvrluVDBZSY2K45Xr0x7fX9arva+bGsspVADliSFPbt7H8P0qTQZrWHWrRvOAVHxuP3cjnj6e/8AhWc2pRaIlqmj15yAcDcWwTkcZPXP45//AF5po2jLcck9Og5/n7+tIvzrvXkEZA/z79qBuAJzg/TOO5OfQk49B+QrzonmkhwFwBg4zsxjr+HH8/5UAgbSDhgM5Un7uRgjn0Pf+tRHcTgMeeNuRntx6ZwB70Z+bkNxyRnGPw9evtTSAdI+3ayqzD+6pzuxjAzjkjPJP44zUpUlVAUcHHXjPt/n1qJV3PheDjJ+mTz+pFL5bAg98Y4OQOf8/wA+nFPYCuunwf2j9tKhmKgYzyPT/P8A9arYwYypUgAbQNpP4Y9OlMyAMgEA5IJP0/XH4j6nhyldy4JyGz1z/k+w4xz7BPYd2TsxLODgkE5Y9z9M+1P6EFmIOc884+vc9jxzUKHHJYkKp+THA+nHTjr/ACqXbhSEBB9AuR9R9cH2z60WJ2Hr8yBRhcZwCeRjp/hUmSC2ME9Qvp65HqME1EgUL8oUKeM4xtxwPx5OSP8ACnpISzHGQT2xzjB4Ocfl1ApWEypruqR6Bot7qVwCVt4ywGcFm7D9R/XrXgl5L4Sj1e6vp5nkvNUkTzLpo97WLcElWPTOQMnp7cY6b9oLWZtLi0SyKNHpU+TO8chyTnADD+77/wCGD4ze39zPFrQFhA7XZSJb4tsiaIABUXHDNwDn1HtXvZbhvcU77/l/WpvDljG73f8AS/r7zW1LV9Q/4SaSwiuEtbq7YE3GnXYTbEoOzkAkMwOW2sMj05zxlhpFxcyXE1sIpbSGR2luk+8UH3sEk8Yyefz5p9/4fu9EsLa+a6iZWYq0trKGZMr90cg5A6jt/Orog1O9gMGmnyYzEYXCvhZATyDzz16egr24RSV4/wBWMJay5ai1/rQ7PwX4PXxTbzXWkTWqXmXxp0rNvjiwf3q/7XBIx6Vx9rol5eJeI8to1wkwGJ/ld256Z7HP+ea1LDxrfxR2Njcww/u0FstxCMOIs4wOx571iXmpzXWs/wBoXDbkuJSWLr/D9088DOO4P5URU+Z83yHJ0+WNvn0Lclomk69az31peWltG6EurbxuAB7/AJ9ele4/BrxMfE2i30V1b24v7RsylUyGQkFWGe4ORj0rw3U7DTJbmCDRtTuLuEwPLMJ1ZRG65OAMc59feu1+D2oWXhzXxFqGp2CQajEm8tIQsYycAkdz0Pp1+mWKp+0ot9SVdSstv69D3DULK31C2/0i0gSWIB0/dhieeMY9Of8A61eReM72y8JzQDS0jinWQNeWrAL50ZzlwwHDc49R3GMV63rqXOo6OX0bUksJmO5biWMPHgfwY7ZIHPSvFfiDpdpYaZp1zqjX2pancyG5u2hUeQVVSAqn+EZ5OOo9+nFgHd2k9+n9f1cuS93R2KPg3xLfeHfHtv4uCSWmj3Ny0UjSBtssbZ+9j73rnuRX2BqUNnqtjGZra1vYmjDw5I2MSMjD9gcj5v0r4rGp311pLXFvciSa3tmhu7eVgyiP+Fgp4JIxn0x+f1z8MLuO/wDhr4YuLdo5Q2nRqTFwFdRhkAPTBDA9uOM1lnVNJQqrRrQwT+1cr33gPw7dSCaOCSKVehU525xuA5O3OOcenfio4vAmkIA264YDsCBnuPxHv/jVzx9fy2miMbViJXcJwMgcZIOOg68jv6gGvMraXUy6MuqXTcHO5yxYHvn64/8ArjmvKpqpON+Y7aUak435rHrunafY6UrDTrdIS7HLjqfXPPcj8/TFWt5d8ltxORkHJ5xx68DH1OK810vUNWtZ1nluJJcEkebk7hxkMfUe/wCmTXc6LqqasD8rRSqmZIjlhyQBjPP+fqazqU5R1eplUpOOr1NFjvXOOQTjIz0Hpn6f55pQcgHJJ5Ck5Pbkn2xn/IpMEgjkknPT07+xHXjnr1pEKkjB6/iPbH0/zwayRkODBhyCc/NyOCD0z7YGTRuI/hO4D+IdSPQ9Onrx+eaYWAHylirfKO/J6nrx0Apob5iDGrdMgHgD3Hr19u9Ow7DxyRty3OM5556nPpn09Pekkzggq+wryMYzk8H+f/66Rhn5iCzgdeuc9fwwaCRhsZG0ngcY4Hv/AD44o3Aa4VmJZcso3Ek5xngHHrjj/IpC2Bkjlm5OQcA9M/gc09uQAB74U9v8jgj+uaZlwD8xBb+L+9nk9un+e+KtAhCGGNzMOg5P4fpzx+VQkspzg4zyAxyOSQSfw+vX1AqZuVGAQACD24yAQPXnH9OTzW46HaF6gNxj8M9evTqeapAhHcFQHIIBJ29cHOcj2IGOe/0OM7UrVbsRxTpC1qqkyIUy24kFSrA4ABznIzz273Ll/KjLhJpTlQEQfMcsBnBxwOvoB6HimTDZggY6sAOQfcfX/PPNVEpaPQ4fVPBv7wS6fMY8nKqw2henfPfIrOTwpeea8hdCc42N36ckZwB9f55x6A/KyRqxLDIwCc5x/P8Az1yKrsEXcAVZScHHB7dOOT/n2rVVZdTZVZHIHw3cHf59wdxUDqe5Ax79vb9aVfDVgFG/zd2Oef8A64rpXPzAqoPUDHA9euPYfXvVdd4HyeXjvvJPPf8AX+tWpy7/AHFc8maJ3IT8x+YkE55//Xiua8R+F9P1K4WWRTDNK21JY1zlgudpGeuNxH0I7gHo2JPAHIOfl4wBg5x6VHcRl18sZVlaM7Rk/dYNjr7DP69MV50JSg7xZMZNM48+BBgCLUEIbpuXqfc/09frWZr+kw+H0jUSK80mMOeMjgZ/l9K9KVhkAgqP4ht+mP5cVxXxNhPl2c5AwMg5/wA9vf1/Lpo1JTmoyZpTqycrNnCzXrzlEY5Oeg6HtgA/Wp9Ktp5rlYzltw6n07EjPuSP6VRSPcUXbkkZ5HIzxjpz6fWu58H2aSXICBQOSSFOSe5OT146npXTN8sTqlLlRr2tteWtooilIdQcDJAwDgjB/Go5tQ1K1Ry88mzd94n6Z6d8cc8euO3W/ZhsOwKHA6Me/wDdP4en41zHici2tiXJ+Y7SMYx6n68jpXJC0nsckZ8zsyvY+J9QFykGDO+7aFx2+n49q3ta8VQaLY7tSSQXxVtlsp+cjpnPb/PU1z/wssjPf3V64YeUQi5ycZ657kn/APVXLfEW6afxhdIQSsQUKAfQcE+/J6f/AKtY0YTqcttinCMp8tiprXinWNWuSbi8mt4mb5bdDtRR0OSPTj29PWqWmapeWd6JYNQu0kXO4CUtn2wTj+n1FYl7KT+6TG4+nGcf/rqKOPlcDOc7c5/z9PrXZyJK1jsUVax714J8Tf21E1tfMhulXcJUbAcfgeoB/wAnIrqhEYgvlogABJO7v2PT27c8ce3h/wAPLx7fxLY7i22SQIY2/wBr2PP/AOqvd3GHHzDJGSTx0Pr68f44ry8RT9nOy2PPrwUJWQIQhPl4OM4x1AHf9M80uAcZ52/xgfhkY9eOtIBnO3689Bx6/lTvlI5XOc8A8njnJ46DH54rDoYCIpRQTxnOCDwvP9M9uKkAGFHPTsMDj09hx0pq4JySvTrk5/A444z09venKhGCCcjPBGcH3/Afj7Zp2Ezzz4y2sKWWn39yiG3837PJuwQcjAGDx16+v1Jr508b6Y1hqtnEthNYWsrBEm8tlWZ1PzOqZx/EvT2x3r6j+LFvNeeDWW2so7lFnRp4woJWPoWTn7/OQR+vNfNfivSZlvWs9d8RxrbadbmXTfPUs88bEkKxHQ5GPX2xzX0WUz9xL1LfvU7HOeL7eU3TyLYJFswss0Sny+fu5/ukjBweTmsrTGaLBkZmtlYgmNsFSRyeOvH8u3WprrxDczIkaLsthgyxZJEpxjLZ6/0qeSLTp7Zry2c6dKnzRQSZcORycNjjvj8q9eD103WhlU5ZycovzCGytbgyWE++DVHdUhZhsh28ctnkEg/y6VqeP/Cy+GEs7ZdftdUbywZI7dvlgY53L6dRz/8AXrndR1H+1NYmv58+bIQxz8wLcZz2wTn6e9ddruq2ereG7ITC1hv72d52a2JPlMMrtZB90N1GO3rTfNKd+mwoKDi11RyUF09rpzxLK0UsrqV8s4bbgg7iOxyOPz7VcshZvaLa21u8+puzZm/gKkAgDJ4II6+/0rMuygkPlsrKFCpv4xg+nbofzpsN/NG6KhYxq4kCYxk/hyPzqpSVN6mSd9z3X4ate6zoU9tLrV3eXUdwkjW0jMGtn+6VJPVSABjoMcd66Lx5rMP9l3FrqKvbwpGVRpf3RUkYB/2iTk8cc9uRXiXgLV72w8RSzaZKsEVyjmSEP94DkIGPJOcDPXr16H0aeZtW0ZriaK+xaqbmG3G2Rl3fwuDwTnHHpxg5rklQ/eqb23Nk7q6djA1jwzoV7oWnC0m+y6nGAk6xp5m/IG0uM/Ln19j1r6U+EV1p958ONI/sff8AY4VNsvmIVJZThjgjk8/j7Yr538E3ej2+jSJaXbXOt3ab7+WdPKEDEt8i5+9gc+mevHFfUHgzSxo/g3R9MjlaYQ2y7Szbixb5ic/Unn8uvPDnFT92otvf/h/u6XM0kkZnj23MmkwSIwPlOwwGySW5yfXkH+fasrw7arOByCV5XGM4PbP+ffg13V1ALu1lt5TxIhT5uxGMYPqDjGO9ef2zzaRfmC4UBg2AduM46/XGc/j7V41N3jyrc6qUuaHL1R0L6ZHIrugDKRnKqMgDPfvkYHAzx3JwOf8A32lawktu+WEQU7W3b1B+6T7n0/TmuttbmK5jUxuGB6YGSc9j75J9ufSsrxAhjZpiy7AgUkcYJJwcfgT7jpg0oSd7MISd7M3YbiG6top7cny5BuAz9w469uP06ZpQrFlbB4DYGPYe/JHsev1rD8I3ZX7TaSAgk70DHqe4z9cH36+lb5Xn7vHIOBxz7D3OffviolHldkZSXK7Ee3J5Ix069u3Ptnv/AD6tYk5ViwweGHPJ4yB06nk1M3I+bAUnIyAOnHp1HT8/WogGEjArgAHknHT3/Dke2T14lAC8spDgoAdw6kn3OcdO3uKRfmXAAbPHyrkE9hj3H8/wpxB3/O2+TkDC4x6jHoM/TnjryFcggkMRnocBsc59cdf5+1PzAY2GAzuyQWBzx68HPXHfv+lLIwGDuYDJwDx6ZyPy9vTHOFwN7N82TjJ/rjOBjPbqetNIUnlSCpzwAM56c46Ak/j1qvMBJAqrnawP4YGP8MVGx2sQQFAyTnjj39hnPPp9ajvDP5BNl5fnjDLu/M9Oh+v60qglB8u1uGwvQduOehPp+PpVWsMibq4IKsud3Xn8CPQioW5JwhHXgcegzwen19PapZRwGKtyxHH8v5+w/lSvF/csC2CRwR8rZDc+3bPPXvVeo0MDMyA5Jzxkr16dRn6e/H5MlUNgHOPmA3Hfxnn2Gev+NEMUscJ8zDbmIwSMj/8AUOvv16UFTIASdwOCBtwDz368EnP5VXUpFCcjL5Ye49D69OMfr7GoGIV2wiNnknFXXQBjnPyZHzJzjPQ88cn6evrVSRd7ZMbN7gj8R+eauN+hadjQcHAMgYjO4EgfLyTyPr/ifZyg8KhwBnpz7k49MEevtmnFC5JICEZxjnjPBPHXA/8A10jsEQuwYJjcCvOfTAA5/wA/SuFE3BQpYZ6ZBB7ZPTHtkH8R3xis/wASaWdX0mSJDtcAFNwx83XHQcnP69zWmEYygR5UtnsQWyOn5frUqluWJUqRwx5x3+pBznt+PZxlyu8QvZ3PEBaSWkot7lSDGcMpH+c9Rz+fNei+FzaJGhTBIxk44XqOOnTH+Rmr+ueG7TWFWRSYLlRwY8Y/n14/yKwpfC+oQ/Jbt5mDkYyOvT/IrslVhVW9jpdRTjZux0s2s2cKNvmD7STlRwB6flx71yWtzPqc6RwruV8hdq9e/Tt65NXbHwrqE0iieWOCMcYzknnsPz+vbNdVYaDa2O1oAxkbP7xzg+w+n/1/pURlCltqzO8Ke2rI/DOlf2HoohB3u2ZZF6bW7j+Q54/OvFddlku9cvbqSNkLMRtkznjg57cY7/pX0ErtuVjvDDI6jJP1+hz9Peuf8Q+DtP1t2lQm2uZDjeinY/1H5jj8ecCihXUJNz6ipVVGTcjwELvuxjOWPALc4788e/PQ+54rcttLMkLFvmyAHJ6c9Pr/AJx7W9e8N3Gi6myXm3y2wUaI/eBx3545xU2m3JVVSIf7OMe46jPAJxmu6b6xO5SuropaeX0++iuCGDod3qCQc9fXp0/nXu2kaza6pBHNGwWQjO3I59cfiD/9bqPFntVkIaMl+4YtyefXHHPp+POa3reWTTbeCWKRkm5AZhw3bA9/r/WuetTVRK25jWhz+p64QNikgMFyBg9B27denX+QzQ+RuHBH94nPPYj36/144rJ8Jawmr6aHbC3CnbIF5z05H1z/AJ7bR+Xg/Kc9QflzjOc+hyfr9K85qzs9zhaadmIThhu+6ARgc/Xk++Pf604cYZQpPHPGTj1PToAOPQdM4ppRSo4zk4xjBJ5/LJ/H+dSgAYAwcZIbHHHOT659vXHGciVaxJBcQLf6fc2zu8QlUx+apBKk9CDnBxwffAIr5B+Kml6joviWbTri5u7r7I+5C8IEbZ5yCDyee/TnHpX2MFAXCsU65GefY8+vPTpniuH+MOmRN4XudZj00X01rDtmtwSpaJiBvXjOVOCPavTyzFexq8rWkvz6f5DWq5O58jyWFtdu97562cabTMrIQoY9VTGST1OMAe9WNReI6nHBp5tri0kiIiGSfKDZGGJ6EdcdPp2fqv2rTYimwXOmz8o9xFgsxUHk54Zcnv7+lVjc/YNIjtrqwhzIfOilJByMcdOv+c19XZJ3Iuttu/8AXYs3GiLZ6LazWE4uNQaJ5rqEqoMChjhk5+YbRkntnj1q94QsY7TQLnxNNbG5itZDDIisAE3YUEZHB5/I1BoOuQnUJr7UdHN3bRIqnyWwLfggHHQgk8g9azNP1lNOS8gZJbi3u1ZJYncqv3gVbAPJGP8AOKlqVrdP62KTpxakvP8A4DMue1EaowkRomPZ9xGexxWpoPh+71azubuySK5+yqXnt9+JNgGSwGP84q1plppFxZLdpDcM1vMDdRyzDYYSOoIUEHPH5VqeF7XwxtvorzW5ommt2VAkJClieBuPI9xjn8qcrR95EQpXtzbM5l9ONtbWM8wOLltyCNgXK9Dkdj6Z616O97Cmp6JY2YnuFvYk2zG6UMjbiGV8rgsOpzg89q5jw5ocUniBrYXIawt9yvdsTGqyEYDDnhgcYHtU1vqMugy21lp9rb6hfJLK8xdfMPmOQqgEH2HTHJ+mKcU1b+v6/r0za5Xsd34I0vw3qHim58OWEVzdajPIYLma7+aOUb/mZdvQDB9D9a+qUjW3t4oIhtjjUIg65AAHtzgD+deI/BLwfD4P0268ReKbVotduCSscnOxDzleepzyc8fhXQ+IfHt9MzRaaotkzzkZdh2IP5H/ABr5rM6jxFZRg7pdX/X9am9PDynpHY9LGcYTCgcdemT9Pr/nrl61olvq8OJSq3C52S53Doc5Hpn0569814+mt6sZRINRuBIqkkKdozzzz3/Xn05O9onjTULJ42uW+1WmSoLjawXgkZ/z/WuH6vOOsTf6rOHvRZbkj1DRb3y7pPMYgkPkYI78+n+ec1el1JbhSvQ7eCjHgdj06d/oMjpz09pdad4i0pZ41R0DbdrA7kPXnnIIHp19+2dqPhxfm+ysIwMko5JHXn6H9B7U+dP4lZkqonpJWZk2Fx9l1GJ8KVUgE7cgjtxjjGf85xXalgeRkr15HGfU+3+ee/nd5HNaXHkSx+XJzgFuM9Tz6+3r+NdvpVyt9o8E2z+Eqct1I45/HPH+NFWLspCrRWjRacAbhxkKAOmT2x+f4elNCgpjBPUA9TgHt+Ixz0qRpMNjOVzkYH0xj6dcDjp70iAAjLfKTyPUA9QT2yBwawsYEeDj5AhAxuLqcY9Rj645469M0oXLbc5XdznuM+vtz647+7sEruWMFCSTx/Cep98HH+RT3XPPGc4PA4/XkYNAyvbB1iUTsssgGXZU2Kx6kgZJAx2JPGecUmMqoGGYZ6f0H5e/epcAqM5Lk9hye5/PGfXvSEDcvI+UEFsduec+mOePariFyE7ipwwIJwQT6HjkjpnHt61G6+XtLfczxzjPXp3x9OfoOaw/GXiT+w7EmJQZ25G84HsSMdeD06ZrxrVvEOrXs0kk+o3OcE7UYqB7bR6en5c1vSoyqLTY3p0JTV9j3tlC/efcSxyckjHAI69OPz9MmoHDlwW3ZHJBJzjsc9e3+cV4HpXinXtLuY5bW/lkA+YxTHcrDI456evtnmvafCWv2/ifSjcrEYbiI7JEP8DY9fcH8RV1MPKmubdBUpOnuXdhCAliQOnPI+hz7fhionSTnZv9xnHHqeO/HTv9OLjIQ3Bw5HyuOv4H14NQTAOuAoIIzgNkY6nHf1/yc1hci5nujY5wE7gDoM9B7e3r+NZ91fJbSBGwuVDbcZxWhczpbRNNM4UoCCAMg+vc8gY4P4eleQ+JdbN5qjSxs4Tbhcvg4yf8a1hFy2N6UOY9qI3P14GRkZ9eR068c/400dVYkK2RyeMk8fmcjr/WnuVbOSQo4544B/px/wDrNRnkbSgY85UnqDwfwPt+lecjIVUcyLIHcRqCMEZJ/njp/noItS1O10mJpbqQIcHCZyxPH1yfp3+tM1rU49L02e5lbIVeBk5J9PocD+ffnywzy6rqBkuyWZ2yGJwAeMD6Zz7fyrpw9D2nvPYcY82508/jO+unVbG2SKMcfNySOc/1/KrlrrWqRpvljBVT17duvvjHtWhpOkW9siSGAFj8+cDnjgj8R2rdURFcOqYJ6Ee+Dz6fr3q5TgvdjEblFaJGZpOvLfFre7Jt7jIxnq+eo574HPf6Gt1V3MTnjg7lP8vXv/8AX5rlta0VLlA1vEE6sCFK9Of5j8PzJj0fVJ9JnFnffPGxwJHXn1yPz79/rUOmpLmh9xLSex15VlZuDg8ZABBxzn8PX8qazLGkjP8AIoBJJ7jHp36kf/WoOefLAwx3DPp+fUZ6/wCQ9VBRw2cMCCG6bf8ACsdiDzfxTP8A247CTAIBKAHJ6YP+T+Hvxq2kttLjYwVTtzggsf8AOev6nNex6n4ds7xGMI+z3ByA38P4j/PvXnmrpc6dKYbmEryVwRuDe4zx69f/ANXoUpprlidlKorWRT0mKS5dBsJOAMYxxnk/TofXPHrWj4gvFmVIYADHHwob+I8de2f889RCutu1q8SrDFuyS6AqffJHQYP+eazL9wFCsSd5OVI3HHoBjv8Ar9atK8rs23d2bngO9e38RW0cOSk2I39z7+3Uc/4168TiQbSwydozjcRkcH0Pt9e2K8x+Gel+ffNqEykoiYT3Y+/foOev8q9GuJRHESOSfQZ79f5/z7Vx4mzqaHHXs5aEqjJzuzkAYJyCByOMZx6f0xkPwmFIXkDaGz05GRn0H5+nTmKKQyxo7AoxGW56Y7/T69PrWZrV66uttG43sdzcnoOv4ZByPXrxxXOotmKTbsia/wBaiibYgMkmSWUnk+n4kA8/j6iq1v4oWKUebEAjHBcEgc8DPpn/ADg1HZaVGYlaXkFcheBz3/Luf68U+bQoWUNAxV1Gdx56jqeep9ev6VslTvZlrkWjMbxv4YTX9MnbQIoZDendPA+PL56yKP7w4H4noa+Z/GfhU6brE2jwWd5FNaRrNM78RKHwc89gCPmyckHivp63lu/D947PHK0WMKkZ5Y+ozxng+2M10WpabpXiS0239rHcRSKVZgvJX69fwNd+GzCWF92WsX/X4ClBddV+J8N3/wBr0qcaSt3blIpGbzbaTKvuA6sp6YA47ZNLqLaXeedNbxtaudgWDcW5x87cjoTyBX0L8QfgadUuoZ/CktkIEA3WUo8vzW9d45Ix+P8ATnG+B15PMgltFs7WJmE0zXKguGA2sh5AUN7dMZ5Jr2qWPw0oX5l89P6/ExcHtH+v6/M8JFsDDI6MztG2GG052+px054/Gta08O37af8AaJwqWsiGSNQwLy46hR1z+H9K+irr4Qaknh6e18P3NvY3z+XGzybQZdnB3Mo6Y5Pvn1qGD4JaqkenR3/iaJ7S2Mi7EgCn94fmCt1z3y2T6YpLH4VaqX5kqGvkeH3uo61qfhBtJTT1t9L0txNIsS7RuztLOT95ue3HPSu7/Z98NT3PiKXV7oTWuhRWxHnXAwJ5eMqvTuCc9sAHrivYrL4ZeD/CWm3F1fJPqVvGgJgv5PMj3eoUADv9O9chrPiKTUGRdyQwRqEjtkjVI4UBGAFx0+nYduBXNWzGNWMo0Fv19f1+46aGHdR3b2Oi8Uamt5evm53xqzBCz8AYHX178jt+Fc1OC0iKMkA5BJHXOAecAYPTsMVkSNMMkM2Tzz1Jxxkde/ertnOsxADMFJPy5Jwc5zkgc84wOD/Pz1DkWh6UYqKSQJPFLEWiWYqxOC8bxMW45KuA3cYP5VJK5GSseFZtuVbIBzxg/wCfw7E8Rj/jkeNmwMEngcdeoxyff2PFRqBgbeWUctnsAe564yfw/Q2ZSPQvhReNHf3lk7bg6FwATgsvH8v0r0VhtRsDO3ng+h/+v9OTnqTXkXw1ZovFdkFZSrBgRkZAIPt6EHB9a9fkCo2COc4ABwQf8+vWuPEq079zy8SrVCvNDHdApcRxyruOEcBgMcenrjpwD060BUWEBAFUD7oIBwegPrnHf8KmJwQpIy3A45OOSB9Ac/z6CmNzg5GWyWxz27fhkf8A66xvoYCPk7hnL428Hke4GOpGf58804bmJGV3k9DjAPA9e3HvTWLBSWwgxz83r1+h6GlYBfnAG3sSOO/UY7jI/PPFO/8AX9f1cBMh5A6ghMk5PXPr+PHX+uaRlTyxtCFOnzDqPTGOf6Z/CkB2hTkHC59cfhnpgk/5FODKCoJTggAsfy5+mP8A62aVxgxABAB55I65OQD/ADB4rN17VYdD0qW+usfIp2LnHmHGBj8Dj6e9aO8bTjblgWPPToCPqTgeleWfGy8kD2FruzEULcHkZxyfU4/l+WtKHPJRLow55pM8617WbzXNUmur5uScqq/dx6AdvT8fTNZUpcKDuccnJ46dPyOevr+dPMnztyv3huLHGMep+nT/ADiW12lgpK8cMV9eO2c9+frXrKyVj1rJIgBOAHAXGCCuBx7/ANP15zXovwhkZdbmEOWV0ZX2jjcvcnpnBI/w6VyN5Ywi0UybHJUAEH6cj8hz/hXTfCmVbPxEsO5AssbRhF4AIOeB/n8O5N81OXoc9fWLPXJwA7Eu209Bt6HgdO+f0+mcU7kiNTIdxHrxyenHr1H1PvxVqRSZ5WMkhLgcMS23AA4GeOx47885qpdwQXUM0N1bx3EMmDIkigq2CCM59Dgj6DocEeUjgRy3ja0vrqySOzDuknyybcjnoATn+fcfSuQXwXqEqKfKh4GMMwBX26/5NeoTSl2Zy+45be2SD75P4mqbAl2xsfnkuCx/St4VHFWRvGrKKsXHfZIDlyTgDHHAxx9cZx64pkRIGM4UZyRjGPUD6cfhxijI2KFJYkD5iMhvqcenb+tNQjrg7R836c59xjt1+teeiDh/iRfMb22sixMYXey5/iJ4/E+3+Nc/ZSIJAWG10zjDdB/9bHH0rX+JlsRqFpdB22GPaw5xjjg+mePx9a5qxzKVVeWLkDnr/LuAMf8A1q9iil7GLNYbHrPhu/e5sQJCd6ruBxjr3/L8c+tX5Y9yOFYnqM54z/XoOv8AWsfwzZtbQxvJIzu4XaCenHT6YI6f41tQthVB3syg9eo4x/WvMmlGT5TF7hEDECCzZxj5jwOhA69fr+lUdat0NtuJAI6t0Cnj+vr+lXplSPDHBK43FumPXOOhH4Vi65emREtLFGmnJACdAcdTnsf1x+Yqmm2rAlqWfDmrRNZC0upfLKFhtf5gR7nHI78/pyB0SPGyrIrqytltwY4bnOcjtkdR+Hvh6HpduLBRLGWnLFW8xMEZA4we3Pf8cAjOvCY4B5cO1cciMcemO3QjHHoKipyt3iErXJWZUjLH/VKcHjn68d81Tvbaz1e2ZLmHeFOCXXnP4e34fjkVFrOuadosJbULhQcZEYwWbnk9vYYPPsCK851nx5PelotNga0tt2N2SW59R0HAz/L1FUqc56xKhTlLVfedNfeCrAQvcKzwIBg5chAB2x2wc9f581zwsNAs5ld72eRkyCkbkpJnuyj7xB5B6j35FcxPqFxdMWvJproAdGYt39M+o7/4U6K8jSMp5YUDIJQ8DH8z+tdkYVF8UjsjTaVmz1Xw5r+jpbpawXCx8nAkUgNx1z+fXj0zXUBgEDYbDcgew9ePYmvE44A6eYo+TO0jqPoPft/9evZNIVk0ew83AcRg5PXt6/j0/WuSvTULPuctaCi7oubhv52suSSDxxnn8Rx71xd3cE6tLvIdmcnkcFvXB6HA+h69OnaBQSUxg56nrjt3+v5d64LxTFLFfSM27yiGx6jp36Z7nH6c0qKTbJpWbsdfps8dxZiRWDqByVHU/njGQf8A9QFXz8jFsAAAn3H0Htj/ADxXn3h3XLXS5Zo7mQBcg4I+7zn6YHA/zzo3vjnT4GVIgZGzj5OTn1GBjI547fXFJ0pc1kglTlfRGz4lVRYiUKN6MOByxUnsc9O3pS+D5PM06QEN8ku0d8HsBz9c+/p35a88QSaviCC3IIOV3Hn1Bx+HUZ98ZrtNCsH07TFhyNxyT2AHpke/4fyLmmoWYSXJCz3NLcMrknAyq88dOPp0/TPGacHKP83CFs4bsTyfx6D8e9NQ4wFyNoxlPw4/l14pq4VFdcKBkDb2GQR0PbPbpz61gjEl3My44PynOeevfoPTPHpn1oEgD7mLA5PBPPXgfXBHPtnvgM5BCkfTJ4wOoH6U5T1wSAMLtbnPrnj3PSn6COa+J4lk8GSJCWIMybsEbsAg8DuePw98ceMWEUkjKFCBe3Yj6e315/Wvoi6hgu7aa2uceTIpVsr2Ht7cf/rryzWfDlxo1yGZRNE7AxyKCQQoPGOzD+fp27sNUSi4HZhaiS5WM0vSRcWqF8jC4GflJBGT+HHfuePfI1ex+w3x3KdjE5JwMkZyPqCR7H25rqNKvDHCPNGWzhtwzkZ/p0GePT1rN8TyR3MTIpAPJHykFj6A+oH69K0U3zW6G0ZS5tTNiVLuz3DzchctufG7HU57YP8AnpVS4nd5HdiFbfkqoCAsT1wOncjA/wAKTQ5iblUyAH4HHU/5Az3/ABrZj8OX+panstYCdx6t90Hgkk+meOO+fatHo9S3JR3Nn4W2hl1VrnP7uCE+n3iccD68816ezK7lh8yn+6cc+mfUkH/PBytA0qHRNMitIgJSSZGYLtyxH09D3/8A1aDMrMzBU8wgnpjjtknnBwDXBVnzzutjzKs+edx5wzESKCuOVYZyAcjj6+nem5JTucDnuOegPrnn/JpC4jQvJhEHzMzD7ue+O3+fU153rPxJht7kw6bZmeNcjzJWK5I9B6cHrzz260oQc3aKCFOU/hPRHbq2T0PJPJzjj0z3/wAKjV3LtnHHvwOmPxxz7/y4XRfiZp10yR6nbvZyH+NfnUg+vHHpxXeQNHcQLNaypNC5yjLypH0/OiUJQ+JBOEoaSQ922j5sggkfjx+oPrx+FMLOFHLA855H8u/H5/jQwO0EEhjyAfr1z6den60iAgEBTtxkAtjAHX8Of8e1T5kIa3KnAyvcYyDyOnbGM/z9a4P4taHJqGmpf2wd3tlIfI5xkYJ+pP4V3rAIuQFAHGCP0x6jjp/WogGkJRkO0tyF/iAyMdOh5HuR+Fa05cjUl0LhNxfMj5fVJNx6bgCAGI4wc/jx+H0zzYiLRAsJFIUHC7QCPx+p4z6V6R4z8G2NndNdW93DBA+5vLc8D3Ax057e/sK5i3tdPSQLNeqilsH5Dg+h/PtXpxqRmtD0Y1VKN0YztIYyFBKKSxbdx1wfr2xnj+VdH8P7O6l1iCZILhoEJd5FXj6Z6Zwevp7iu90HwvpEllFdR+Vdw9Rhc4+v9e/410GFgs2jRFjQA5UKAOeeQPUg1lPEpJxSOaddS0SJJmZgcqSwGNrAde2T0wf8461WlKkkb485IJPb3PHXt+P1pJGbjaGPy4U9zwMj8unv+VRPMZvmVwCjZ9uvTp3wf51xWOdFUnLFhk4z2ycdD+A9+v5VUkkSOaQMFbJB6FgOB0P9KtyPzgc9gWPXoeMfT/JqjJsJBkPbjLdv85qzWJZg83yg1z9/gNjt6Y/+v/XNSqcOm7edvyhgN2MA89OAAD19foCrh2b7wAyQO/se3t/h3pEzwVU4B4PT6c59M+341xXEyjrmlRatpMttMQpOSrYOF9Djv/nHWvKJ4bnS78w3UTI0fQ4GGyOD9D149s8Hj2nyyq5wB3GBjAPf2yf0/OoL/SbLVI9moWqzjJbcVz/k4457fjXVh8QqS5ZbDUrHFWHjOKO3dZkbcBkqBnHHP4EEdOOeOtTp4wM2xba0eaQ8ZTJHP+f89rTfD3SjcRyCWeRefkZ+DjsT9COn69K3BpunaVanfHDBGONypkgDqCffn/Iq5SobxTbHePYxob3VNSCxiCON3BXbn7o/p/8AX9629K0m5s9Wmlm+wyWD22DkMLkXG7/vjy9uf9rdj6VgX3i6KzJTTbWN88eZL1Y/zzj0/HFQJ8QpxIyTWSso4JU8g/Tn357fmaThNpqMbIbpza0R6MpO4krnrtzxnqAMf5/nWdrVxBpmmz6lLGxeFSyfNyXPIx6kknr1rM0bxfpuqIy72SUZUpJxz6H0wSOnQ4+lO+IFpJP4WuRbMDyu4AZGB/Mjj/PFYwh+8UZaGag1JKR4zqF5NqtzLcXbGS4kyx2nHsOO38/1q5Y24l3FtpJOOOh9vYZPbv69KqpaBYxtXLY5XGOvTr36fQHsOanilKbsPhv4toxz7+3T/wDVXpS20PSXZFqOCPzP3mepJ55PT88DH/6+King3S7IgSMHH6Yx+Xf36UkG9mXJbn7pyQcZz+Hfn/8AVXoHhLwhJcRrPfhoosdMYOc5P0PUfzqJy9nqzOc1BXZD4G0N7yTzJVCW8XOcffbjAwfUEc/5PprDfIVEbKCcdegHOPx4/TtUMFvDbW/lW6LHGB8oIxj/AB6Y9DT3ATkIT2wBuI7cD6V51WftHc4KlRzdx4J27iOCeRwBnPI9s8H8j6VQ1Wwgv0Mcy5ba21iM5wRkduOn9OlaBQnOQSc4OcfL+nfP59KdtyTt4U9QR69Dn3wPxx6ZqFpsQnZ3R5t4g8JtGvnAGWJcllJ4z9K483dvayskeJHA+bHOR6fTvxXrvjG4MPha/MQO90EY2gKQSccHPp/nHFeTW+mK/wAwQtuOCCMLnjHPt1we4/CvQozco+8dtCTkveNTw/4gghuRLLakRD5GlUAkDPQE9cnJ/E+1evWssVzbx3Vs4licb1dc8DHPb3/lnGa8RktxGQSpDuMjP3nGc889OBXc/DnVHZJ9Ol+ZWBmiJY8cjIzjrnn05561nXp3XMuhFenpzI7cgD76gADGQOw5A69Dkfl6cU4AgnBOV43AbhkevPJ+tSOmzIYMp9l6H0x05yP/ANVRvCsigOu4na20ZGNuCOh6DA69cc5GRXEjkTI4wEb5M4cZYDt6Z9Mfn19adAOM7iwIxu6gg9TnPTGfb65pzl1QBCN4GUU+uO3qPT/DoyHcQRMQGORzweBz9Tjr6fmSxj8koWGSDzuPU49fcDA49aV2Vs79rc/NkZ59ceoOR79qUgMG3YIyQeM/MM8fn/nilkX5yCATtx1x0GT+PXp/M07CMe68OWFyWdRJDnKtsbIyOufp6joB69MLVPBEtwCLW7Rg5yqSLjntn8/oK7ZowjjJw2MBscLjODgEepP/AOus/UdUtbHJlkBbnGGJP1Hrzke9axqTT0LhUn9lnnuleDdWt9WtvtdmpthKC8odSu0Hqec/nz656V6o5UfuogqIQcBQcHPt2OSOv6VyR8a6YIwxW6VDgEKoO30zz0/r9a3NF1PT9XEjWMwkK53ochl554PbAA+tXVlOeslZIdXneskXcknjIIyQwfOee35k8eneodR1C206Az3Uixxo2DgZLH2Hr344qxfTJZ2l1eXDMI4Iy7svpjjj8+leJeINZm8Sa29y7eXApxHAucISRtJx+pHr25qaVJ1HpsFGn7R3exseJvFlxqbPb2SGKzXPbc3XOWJ7c9PSuOmRifuncOp/vf8A1+Bx145robCxSVUZtpOBuK5IDZyOnrVy40dPJLqMsmcAkkjpzn168HuD34rtjyw0R3xcYaI4toxvK5XBHXOCRn14689Ov6V23wu1t9O1mPTZ3P2S6/drnoH4+76c9ugPpXPz2yrM+0YycBQx2jr/AEzx0/XOhpFq1td208TuziYSqpkJKqMfKuTlR7Dpk49K0dpR5WTVSlFpnuDqVYAYyM9/T+R45qPbyOCNx6e/f8jkf41Zl2rgYAXHK/3enH4Zwf161H8pPYjGD82OnqPT/PtXkrzPKTK+1mCtnOe7HABx/PgdOKztQvbbTYTeXrrHjK8cEd+BnLZOD6kY6YrTmYRq0jAsq9/p6nj26/1rx7X9Ym1jUJPNLCEMwVccJg4A/nz/APrrelBzdjalT9o9djnPF9/PrmqS3MjExY2xoRgKB6YH0/rx1wXjkWQsgIBJOGHY+vbt/wDqHNdYul5Utj5OFCjGBkccjv7Djp2qlNp4VRvO4AjBAOVzjJHt0r0Y2S5UejGSWiN74V6/Jb6kmk3TJ5NwS6Kyk4KjgLjoScdePxNepXKCMAORgNtUs4GeeFye/X689a8F02OS31OCRduUkVlAX5uWGef149a+gZikkUTOgbAyu4A7WHQ/UZ/zmufFKzUl1/Q4sQuWV0Z7xZyTkgHO3OSOnT8B1qnHbhYxs4B44OD+APXsPrjitTHBLjEZHIIycD049h9frzVZWcW6LdmMz7f3nlbtjMeuM89u/wCvBPInYyTM+ZDnjIPQjHB/z7egqrJGWb78w/65r1+vv/8AWrWlwBlQSAvyZbjk5646c/rnrmqbJk4IZcccMQPy7VabtoWmPdPmY8HPJVT+AyMY7D8qQ5+8MA7uCWwOnX/PNPlIjjblSq/N8wx17k+nJpQMnd8uD90NgDGe454HJriTGIACx4BA9Oe/oecjHalUZKPgb1zj1XPHtgnJ/rSk7cAgEjJ54J+tVNZuZ7TTTLEqlxHgEEkjJ5/DGP8AOaqOrshLXQZrWr2+mQKzEPIeUQcn/wDV0/8A1159qGoXOot5k0hIySEB69/1wP59elS9kuJpDJdM7OWBLSPkrj+WMU63UEckrz97OPx57+3Tn2rvhTUF5nXTpqCKwt/McAkE9fXOPp0x7fpxVa7gaNlyRuJIUE9enTtj36etatu5ilAYbQT0H9R+HTvis7VNQXcsTKcTSskewgg4UuXPTaMAjHXgHnPG0ZO5r1KEO6NvlyDng57D0Hbg9/1r0Twp4sEFmtjqqo1sVK+YxyQD7Y6cf/r7+fpHI0gVgAAMlQDz/k/z79rqrK7xpGrB2RgSq9OR0+nr+WelFSCmrMU4KSsztNT8KZAn0/bdQnlfLO4qOvP6jnj69KqWXgjULpmeQLEAOXbJxzzx+XT+fFUNMv7vSRuiuvJ287MnAGeT7jnvz16Zr0nwXrR1zT/NkuI5ZBgkI2WXjHTHGBzzzWFSrUprXXzOecpwWmxBoPhDTNHkM8oW7ugpPmygbUGey/TnmuhJLoSoA4HGP6Z6/T8adJDlB5YAPX5+me2ee+fr6ZxSSNGkhUybCei5wxHOBn/I/Drxym5u8tTlcnLViqCGOwgAgjcv6gn0PP8AM4o2lUwOAB6cY7857Z/r60/BIyORnI2nHpxj/P61IB8u5yGA59uvb8am9ybkRU8leGJ69O4AP1+vSnvjaTtY91K9cHqcZ9B2qQ5Cg4wQT9CQByB6nmjP3lLMdvp3I9TjGPrS6Bcw/F1qbjQblDk+W28r26c++en174zXJaBpkdw22VmZhkZ288E559ck9efzzXo8kYlVo5lJR1KEdMjuB9fX6Y9K8+vVk0LUXSYugcZVs5GAAR29DXVRk3FxW5vRk3FxRX8SaZFFuMPAwP4ei9M/gMcnv9Kq/DuNn8S25hycIZGIxyOPb3//AFmpda1KK+QeUyHqz5+Uqc/X2ro/h7pYs7K5vmU+ZJ+7CDAfbweRnjPB/XpWsptU3zGs2407SOsfapO0gE8Dtj9f5dvUUjDIxyckjO7POen6/wCelSleeAQCccDrx09uB+fbmgjAUKvAyPwByQO/B9fUH3riOJMYE+U7OCxx8vGOmPzIH+RinfKQMOdq5PTBXByfx6U48Bs4OM9zzgD/AB6ev1qKdJ2a28liFSXMmTnjp69Rj/JPCW4XHbcnJKEgHPOR/wDq/wA+1R3NxDaW7SXD7I1GTuIGPrz1JyfT6cVPcSJbW7SzYVEG5s8YUDv/AJ715H4o1h9dvJIxI4sxwioeG988en49u9aU4Ob0NaVN1H5F7XPGN3dymPSiIYPmAkC5JAPLH+6M/h+dctNbNM7M5laViTlgRgZ/PPTn/wCvWtYWmVWQkbvmkwozjA6D1GB/LtWhIkartVMJt3bCMjPGOvXqef5V2x5YaRO1WhpFHLy5DMHRSSMbSccnHT68dK6D4fwzP4ssGicsi7zIAT8y7Tz6YyR1/GsmUL5mVC4PTceefXjA79O3412Xw60yVtTW9VSsMClXbAIyQTj8sGqnO0JPyYq0koM2vitK0Xgu7MbbfMkVXOONpYHPXv8Az/A149p8WJIvlBBJJHf0IAPfgZ/+tXs/xMsLjUvCsi2wJEUgldFwSAPf8ea8gggcM4KjeCQVX1/+vz1/qcThfgdjPCNezsbdiVEBLMSpG3K/xA/Q+x+uOfUpJfMSyIgRMleCML0wD6DjA/8Ar1XjeQxbQQBz8v8Ae7fzH6fSo4I2eZt5JUeo+6fUeowT3wB78C+W+5v5k1rAl1IzlAY84kIOeeh6jn1rZsoftd4PLVCuQzMfqB09P8nHfW8PeGbm/KPKj29ljJlYEbu3yjHU56/X1FbmsRabotk2CEjJI3YG+T1AIHJyCfzrOdRRfL1OedVN8sTk/Fmr3LsLeCcoB1Kk55zx+WR9fxrlbfUdRtbtpotQvUdlQbTMSi46MB2JBGSOTtXpg5v3NzHcyk7QCwJA3A8HPtn8/wDGs0C3MgcE43MCSo+YE9fqeePerpxUVZo3jFJWsei+C/Fs9y32TWQW8w4WViAc8cH2xXOatpIsNduVEZWJtxA4GAe3bnGPwxj1qjpkSSTYO5SqjBPBxycfhzz2/IV6BqOjTavZWt1bgNOYgrhjgnHQjP4mpajTldbM5pWpTutEzjbfy44k3hBge3QnnB9MYrP1OUS8Kdx6EMR6+v6jHoadq1rd2Vw8F3HLHJt4Lg8+mD0wcE/X0qOxtpr66ihijZpTgYHOfT2xyffPryDpFdTXT4hmkaQ2o6rbwIuWLhtx/u9cn2/X+deuvtO1SxU4+6OB9R7HA69Paqvh7Sl0awboLlsGRuMKPT6dTz3/AAq0CrqdwLMu7nac8gE4+gIHp09q5q1VTdlsjjqVOdlWdSm1mUA5wzAZK56NyemQB+HpTJkEmDwUAPB4B9efXirLhVYAYGcjrjJJH65HX1/HNedgGZiR83K5HpyB+Bwfr17ViSinMwZsABiWAPzbeSfU8ZGT+faqmPYn6jOP0q5Mv7xSUKkDBY/w8cD8efb8DxnXVoly6v8Aabm1AXARHUZ75O4E55/T1yTaLRgr40gBBktnJJLhsDHJGOvfB/TsemrpWt2V6GCP5B5G1un4HPc/WvOLPTZJYkXnJOCWboSOmT+XP+FX47cwRZJwQSRyQep6Zxg5B68Ypyw8Om51ypx6Hod5qK2qv5I35X5QFHGeevpnHTp78Vy0uuXUswmniPkhs4J+9n+H+Q/DvWNHdXEEo+fLnkrkgn8/TIz/AJxdXVmEgWcLL8xwGXsPT2x6/pRGio6WuKNNRL1oun6mubiPM6/MUIwF9hjr2GTzn2q0PCzzRO9oyu/AKPnOemfoOfauZu3l3h4WKK2SFBxt/l7n3/Ou18Eau1xC9tcEKyfdZjgn8O/ce/anPmhHmi9BTTiro5LVtDv4BlrRznqoGd3Tg++Rjnr9KzY9D1GVR5NncEZOSI+uP68df5CvbmUqUOXIUE9Oceh56UfN5ZAUEDBJxu59Oe+cUli9NUZrESR5hpfgvUZAzSwiMkc78jgdc/Tkj/64NHimC28PxLbQKZLp03NKQPlGeg9+g9/fqPUWPygngLnqeDjGPwBzx+favOfiZYM99FdBXZXUKRjOCPb6k9OM/jV0ajqzsx06rnP3jg53cyKSJJC5ILenB5Y5z68+p7cmpLC8utMvEmtJpElB+Vl6cdj2x39P0pfLLkrxluCRyQV4/Q8/n9KtxWTeS5VQCB0Bz3/+tn8K6Xa1mdjt1PYfCXiGDXrQgKUvUGZI2YEEcfMvt7CtpoEaQvt5x8uev1PuSc8fXmvFfDl8+m6tbzBn+RjllbGcEdvU/r3xXtdnNDcWaPZMnlMpC7iW2N649Mnp6enbza9P2ctNmedWp+zd1sx5QMVG7af4e3HTB/Af5FHqFUnrgkbc4Hr7ce3SpAgwRkgH5mH93sMfX+tIqgszAMAe5GP6e3esTEbg7jg5OcEenOOv5fWgcoDuOV53kYA57/hx/wDqFSqvGBlNvbnBPYfkDzTZ0kCxmN8MZF5J+Xb1I57Eenfp0o1C/QjMXC7QATzwe2eh+g9P/r1S1nSrTVbYxXcYJAOGJOR+Pp7fzrVwGAIBwScD2Bxg9OBSYJycDv35GCOc+g4/yRVKTWqBSadzk9L8G6daTefOWukzhA5IUD6A85/znmuoGX6gkAY47c8YHr1/Gn7Fwp5Izj/e54x6DOTio7uWO1tJrmYhYo0Jbjg47Efgf5VUqkpvUbk5PUry3ENtFI9xKBGi4Ynp/hnkf4evMX/jvTYX8uJ5JiGKnyuB7YP4/wAq4PxLrV3r10d7SpZx5CQ88g44JyM84P8ALPana6d54JAxuBztXdg4+XjoccHB7jtXTHD2V5s7aeGil756OnxD0vhWWdcZBO3pjrxj37fp26jRdQs9XgWWymEmOCpb5lI9OffHH614r9hlS2RZ43EkfysivvywABOe4ODyec9QO+l4buX0fU45l3HAUPtxhh3Bz69sc8cd6U6EWrxFUw8eX3T0D4h+anh9UtgQsjYb0xzx+Z/xrzaOzkJUkAknBGQVf6dfQ17hp1xb6tpolhEc9vNkMGGenBBHc5Hesy88KadKSITLCzHHGDjnt3B7flmlSrKCs1YwpV/ZrlkjypHwwRWUSAja4/hIxj8P5n8aSWVXjDSNswd3UADOO+M4+n4d66bxB4Wubd8RTLIJQVAQ9vQ+x/L055rJi0G8V/uFNwyWP3evc+/Xjr9a6FKLV7nXGpBq9zLsokkuIygJYNkBhjJ+nT049fwr2Pw1YLYaLbxw4BZQSQc8/X6eteYmP7GAsIDygFt0i4xk4PJ65OP6V1Hw+1CQ301tPI8iSpkGQgjfnkDufxFZVlzR02McSnKN10O24DEhQ2eM54GfT1yMdfxrE1Hwro99I0jW3lOx5aI7Q2ev5njj+Wc9CVKnG888Hjr/AI9/8kYiUEgDrj9fr9Cen0rmjJxejOFSa2ZzkHg/SQx3o8+Tu+djnnAz7dBx6du9acejaXblfLs4wyHgsN3TH6AEcD8a0mByNxJxgkMcc5zz/wDX4xTY2yQFbbjvnH4Y/H3q3VnLdj55PqQ3lwLa0lmYFhEu7avp/wDX/wA+/iOqahc6ncySXJyrkqqDhV54A9BwPf8AUV7ZqkZn0y8QDl4yMMeMH1/LtXihiGSCDlSQScDtnr27f55rXDrd9TrwlrNjohlCo2lB0yfujvx9Aff88VuaN4anvw8vl8Idrbxn8COnQnj+YrNhTOExknA3Ad8Z4Ht7fj7dZpOvi1tHhGAFHzMxAHuSc4wBj6n8K1lKSVo7m1WUre6c1Pp32G9SBSC4OFSMjqTxg9j7ivWY0VLaONQQojwV9OPT2468d64XToG1DVTLMG2Elm3H35A459P8mu9dfm3ZJIJY5PI7ZHH8+2etZ1pXSucleV2kylqdnb6hEEvoElK52lh0H9Bj1/So7SztbKMJZQJChIztAA69/fGelXXXGRtyM49B7Z47e3v68ROcjLL3OCT0POf6e/61gm7WvoYpu1iB24PQ4+UHHTOOvt16fh6ivKrrJne3HykM3IHBBx3I56+vpnNl3AGSCSpK9c+lQsMbc4YA8e4HPr2z/wDqplIjMnAG0E9cKc5OR+f/ANf0NVp2K4C+45xjrx+XAPuexziyR8uOOeMKeO/U+hHcdOfWopiQFwvyjrjvz7e/6dOxpopFF0O0AKM+vOB0/XODxVNyoP8AGRjjt/SrN3IkILMyKi7nBHAwOhPJByCfbjjAzXlWu+MLiTUZPsYUxL8uS5GTk+3+frmtqVKVR2iaRjzFYXzQZ8ojAyDtUsfXH1zz+FbDMPs8JO4noxx2x15+ves/QfD9xqsim2KCLLcyHr7H2PvmvS7PRLG0s1jeLe65UyN2x6fQ0VakYPU6qklE88h3GELsVXYZKhmZQ3fDEAkZPXA+nYQWqokgkml3kn7qkfN0wOvfgc/4Vv8AijSrmNB9nZRHISu3OcZIHqPUf4HmuYitrhZsMu1zyVV/un69+v1rSCUo3Q4y5lc1Lidrl8nAGeijkccdPwH4VUku5rAj7OcykHA6dfX+WaPNWBxGrF7kg84xs4HA7dCP88Bq2jzsGbBOOMHoAckj6c0JJLXYtI2PDHifUF1GH7dI80LkeYpOT7n6Z9PSvWFO6NWCDlcDjr3/AFx27V4vp1myXMWCoBz97p16k9cduma9j06TzbC0k6sUAZs45456e1ceJUU1ynLiEk00WVGSM7SVBwMHjp/9es/W9Ii1TTDangj7rE55z1Pua0QGKnC5U8HB6emf/rd+faneY2epOOoz1Ix0P49+v6VjCTi7o502tUeIatpF3Y3LpIgjMeMjn5gT19x0qGa7ZYvKGRyMEHH8u/Hftn6j2bVdGsdVgaG4jAbOC69Qeh65z1H149zXmHi3w3d6PKSzrJCzFVbPXnHTPbmvRp1Y1VrozspVlOye5zDTB5kGG3sDtIGdw9Mj1GfoOlbumalc6dCJLZ9pHDAMOnbP4H6/oKxo4PMuUAUq6gncv1AxnP09/pVyW3aK3KyNvcsxKZ+44Y5wcc46c/hWkrNI6JJPRnZaR45uInAvfLki3BSc7Tk8ZB9T79f1r0LTNQttUshcW8gIyQ6Y5DYxtx+Xt6dq+frIN5ap5juQHxJnnkk4z6DIGetej/D24mg1CNVB+zzqQ4B64zknnrXJXoqOsTlr0Ypc0T0jYPMD8FiNgfPJ5yR+JA6/1pFOVAHOR7nI459xnBz/APXqQqQfug/w5HY44FM2kMo2sS3UnB6HI79cn689a4jgByRnO7e2fpx0/E9M9zx6UcYJJOG4yBz0/LIHp2pqrsXHyxqxHbIz6YxyMfyp2B744J3AevI/Aj3qkx6DApY5POQcrjr6H8B6fh3rP8R2bX2h3kFuSrMhZcDg8ZGTnvjv6D3rTKjYOmw56dOmfT0P508DYS3scqAOemR9eR7c/WrjLld+w07O587wpsZBIiIys34Y6EevBH0PtxXR6YieUoxweOF/HjnkkY5NVfEVi9v4guYkieNFc7oyVIBI6Dk55znPHQjpgutCcxgAhmyRzwex/wAmvRnqro9e/Mrmpqbp5I8sg7jnIGencn35znr3zWPKCXCsibs7SpJzg/yGeMnn6dRoENcShBkuwYfMchgeN36d+uPSo2tGVsMiYLFNq+o/+v07etZxJiktDtvhlcKlvd2sjkBjvQMcE44J9M8//rGK7N8gvuAOMgnbj8f1P+enlHhy5eDV7SSN/k8whuORnAwDjgcHseT2xz6zdQb7aTy8DK4A9Pp+f61zVl71/wCv66nn4iPLP1OC8QanLPfFLQrkE5I6N6D2HX34qqkV5dSIZ5C6EliAPlxkE+vOcdOf1FJDHi9YPhcZ/Q4//XXUabYR7BJwpX5fcD0z/hWukFsaSkoKyMA6bD5ABkJK/OpzwSO456AEe348VV0i2MWr27rgOZMgtkZ+pz9a6C+iEcuVbAOSeMbhnjPP+T1qXQLPzbvzXB2rnKse+MdPTGKSn7ruJ1LJs6PbkKc42gnD8Hn+p57frSjbng4Ckg9T0xn69v8AJpx5XDdOv07fz4/+tSMGBOMbxySfw7+o4/CudHINboAoAcZ4B4B79PQfh60nDA7m25z0HXPBGPzGenU1KwGdw/h6Y4J6HrTFAYYByp7Hv/n+vPU0NoBAm/IYcH5euSOv5f569/J/EenPY6pIojG0HIwex6fjjPt9civWH4Af+EZwQOnTiszX9GGrRAoFSeP5UYgcjOMd+/r6/WtqU+WWptRqcju9jyYKrBh97AC4z0556c4yBW9o9mJV+0XJ2Jk/ePUHB7cYGf8AJqaHwxdyMRAI5FEjR7w20BlOGGOxGCCQMHHfrU+s2LabpawsjKDksmRlgOvc+mefXtXS5K2jOuVRS0TIJtdWy3nT0GD90t7jHp396n03x0yTeXqluGi4PmxjAX8Pr+H6Vg21ub1Wk2DAA5U44PTP8/X8elq60F1jaSTABIzuOck8dR60nCG0hOnT2kejxSw3MCTW7CSNgNpXk4749wPTjgdzURLKn7xQrAsMIx6Z4OTjqADz0ycEjBPJeDro2VwbSTCwyMxVcElW6ZHPfB712UiEuVIU9Mj8enTr+lc048jOSUOR2IGx0HQkgEDPrn8SOMf48ZepXDJEvljL9lAzgY6D3zj9a1JRukDEkEdGU+/b25+tVpo1cfvEXnrgdh/n8aItJ3YIpWUsjwAzdSDgkYx6/ljtSSSAAMRj5TnPYZyefYDp7fWpmUwoqnCgHJCgficfn+vrUM2AzPJ8oAZuB0A9Pfj+dNvqUkcv4+uHh0SZUwRJlG+mQf1yOvrXk6wSdSCxPJ+cHmvaNct4dT024g8weZsJBC5xjg8H8etePXVrNplzLaXEaI8bkYIDcZ9q9LBSVmrm8Phsf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear showing a normal human promyelocyte. Promyelocytes are larger than myeloblasts and myelocytes (&gt;20 micron). The nucleus and nuclear chromatin and nucleoli resemble myeloblasts but the cardinal feature is the presence of many violet granules in the cytoplasm with either a dense or coarse pattern often obscuring other cell landmarks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Baehner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21908=[""].join("\n");
var outline_f21_25_21908=null;
var title_f21_25_21909="Pedicled TRAM flap reconstruction after mastectomy";
var content_f21_25_21909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Pedicled TRAM flap reconstruction after mastectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 699px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One of the most commonly used autogenous tissue reconstructions is the TRAM (transverse rectus abdominus myocutaneous) flap.",
"    <br>",
"     The drawing depicts reconstruction performed in a delayed fashion, which is sometimes necessary to allow chest wall radiation. However, the procedure can also be performed at the time of mastectomy to provide immediate reconstruction. Either the contralateral or ipsilateral rectus abdominus muscle can be utililized. Incision placement and size will vary based on the patient's body habitus. There are many ways to perform nipple reconstruction, one method is pictured here. The nipple is reconstructed after the flap heals and is then tattooed to the appropriate color so that there is symmetry with the contralateral breast.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21909=[""].join("\n");
var outline_f21_25_21909=null;
var title_f21_25_21910="HCV cirrhosis Light";
var content_f21_25_21910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cirrhosis in HCV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a liver biopsy stained with Masson trichrome from a patient with chronic hepatitis C virus (HCV) infection. Areas of hepatic fibrosis and nodule formation are seen in blue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21910=[""].join("\n");
var outline_f21_25_21910=null;
var title_f21_25_21911="Candesartan and hydrochlorothiazide: Drug information";
var content_f21_25_21911=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Candesartan and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/41/30357?source=see_link\">",
"    see \"Candesartan and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atacand HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Candesartan HCTZ&reg;;",
"     </li>",
"     <li>",
"      Atacand&reg; Plus;",
"     </li>",
"     <li>",
"      Co-Candesartan/HCT;",
"     </li>",
"     <li>",
"      Mylan-Candesartan HCTZ;",
"     </li>",
"     <li>",
"      PMS-Candesartan HCTZ;",
"     </li>",
"     <li>",
"      Sandoz-Candesartan Plus",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F145037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F145023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension, replacement therapy: Oral: Combination product can be substituted for individual agents; maximum therapeutic effect would be expected within 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Usual dosage range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Candesartan: 16-32 mg/day, given once daily or twice daily in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrochlorothiazide: 12.5-25 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F145024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F145025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum levels of candesartan are increased and the half-life of hydrochlorothiazide is prolonged in patients with renal impairment. Contraindicated with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F145026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution with moderate hepatic impairment. Contraindicated with severe hepatic impairment and/or cholestasis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 16/12.5: Candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg; 32/12.5: Candesartan cilexetil 32 mg and hydrochlorothiazide 12.5 mg; 32/25: Candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Atacand HCT&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     16/12.5: Candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     32/12.5: Candesartan cilexetil 32 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     32/25: Candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9460245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F145006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; combination product should not be used for initial therapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F145035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions which follow have been reported with the combination product; see individual drug agents for additional adverse reactions that may be expected from each agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3%), headache (3%, placebo 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Abdominal pain, abnormal ECG, abnormal hepatic function, agranulocytosis, angina pectoris, angioedema (&lt;0.5%), anxiety, arthralgia, arthritis, arthrosis, asthenia, bradycardia, bronchitis, BUN increased, chest pain, conjunctivitis, cough, CPK increased, cystitis, depression, dermatitis, diaphoresis increased, diarrhea, dyspepsia, dyspnea, eczema, epistaxis, extrasystoles, fatigue, gastritis, gastroenteritis, hematuria, hepatitis, hyperglycemia, hyperuricemia, hypoesthesia, hypokalemia, infection, insomnia, leg cramps, leukopenia, myalgia, MI (&lt;0.5%), nausea, neutropenia, pain, palpitation, paresthesia, peripheral edema, pharyngitis, pruritus, rash, rhinitis, sciatica, sinusitis, tachycardia, tinnitus, transaminases increased, urinary tract infection, urticaria, vertigo, viral infection, vomiting; rhabdomyolysis has been reported (rarely) with angiotensin-receptor antagonists",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F145009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to candesartan, hydrochlorothiazide, or any component of the formulation; hypersensitivity to sulfonamide-derived drugs; severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); severe hepatic impairment and/or cholestasis; refractory hypokalemia; refractory hypercalcemia; gout; concomitant use with aliskiren in patients with diabetes mellitus; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with angiotensin II receptor antagonists; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with candesartan/hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with moderate hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy. Contraindicated with severe hepatic impairment and/or cholestasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use candesartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use candesartan with caution with pre-existing renal insufficiency. May precipitate azotemia; discontinue or consider withholding if renal impairment occurs. Contraindicated in severe renal disease (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anesthesia/surgery: Hypotension may occur during major surgery and anesthesia; use cautiously before, during, and immediately after such interventions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F145032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F145018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may potentiate orthostatic hypotension).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F145012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F145028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F145013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     Candesartan: Avoid use in the nursing mother, if possible, since candesartan may be excreted in breast milk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Hydrochlorothiazide: Thiazides are excreted in human breast milk. Benefits to the mother should be weighed against possible risk to the newborn if used in a nursing woman.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F145014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be given with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F145011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Atacand HCT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16-12.5 mg (90): $429.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32-12.5 mg (90): $438.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32-25 mg (90): $474.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Candesartan Cilexetil-HCTZ Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16-12.5 mg (90): $368.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32-12.5 mg (90): $375.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32-25 mg (90): $406.05",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F145002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assess weight, I &amp; O reports daily to determine fluid loss; blood pressure, symptomatic hypotension, and tachycardia; serum electrolytes, BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F145015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Atacand D (AR);",
"     </li>",
"     <li>",
"      Atacand HCT (BR);",
"     </li>",
"     <li>",
"      Atacand Plus (AU, BB, BE, BF, BJ, BM, BS, BZ, CH, CI, CO, CR, CZ, DK, DO, EE, ES, ET, FI, GH, GM, GN, GR, GT, GY, HN, IE, IL, JM, KE, KP, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NO, PA, PE, PR, SC, SD, SE, SG, SL, SN, SR, SV, TN, TR, TT, TZ, UG, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Blopresid (IT);",
"     </li>",
"     <li>",
"      Blopress Comp (SE);",
"     </li>",
"     <li>",
"      Blopress Plus (CH, CR, EC, GT, HK, HN, ID, NI, PA, PE, PH, SV, TH, TW, UY);",
"     </li>",
"     <li>",
"      Blopress-D (CN);",
"     </li>",
"     <li>",
"      Blox-D (CN, EC, PY);",
"     </li>",
"     <li>",
"      Cancetil Plus (KP);",
"     </li>",
"     <li>",
"      Candecard H (BG);",
"     </li>",
"     <li>",
"      Candesa Plus (KP);",
"     </li>",
"     <li>",
"      Candesar-H (IN);",
"     </li>",
"     <li>",
"      Cansartan Plus (KP);",
"     </li>",
"     <li>",
"      Cokenzen (FR);",
"     </li>",
"     <li>",
"      Desaltan Plus (KP);",
"     </li>",
"     <li>",
"      Hytacand (FR, PT);",
"     </li>",
"     <li>",
"      Tiadyl Plus (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Candesartan: Candesartan is an angiotensin receptor antagonist. Angiotensin II acts as a vasoconstrictor. In addition to causing direct vasoconstriction, angiotensin II also stimulates the release of aldosterone. Once aldosterone is released, sodium as well as water are reabsorbed. The end result is an elevation in blood pressure. Candesartan binds to the AT1 angiotensin II receptor. This binding prevents angiotensin II from binding to the receptor, thereby blocking the vasoconstriction and the aldosterone-secreting effects of angiotensin II.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hydrochlorothiazide: Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F145008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/25/21911/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/25/21911/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/25/21911/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K and Kjekshus J, et al, &ldquo;Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/25/21911/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, &ldquo;Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/25/21911/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/25/21911/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/25/21911/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/25/21911/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, &ldquo;Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/25/21911/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reif M, White WB, Fagan TC, et al, &ldquo;Effects of Candesartan Cilexetil in Patients With Systemic Hypertension. Candesartan Cilexetil Study Investigators,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1998, 82(8):961-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/25/21911/abstract-text/9794352/pubmed\" id=\"9794352\" target=\"_blank\">",
"        9794352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/25/21911/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8997 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21911=[""].join("\n");
var outline_f21_25_21911=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708656\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145019\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145020\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145037\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145023\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145024\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145025\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145026\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145004\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144989\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9460245\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145006\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145035\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145009\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144993\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145032\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144997\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145018\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144999\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145012\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145028\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145013\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145014\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145011\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145002\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145015\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144992\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145008\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8997\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8997|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/41/30357?source=related_link\">",
"      Candesartan and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_25_21912="Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy";
var content_f21_25_21912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/25/21912/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/25/21912/contributors\">",
"     Angus Wilfong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/25/21912/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/25/21912/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/25/21912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/25/21912/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/25/21912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     SEIZURES AND EPILEPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A seizure represents the clinical expression of abnormal, excessive, synchronous discharges of neurons residing primarily in the cerebral cortex. This abnormal paroxysmal activity is intermittent and usually self-limited, lasting seconds to a few minutes.",
"   </p>",
"   <p>",
"    On electroencephalography, a seizure ictus is characterized by sustained, abnormal electrical activity that has a relatively discrete beginning and end, and goes through an evolution characterized by changing morphology and amplitude (voltage) of the abnormal discharges. A focal seizure has a restricted regional onset followed by spread to neighboring or remote brain regions. It may spread to deep subcortical regions and result in a generalized tonic-clonic seizure. This is called a secondarily generalized seizure, to differentiate it from seizures that are generalized from the onset, primarily generalized seizures. When the seizure is prolonged or immediately recurrent without a return of consciousness, this is status epilepticus.",
"   </p>",
"   <p>",
"    An individual is considered to have epilepsy when seizures recur over a period of time without obvious precipitants. Epilepsy is not a specific disease, but rather a condition arising from a variety of pathological insults involving the cortex, such as tumors or genetic channelopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/1\">",
"     1",
"    </a>",
"    ]. Serial seizures caused by hyponatremia, hypocalcemia, high fever, toxic exposure, intracranial bleeding, or bacterial meningitis are not classified as epilepsy unless they become a recurrent process beyond the acute illness.",
"   </p>",
"   <p>",
"    A seizure may be an isolated event with no obvious precipitating cause that never recurs. It may be triggered by a transient disruption of cortical neuronal function such as a disturbed metabolic state (high fever, hypocalcemia, hyponatremia), temporary cortical disturbance after minor head trauma (concussion), ischemia,",
"    <span class=\"nowrap\">",
"     chemical/inflammatory",
"    </span>",
"    excitation caused by infection (meningitis, encephalitis, sepsis), or bleeding (intraparenchymal or subarachnoid hemorrhage). A seizure can also be the manifestation of a chronic disturbance of neuronal function caused by a remote event such as perinatal asphyxia or in-utero stroke, the expression of a genetic syndrome, or a progressive neurologic disorder such as a tumor or a neurodegenerative or neurometabolic disease. Seizures may recur over days or weeks and disappear, never to recur (eg, in viral meningoencephalitis), disappear for months or years (eg, after perinatal asphyxia), and then recur, or continue unabated from the initial inciting event (eg, in infants with brain malformations).",
"   </p>",
"   <p>",
"    Age-related epilepsies that occur in otherwise normal children with specific EEG spike patterns and are due to genetic ion channel or receptor defects are referred to as idiopathic epilepsies. Those that are presumed to be secondary to a known past physical or metabolic brain injury are called remote symptomatic when the cause is known and cryptogenic when the cause cannot be identified.",
"   </p>",
"   <p>",
"    Brief, unsustained bursts of abnormal neuronal discharge that occur between seizures can be recognized on the EEG as interictal discharges. These transient epileptiform discharges may occur in the EEGs of 3 to 5 percent of normal children and are more frequent in near relatives of individuals with seizures, particularly in those families with a genetic epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are categorized as clinical (full clinical expression), subtle (minimal clinical expression), or subclinical (no clinical or outward manifestation of the electrical seizure activity). Clinical seizures are classified on the basis of the individual's ictal behavior with consideration of the electroencephalography (EEG) findings.",
"   </p>",
"   <p>",
"    The International Classification of Epileptic Seizures is used by most neurologists to classify seizure types [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/3\">",
"     3",
"    </a>",
"    ]. This classification divides seizures into two basic groups based upon clinical and EEG data: partial and generalized. The classification scheme developed in 1981 is still the one that is in broadest use. A need to revise the classification is generally acknowledged but attempts to do so have not been widely accepted. Most recently the ILAE published some limited recommendations for revisions in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Partial seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial seizures are \"those in which, in general, the first clinical and electrographic changes indicate initial activation of a system of neurons limited to part of one hemisphere.\" A partial seizure is classified primarily on the basis of whether or not consciousness is impaired during the attack. When consciousness is fully maintained, the seizure is classified as a",
"    <strong>",
"     simple partial",
"    </strong>",
"    seizure. When consciousness is impaired, the seizure is classified as a",
"    <strong>",
"     complex partial",
"    </strong>",
"    seizure\" [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/3\">",
"     3",
"    </a>",
"    ]. \"Impaired consciousness is defined as the inability to respond normally to exogenous stimuli by virtue of altered awareness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    responsiveness\" [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/3\">",
"     3",
"    </a>",
"    ]. \"Complex\" does not refer to the behavior per se, a mistake made by many physicians when describing a focal seizure.",
"   </p>",
"   <p>",
"    Partial seizures are further subdivided primarily on the basis of the clinical signs and symptoms and the EEG localization. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motor seizures may manifest as focal motor activity, sometimes with an anatomic spread or march of activity (Jacksonian), versive movement (turning of the eyes, head",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      trunk), vocalization, or arrest of speech.",
"     </li>",
"     <li>",
"      Sensory seizures can be manifest by paresthesias, feelings of distortion of an extremity, vertigo, gustatory sensation, olfactory symptoms, auditory symptoms, and visual phenomena such as flashing lights.",
"     </li>",
"     <li>",
"      Autonomic seizures may include an epigastric \"rising\" sensation (a common aura with medial temporal lobe epilepsy), sweating, piloerection, and pupillary changes.",
"     </li>",
"     <li>",
"      Simple partial seizures may also manifest higher cortical, psychic symptoms including dysphasia, feelings of familiarity (\"deja-vu\"), distortions of time, affective changes (particularly fear), illusions, and formed hallucinations. Simple partial seizures are often referred to as auras.",
"     </li>",
"     <li>",
"      During complex partial seizures, the patient may have a variety of repetitive semipurposeful movements that are referred to as motor automatisms. These can include oral-buccal movements (chewing, swallowing, sucking), complex motor phenomena including bicycling and kicking movements, flailing of the arms, and even running, jumping, and spinning. Complex partial seizures involve regions of both hemispheres, thus explaining the impaired consciousness and the more complex and often bilateral motor symptomatology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Partial seizures may start in a \"silent\" area of the brain such as the frontal lobe and become clinically apparent only when they spread to neighboring cortex such as the precentral gyrus of the frontal lobe or the hippocampus of the temporal lobe. In these cases, the EEG monitoring can be critical to the detection of a focal seizure onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Generalized seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized seizures \"are those in which the first clinical changes indicate initial involvement of both hemispheres. Consciousness may be impaired and this impairment may be the initial manifestation. Motor manifestations are bilateral. The ictal electroencephalographic patterns are bilateral from onset, and presumably reflect neuronal discharge which is widespread in both hemispheres\" [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/3\">",
"     3",
"    </a>",
"    ]. Generalized seizures can be convulsive and nonconvulsive, depending upon the presence or absence of significant motor concomitants. Patients with nonconvulsive seizures, such as absences, may have low amplitude myoclonic movements as well as mild tonic involvement of the limbs and trunk and simple motor automatisms, similar to those seen in complex partial seizures.",
"   </p>",
"   <p>",
"    The terminology of seizure classification, \"secondary\" and \"secondarily,\" can be confusing and is often misused. What appears to be an idiopathic generalized seizure could be caused by the secondary generalization of a partial seizure. Benign rolandic epilepsy of childhood (a genetic epilepsy occurring in normal children with a benign course and prognosis) is an idiopathic partial epilepsy manifested by seizures that arise from a discrete focus in the inferior Rolandic (frontal) region. During wakefulness, the ictal discharge remains confined to this area and the child experiences twitching of the face, drooling, and speech arrest often with retention of consciousness. During sleep, the clinical seizures may appear generalized tonic-clonic. The EEG, however, reveals that the seizure begins in the inferior frontal region with rapid dissemination to both hemispheres and probably subcortical areas, thus indicating a secondarily generalized seizure. Secondary generalized seizures, on the other hand, refers to seizures that are caused by a presumed central nervous system insult, rather than being genetic or idiopathic; for example, seizures associated with a static encephalopathy from a neonatal hypoxic-ischemic insult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Age factor in seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures in younger children differ significantly from those in older children and adults. Children older than six years tend to have seizures that are quite similar to those of adults, whereas younger children and infants have less complex behaviors, particularly with complex partial seizures. Determination of an alteration of consciousness is difficult in infants and young children. In addition, their behaviors during a seizure tend to be less complicated and more fragmented than those in older children. Typical generalized tonic-clonic and absence seizures are extremely uncommon in the first two years of life and never occur in the newborn [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/5\">",
"     5",
"    </a>",
"    ]. These issues, unique to the child between two months and two years, have prompted proposals for classifications specifically directed to this age-group (",
"    <a class=\"graphic graphic_table graphicRef53102 \" href=\"UTD.htm?29/37/30299\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with similar seizure types often share other features, such as age of onset, level of motor and cognitive development, and EEG features, which led the International League against Epilepsy (ILAE) to create the Epileptic Syndrome Classification in 1989 (",
"    <a class=\"graphic graphic_table graphicRef53661 \" href=\"UTD.htm?0/60/973\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/3\">",
"     3",
"    </a>",
"    ]. According to this classification, an epileptic syndrome is \"an epileptic disorder characterized by a cluster of signs and symptoms customarily occurring together; these include such items as type of seizure, etiology, anatomy, precipitating factors, age of onset, severity, chronicity, diurnal and circadian cycling, and sometimes prognosis.\" T",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Performance of the ILAE Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Epileptic Syndrome Classification has been shown to be reasonably useful in the clinical setting, but its limitations have prompted calls for a revision and a classification based exclusively on ictal semiology (detailed clinical description of the child's behavior during a seizure), as opposed to the current classification, which is actually a classification of electroclinical syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/9\">",
"     9",
"    </a>",
"    ]. The International League against Epilepsy has appointed four committees to prepare documents on terminology for ictal phenomenon, classification of epileptic seizures based upon known or presumed pathophysiological and anatomic substrates, a classification of epileptic syndromes and epileptic diseases, and a new classification of functional disability caused by seizures or epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/10\">",
"     10",
"    </a>",
"    ]. Most recently the ILAE published some limited recommendations for revisions in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One group reported a study of 613 children, less than 15 years at the time of the first seizure, who were prospectively identified by neurologists in Connecticut [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Using the Classification of Epileptic Seizures, they were able to accurately classify most patients. Generalized seizures were recorded in 45.4 percent of the children, with 51 percent being idiopathic, 36 percent cryptogenic, and 13 percent remote symptomatic. Partial seizures occurred in 55.1 percent, with 14 percent idiopathic, 63 percent cryptogenic, and 23 percent remote symptomatic. Fifty-three percent of the children with partial seizures had at least one secondarily generalized seizure. The remainder of the seizures either could not be classified as focal or generalized or were staring spells or tonic-clonic events of uncertain onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age-adjusted prevalence of epilepsy in developed countries is 4 to 8 per 1,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. An estimated 1 percent of children and adolescents in the United States will experience at least one afebrile seizure by age 14.",
"   </p>",
"   <p>",
"    Of all children, 3 to 5 percent will have a single febrile seizure in the first five years of life; 30 percent will have additional febrile seizures, and 3 to 6 percent of those with febrile seizures will develop afebrile seizures or epilepsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3226?source=see_link\">",
"     \"Febrile seizures\"",
"    </a>",
"    .) There is a 3.6 percent risk of experiencing at least one seizure in an 80-year lifespan [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The highest incidence of epilepsy occurs at the extremes of life [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/17\">",
"     17",
"    </a>",
"    ]. The incidence in developed countries is highest in the first few months of life, particularly in the immediate postnatal period, falls significantly after the first year of life, is stable during the first decade, and then falls again in adolescence. Incidence is lowest in young and middle adulthood and begins increasing in the 50s, with a dramatic increase after age 60; by age 70, the incidence exceeds that of infancy. The incidence profile is quite different in developing countries, where the peak in the elderly usually is absent and the highest incidence occurs in young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the 2007 National Survey of Children&rsquo;s Health, males are at higher risk for epilepsy than are females [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/15\">",
"     15",
"    </a>",
"    ]. No significant racial differences exist. The incidence is higher in lower socioeconomic groups.",
"   </p>",
"   <p>",
"    Overall incidence figures show that partial (focal) seizures (simple and complex) are the most common seizure type in all age groups and account for more than 50 percent of all seizures in children. Complex partial (focal seizures with alterations of awareness or consciousness) are the most common subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/13\">",
"     13",
"    </a>",
"    ]. Generalized seizures are more common in children than in adults, with generalized tonic-clonic, absence, and myoclonic seizures following partial seizures in frequency of occurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually any insult to the cerebral cortex can cause a seizure. Most seizures are self-limited, and once the inciting process resolves, the seizures cease.",
"   </p>",
"   <p>",
"    Seizures can arise from any site in the brain but typically are localized to the neocortical gray matter and the limbic system, particularly the hippocampus and amygdala. Certain seizure types arise from subcortical regions. The thalami, basal ganglia, and posterior fossa structures, including the cerebellum, are considered incapable of generating seizures but participate as neuromodulatory influences or relay stations for the spread of a seizure from a cortical or limbic origin. One case report, however, questioned this long-standing dogma by describing electrographic seizures (recordings from surgically implanted depth electrodes) and clinical seizures arising in the cerebellum of a six-month-old infant with a posterior fossa ganglioglioma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/19\">",
"     19",
"    </a>",
"    ]. Seizures that arise in subcortical regions may be undetected on the routine scalp electroencephalogram (EEG). This situation may be particularly relevant to neonatal seizures in which a significant percentage of intermittent abnormal behaviors are thought clinically to be arising from the brainstem and are not associated with the electrographic signature of a seizure.",
"   </p>",
"   <p>",
"    An epidemiologic study in Rochester, Minnesota reported that the largest percentage of individuals (children and adults) with epilepsy fall into the",
"    <span class=\"nowrap\">",
"     idiopathic/cryptogenic",
"    </span>",
"    category, followed in order by vascular, traumatic, developmental (conditions manifested by mental retardation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebral palsy presumed to be present from birth), infectious, neoplastic, and degenerative causes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/13\">",
"     13",
"    </a>",
"    ]. In the under-14-year age group, a developmental etiology was most common. The data for most of these studies were collected prior to the advent of advanced neuroimaging; it is likely that the",
"    <span class=\"nowrap\">",
"     idiopathic/cryptogenic",
"    </span>",
"    group will be smaller in future studies, as subtle brain malformations, including dysplastic lesions and migrational disorders, are increasingly recognized. Advances in genetic research also will allow us to identify the chromosomal location and the abnormal gene product in many familial epilepsies, thereby necessitating entirely new classification categories with the emphasis on genetic origins of seizures.",
"   </p>",
"   <p>",
"    A small but not insignificant group of children have chronic seizures in the aftermath of acute hypoxic and",
"    <span class=\"nowrap\">",
"     toxic/metabolic",
"    </span>",
"    events; infections, particularly bacterial; and vascular lesions. With the increase in child abuse, head trauma is becoming an increasingly common cause of chronic seizures. A discussion of all the neurologic disorders that can cause seizures is beyond the scope of this section. Those causes that may be less familiar to the pediatrician, particularly the developmental disorders, genetic syndromes, and brain malformations, including the cerebral dysplasias, are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hippocampal sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hippocampal sclerosis (atrophy of the hippocampus with neuronal cell loss and gliosis, also called mesial temporal sclerosis) is the most common lesion in adult patients referred to epilepsy surgery centers for refractory partial seizures of temporal lobe origin. Although it occurs in children, particularly teenagers, it is primarily a cause of seizures in adults.",
"   </p>",
"   <p>",
"    In pediatric epilepsy surgical series, approximately 20 percent of children younger than 12 years and 30 percent of children younger than 20 years have hippocampal sclerosis. The most common temporal lobe pathology was prenatally acquired abnormalities of neurogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most younger patients (&lt;3 years) have extratemporal seizure foci [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/22\">",
"     22",
"    </a>",
"    ]. By comparison, in adults, 79 percent of surgeries were anterotemporal resections or amygdalohippocampectomies for temporal lobe epilepsy, usually associated with hippocampal sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/23\">",
"     23",
"    </a>",
"    ]. Some patients with this distinctive pathology have a history of complex febrile seizures in infancy and early childhood. Several reviews have been written on this topic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurodevelopmental lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) has markedly increased our ability to recognize neurodevelopmental lesions (NDL) and shifted the relative proportions of childhood epilepsy cases from cryptogenic to symptomatic. NDL are also referred to as cortical dysplasias, cortical dysgenesis, malformations, heterotopias, and disorders or malformations of cortical development [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Developmental lesions result from a disruption of one or more of the three major steps in the normal development of the cerebral cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proliferation of primitive stem cells (neuroblasts) in the germinal matrix near the wall of the ventricles",
"     </li>",
"     <li>",
"      Migration of these immature neurons along radial glial fibers through the white matter to the developing cortex",
"     </li>",
"     <li>",
"      Organization of the cortex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders have been classified according to MRI findings into focal, hemispheric, or",
"    <span class=\"nowrap\">",
"     generalized/multifocal.",
"    </span>",
"    The generalized NDL include lissencephaly, pachygyria, and band, laminar, and subependymal heterotopia. The most common hemispheric NDLs are Sturge-Weber syndrome (associated with facial angiomatous nevi) and hemimegalencephaly (enlargement of an entire hemisphere from diffuse migrational and dysplastic changes). More limited NDLs include focal cortical dysplasia, schizencephaly (cleft extending from the ventricle to the cortical surface lined with dysplastic cortex), polymicrogyria, and subependymal heterotopias.",
"   </p>",
"   <p>",
"    One group has provided a classification based upon the embryological, anatomical, and genetic bases of the developmental disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/29\">",
"     29",
"    </a>",
"    ]. They divided the malformations into four broad categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malformations caused by abnormal neuronal and glial proliferation",
"     </li>",
"     <li>",
"      Malformations caused by abnormal neuronal migration",
"     </li>",
"     <li>",
"      Malformations caused by abnormal cortical organization",
"     </li>",
"     <li>",
"      Developmental cortical malformations, not otherwise specified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical and radiographic findings of 109 children with malformations of cortical development were reported from a radiological database in a major pediatric hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/30\">",
"     30",
"    </a>",
"    ]. Seizures were present in 75 percent, developmental delay or intellectual disability in 68 percent, abnormal neurologic findings in 48 percent, and congenital anomalies apart from the CNS malformations in 18 percent. The main NDLs found were heterotopic gray matter (clusters of neurons in the white matter or near the ventricular wall which failed to migrate to the cerebral mantle) in 19 percent, cortical tubers associated with tuberous sclerosis in 17 percent, focal cortical dysplasia in 16 percent, polymicrogyria (small, malformed cortical gyri) in 16 percent, agyria",
"    <span class=\"nowrap\">",
"     /pachygyria",
"    </span>",
"    (absent, simple sulcation, or thickened cortex with broad gyri) in 15 percent, schizencephaly in 5 percent, transmantle dysplasia (a malformation extending from the wall of the lateral ventricle outward to the cortical surface) in 5 percent, and hemimegalencephalopathy in 4 percent. Several of the NDLs are associated with recognizable somatic malformations and some with well-defined chromosomal defects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are usually stereotyped (each one is like the previous one), random (occur at any time of the day or night), and are rarely precipitated by specific environmental, psychological, or physiological events. Some individuals have several different types of seizures, but most have one type that expresses itself in partial or complete form. As an example, a full seizure may be characterized by flashing lights in one visual field (a simple partial seizure with occipital lobe onset), followed by eye deviation away from the side of onset (version, caused by spread to the neighboring association cortex), followed by loss of awareness of the surroundings with automatic behavior (motor automatisms such as lip-smacking and swallowing movements) caused by spread to the temporal lobe limbic system of both hemispheres, and a few seconds later culminates in a generalized tonic-clonic seizure (secondarily generalized). On some occasions, the patient may experience only the first stage or stages of the seizure with absence of the later stages.",
"   </p>",
"   <p>",
"    Only close questioning of the patient or witnesses will uncover the valuable localizing information afforded by the first stages of the ictus, often called the seizure aura. Close questioning of children with a referral diagnosis of \"grand mal seizures\" may yield information indicating a focal onset. Clinical features of the seizure aura or postictal state are more likely to have precise localizing value than the more dramatic ictal phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, exceptions to these basic premises are numerous. Some individuals have seizures only during sleep, others only upon awakening in the morning, others always at the time of menstruation (catamenial seizures), and some following specific stimuli such as certain sounds, flashing lights, stubbing the foot, or being tapped on the shoulder (reflex seizures). The latter seizures (sensory provoked) are rare, but uncovering this information may allow the clinician to classify the child as having a specific epileptic syndrome and develop specific therapy (eg, special glasses with filtered lenses for visually-provoked seizures).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical behavior during seizures and nonepileptic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some general rules apply to the majority of seizures and provide the information necessary to distinguish true epileptic events from psychogenic nonepileptic events, other paroxysmal behavior or physiological events that may mimic seizures such as those based on cardiovascular dysfunction, and nonepileptic events with a central nervous system origin (eg, paroxysmal dystonia, infantile shuddering attacks, tics).",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodes of sudden loss of tone with or without loss of consciousness in otherwise healthy children often are cardiogenic in origin. Occasionally, a child with atonic seizures will make a protective move during the fall. However, these seizures usually occur in a neurologically abnormal child (eg, Lennox-Gastaut syndrome, other developmental encephalopathies) and are rarely the sole seizure type. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link\">",
"       \"Epilepsy syndromes in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there is color change during a seizure, usually a generalized motor seizure, it will be cyanosis. Consider syncope as a cause for the event if the child is described as pale. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=see_link\">",
"       \"Emergent evaluation of syncope in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Consistent crying before a \"seizure\" is suggestive of a cyanotic breath-holding spell. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link&amp;anchor=H9#H9\">",
"       \"Nonepileptic paroxysmal disorders in infancy\", section on 'Cyanotic breath-holding spells'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pallid infantile syncope is a common benign pediatric syndrome characterized by sudden transient bradycardia with collapse and pallor, sometimes followed by an anoxic seizure. Recovery is spontaneous. These are often precipitated by a mild unexpected blow to the head and upper torso and are caused by excessive vagal tone of unknown etiology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link&amp;anchor=H8#H8\">",
"       \"Nonepileptic paroxysmal disorders in infancy\", section on 'Breath-holding spells'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      True absence seizures (\"petit mal\") cannot be predictably interrupted by calling the child's name or by tactile stimulation, as can the staring spells or behavioral inattentiveness (\"spacing out\") commonly seen in children with attention deficit hyperactivity disorder (ADHD). Absence seizures often interrupt conversation or ongoing physical activity such as eating and play, whereas a pseudoabsence of inattention or \"daydreaming\" tend to occur during more sedentary activity (eg, sitting at a school desk). Absence seizures usually occur multiple times during the day and last only a few (rarely more than 10 to 30) seconds. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link&amp;anchor=H4#H4\">",
"       \"Nonepileptic paroxysmal disorders in children\", section on 'Nonepileptic staring spells'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features of other disorders that can mimic epileptic seizures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although psychogenic nonepileptic seizures are more common in adults, they can occur in children in the second half of the first decade and are more common in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21912/abstract/34\">",
"     34",
"    </a>",
"    ]. Certain behaviors may help distinguish epileptic from psychogenic nonepileptic features. These are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=see_link&amp;anchor=H3#H3\">",
"     \"Psychogenic nonepileptic seizures\", section on 'Clinical features of events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/54/38754?source=see_link\">",
"       \"Patient information: Epilepsy in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=see_link\">",
"       \"Patient information: Seizures in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23661114\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Classification of Epileptic Seizures divides seizures into two basic groups based upon clinical and EEG data:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Partial seizures are those in which, the first clinical and electrographic changes indicate initial activation of a system of neurons limited to part of one hemisphere.",
"      <br/>",
"      <br/>",
"      A partial seizure is further classified primarily on the basis of whether or not consciousness is impaired during the attack. When consciousness is fully maintained, the seizure is classified as a simple partial seizure and these are sometimes referred to as &ldquo;auras&rdquo;. When consciousness is impaired, the seizure is classified as a complex partial seizure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Partial seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Generalized seizures are those in which the first clinical and electrographic changes indicate initial involvement of both hemispheres. Consciousness is impaired and this may be the initial manifestation. Motor manifestations are often bilateral. Seizures can be convulsive and nonconvulsive, depending upon the presence or absence of significant motor concomitants. Patients with nonconvulsive seizures, such as absences, may have low amplitude myoclonic movements as well as mild tonic involvement of the limbs and trunk and simple motor automatisms, similar to those seen in complex partial seizures. &nbsp;(See",
"      <a class=\"local\" href=\"#H4\">",
"       'Generalized seizures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What appears to be a generalized seizure can result from secondary generalization of a partial seizure. The partial onset may not be recognized clinically. Clinical features of the seizure aura or of the postictal state are more likely to have precise localizing value than the more dramatic ictal phenomenon. The EEG typically reveals a focal onset to the seizure or localized spikes between seizures. Patients who have secondary generalized seizures are considered to have a localization-related or partial-onset epilepsy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An estimated 1 percent of children and adolescents in the United States will experience at least one unprovoked seizure by age 14 years. The incidence is highest in the first few months of life, particularly in the immediate postnatal period, falls significantly after the first year of life, is stable during the first decade, and then falls again in adolescence. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiologic classification of seizures and epilepsy includes symptomatic and idiopathic categories. Symptomatic epilepsy has a known cause; these include vascular, traumatic, developmental, infectious, neoplastic and degenerative diseases; any insult to the cerebral cortex can cause a seizure. &nbsp;Idiopathic epilepsy has a strong genetic component. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Seizures are usually stereotyped (each one is like the previous one), random (occur at any time of the day or night), and are rarely precipitated by specific environmental, psychological, or physiological events. Most patients with loss of consciousness during a seizure awaken slowly and may appear confused or disoriented (postictal state). While there are exceptions, unusual clinical features may suggest the possibility of an alternative diagnosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical characteristics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/1\">",
"      Bate L, Gardiner M. Genetics of inherited epilepsies. Epileptic Disord 1999; 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/2\">",
"      Okubo Y, Matsuura M, Asai T, et al. Epileptiform EEG discharges in healthy children: prevalence, emotional and behavioral correlates, and genetic influences. Epilepsia 1994; 35:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/3\">",
"      Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981; 22:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/4\">",
"      Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/5\">",
"      Korff C, Nordli DR Jr. Do generalized tonic-clonic seizures in infancy exist? Neurology 2005; 65:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/6\">",
"      Wyllie E. Developmental aspects of seizure semiology: problems in identifying localized-onset seizures in infants and children. Epilepsia 1995; 36:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/7\">",
"      Acharya JN, Wyllie E, L&uuml;ders HO, et al. Seizure symptomatology in infants with localization-related epilepsy. Neurology 1997; 48:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/8\">",
"      Nordli DR Jr, Bazil CW, Scheuer ML, Pedley TA. Recognition and classification of seizures in infants. Epilepsia 1997; 38:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/9\">",
"      L&uuml;ders H, Acharya J, Baumgartner C, et al. Semiological seizure classification. Epilepsia 1998; 39:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/10\">",
"      Engel J Jr. Classifications of the International League Against Epilepsy: time for reappraisal. Epilepsia 1998; 39:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/11\">",
"      Berg AT, Shinnar S, Levy SR, Testa FM. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia 1999; 40:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/12\">",
"      Berg AT, Levy SR, Testa FM, Shinnar S. Classification of childhood epilepsy syndromes in newly diagnosed epilepsy: interrater agreement and reasons for disagreement. Epilepsia 1999; 40:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/13\">",
"      Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 1991; 32:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/14\">",
"      Oka E, Ohtsuka Y, Yoshinaga H, et al. Prevalence of childhood epilepsy and distribution of epileptic syndromes: a population-based survey in Okayama, Japan. Epilepsia 2006; 47:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/15\">",
"      Russ SA, Larson K, Halfon N. A national profile of childhood epilepsy and seizure disorder. Pediatrics 2012; 129:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/16\">",
"      Murphy CC, Trevathan E, Yeargin-Allsopp M. Prevalence of epilepsy and epileptic seizures in 10-year-old children: results from the Metropolitan Atlanta Developmental Disabilities Study. Epilepsia 1995; 36:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/17\">",
"      Annegers JF, Hauser WA, Lee JR, Rocca WA. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984. Epilepsia 1995; 36:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/18\">",
"      Rwiza HT, Kilonzo GP, Haule J, et al. Prevalence and incidence of epilepsy in Ulanga, a rural Tanzanian district: a community-based study. Epilepsia 1992; 33:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/19\">",
"      Harvey AS, Jayakar P, Duchowny M, et al. Hemifacial seizures and cerebellar ganglioglioma: an epilepsy syndrome of infancy with seizures of cerebellar origin. Ann Neurol 1996; 40:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/20\">",
"      Wyllie E, Comair YG, Kotagal P, et al. Seizure outcome after epilepsy surgery in children and adolescents. Ann Neurol 1998; 44:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/21\">",
"      Duchowny M, Levin B, Jayakar P, et al. Temporal lobectomy in early childhood. Epilepsia 1992; 33:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/22\">",
"      Duchowny M, Jayakar P, Resnick T, et al. Epilepsy surgery in the first three years of life. Epilepsia 1998; 39:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/23\">",
"      Engel J Jr. Surgery for seizures. N Engl J Med 1996; 334:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/24\">",
"      Sloviter RS, Pedley TA. Subtle hippocampal malformation: importance in febrile seizures and development of epilepsy. Neurology 1998; 50:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/25\">",
"      Van Paesschen W, Connelly A, King MD, et al. The spectrum of hippocampal sclerosis: a quantitative magnetic resonance imaging study. Ann Neurol 1997; 41:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/26\">",
"      Cendes F, Andermann F, Dubeau F, et al. Early childhood prolonged febrile convulsions, atrophy and sclerosis of mesial structures, and temporal lobe epilepsy: an MRI volumetric study. Neurology 1993; 43:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/27\">",
"      Whiting S, Duchowny M. Clinical spectrum of cortical dysplasia in childhood: diagnosis and treatment issues. J Child Neurol 1999; 14:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/28\">",
"      Marin-Padilla, M. Prenatal development of human cerebral cortex: An overview. Int Pediatr 1995; 10 Suppl 1:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/29\">",
"      Kuzniecky RI, Barkovich AJ. Pathogenesis and pathology of focal malformations of cortical development and epilepsy. J Clin Neurophysiol 1996; 13:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/30\">",
"      Leventer RJ, Phelan EM, Coleman LT, et al. Clinical and imaging features of cortical malformations in childhood. Neurology 1999; 53:715.",
"     </a>",
"    </li>",
"    <li>",
"     Battaglia A. Seizures and dysplasias of cerebral cortex in dysmorphic syndromes. In: Dysplasia of cerebral cortex and epilepsy, Guerrini R, Andermann F, Canapicchi R, et al.  (Eds), Lippincott-Raven, Philadelphia 1996. p.199.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/32\">",
"      Fogarasi A, Tuxhorn I, Hegyi M, Janszky J. Predictive clinical factors for the differential diagnosis of childhood extratemporal seizures. Epilepsia 2005; 46:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/33\">",
"      Fogarasi A, Janszky J, Tuxhorn I. Peri-ictal lateralizing signs in children: blinded multiobserver study of 100 children &lt; or =12 years. Neurology 2006; 66:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21912/abstract/34\">",
"      Wyllie E, Friedman D, Rothner AD, et al. Psychogenic seizures in children and adolescents: outcome after diagnosis by ictal video and electroencephalographic recording. Pediatrics 1990; 85:480.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6199 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21912=[""].join("\n");
var outline_f21_25_21912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23661114\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      SEIZURES AND EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Partial seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Generalized seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Age factor in seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Performance of the ILAE Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hippocampal sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurodevelopmental lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical behavior during seizures and nonepileptic events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23661114\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6199|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/37/30299\" title=\"table 1\">",
"      Class infantile seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/60/973\" title=\"table 2\">",
"      Classification of epileptic seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=related_link\">",
"      Emergent evaluation of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3226?source=related_link\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=related_link\">",
"      Nonepileptic paroxysmal disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=related_link\">",
"      Nonepileptic paroxysmal disorders in infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/54/38754?source=related_link\">",
"      Patient information: Epilepsy in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=related_link\">",
"      Patient information: Seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=related_link\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_25_21913="Establishing the diagnosis of Cushing's syndrome";
var content_f21_25_21913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Establishing the diagnosis of Cushing's syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/25/21913/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/25/21913/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/25/21913/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/25/21913/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/25/21913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/25/21913/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/25/21913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible presence of Cushing's syndrome is suggested by certain symptoms and signs. Unfortunately, none of these are pathognomonic, and many are nonspecific (eg, obesity, hypertension, menstrual irregularity, and glucose intolerance). As a result, the diagnosis must be confirmed by biochemical tests.",
"   </p>",
"   <p>",
"    The laboratory diagnostic evaluation to determine if the patient has hypercortisolism (Cushing's syndrome) will be reviewed here. The approach to the differential diagnosis of established hypercortisolism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXCLUDE EXOGENOUS GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before evaluation for possible Cushing's syndrome, it is essential that a careful history has excluded exogenous glucocorticoid intake. Ingestion of glucocorticoids may take two forms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common cause of hypercortisolism is ingestion of prescribed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , usually for nonendocrine disease. However, Cushing's syndrome also can be caused by other oral, injected, topical, and inhaled glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/1-3\">",
"       1-3",
"      </a>",
"      ], and by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      , a progestin with some intrinsic glucocorticoid activity [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/4\">",
"       4",
"      </a>",
"      ]. The clearance of some inhaled steroids may be delayed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      , leading to Cushing's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/5\">",
"       5",
"      </a>",
"      ]. Cushing's syndrome may also be caused by the use of glucocorticoid-containing creams or herbal preparations [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Factitious Cushing's syndrome is a rare disorder that refers to surreptitious intake of a glucocorticoid, often by patients who are close to the health professions [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All glucocorticoids, including potent inhaled and topical glucocorticoids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"     fluocinolone",
"    </a>",
"    , inhibit ACTH secretion if given in sufficient doses. Thus, plasma ACTH and serum cortisol concentrations and urinary 17-hydroxycorticosteroid and cortisol excretion (unless cortisol or cortisone is the steroid administered) may all be low [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, urinary cortisol excretion may be falsely elevated with vulvovaginal application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factitious Cushing's syndrome is responsible for less than 1 percent of patients with Cushing's syndrome, but even a careful history may fail to detect this disorder and it may be difficult to exclude with laboratory tests [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/8,11,12\">",
"     8,11,12",
"    </a>",
"    ]. Important clues to the diagnosis are low or erratic values for urinary cortisol, suggesting ingestion of a synthetic glucocorticoid or intermittent ingestion of cortisol or cortisone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/8\">",
"     8",
"    </a>",
"    ], or excessive urinary cortisol values relative to serum cortisol concentrations, suggesting the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    to urine specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/12\">",
"     12",
"    </a>",
"    ]. The most valuable laboratory test is the detection of synthetic glucocorticoids in the urine by high-pressure liquid chromatography [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/8,9,11\">",
"     8,9,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC HYPERCORTISOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further complicating the diagnosis is the fact that hypercortisolism can occur in several disorders other than Cushing's syndrome. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are physically stressed, such as by a severe bacterial infection",
"     </li>",
"     <li>",
"      Patients with severe obesity, especially those with visceral obesity or polycystic ovary syndrome",
"     </li>",
"     <li>",
"      Patients with psychological stress, especially patients with a severe major depressive disorder and melancholic symptoms",
"     </li>",
"     <li>",
"      Rarely, patients with chronic alcoholism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When such patients present with clinical features consistent with Cushing's syndrome, they may be referred to as having pseudo-Cushing's syndrome. However, the distinction is not always simple because patients with Cushing's syndrome can have serious infections, are frequently depressed (although it is often an atypical, agitated depression) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], and presumably have a prevalence of chronic alcoholism similar to that of the general population.",
"   </p>",
"   <p>",
"    The psychiatric literature suggests that as many as 80 percent of patients with major depressive disorders have increased cortisol secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. However, cortisol hypersecretion, when present, is usually minimal. Furthermore, even severely depressed patients with substantial cortisol hypersecretion rarely develop clinical Cushing's syndrome. However, some depressed patients may be difficult to distinguish clinically or biochemically from those with Cushing's disease. Their abnormal cortisol secretion presumably results from hypothalamic-pituitary-adrenal axis hyperactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/16\">",
"     16",
"    </a>",
"    ], and disappears after remission of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About three dozen patients with chronic alcoholism and clinical or biochemical manifestations of Cushing's syndrome having been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Most had liver dysfunction, although the hormonal changes did not correlate closely with the degree of abnormality in liver function. In addition to liver dysfunction, these patients probably have transiently increased secretion of corticotropin-releasing hormone (CRH) or impaired hypothalamic or pituitary responsiveness to cortisol. However, their peripheral and petrosal sinus plasma CRH concentrations are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/21\">",
"     21",
"    </a>",
"    ]. The hormonal abnormalities disappear rapidly during abstinence from alcohol.",
"   </p>",
"   <p>",
"    Clinically, patients with these physiologic forms of hypercortisolism seldom have the cutaneous (ie, easy bruising, thinning, and friability) or muscle (ie, proximal muscle atrophy and weakness) signs of Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ADRENAL INCIDENTALOMAS AND SUBCLINICAL CUSHING'S",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical Cushing's syndrome, mild hypercortisolism without clinical manifestations of Cushing's syndrome, is the most frequent hormonal abnormality detected in patients with adrenal incidentalomas. Some adrenal incidentalomas secrete sufficient cortisol to suppress ACTH, at least partially. Although these patients lack many of the usual stigmata of overt Cushing's syndrome, they may have one or more of the effects of endogenous cortisol over-secretion such as obesity, hypertension, glucose intolerance or diabetes, dyslipidemia, osteoporosis. Depending on the importance of cortisol secretion by primary adrenal tumors, the spectrum of biochemical abnormalities will vary. Milder cases will present normal 24-hour urinary cortisol levels with slightly elevated midnight salivary cortisol, incompletely suppressed morning serum cortisol following 1 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test (DST) and partially suppressed plasma ACTH levels. In more severe cases, urinary free cortisol, midnight salivary cortisol, and serum cortisol following 1 mg DST will be clearly elevated and plasma ACTH may be undetectable [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/23\">",
"     23",
"    </a>",
"    ]. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DOES THE PATIENT HAVE CUSHING'S SYNDROME?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial diagnostic tests for hypercortisolism should be highly sensitive, even though the diagnosis may be excluded later by more specific tests [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. We agree with the approach outlined by the evidence-based 2008 Endocrine Society Clinical Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that at least two first-line tests should be abnormal to establish the diagnosis of Cushing's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We suggest late night salivary cortisol, urinary cortisol, and the low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      suppression tests as first-line tests. We suggest using conservative criteria to interpret the tests to maximize sensitivity.",
"     </li>",
"     <li>",
"      Urinary and salivary cortisol measurements should be obtained at least twice.",
"     </li>",
"     <li>",
"      The urinary cortisol excretion should be unequivocally increased (threefold above the upper limit of normal for the assay), or the diagnosis of Cushing's syndrome is uncertain and other tests should be performed.",
"     </li>",
"     <li>",
"      The diagnosis of Cushing's syndrome is confirmed when two tests are unequivocally abnormal.",
"     </li>",
"     <li>",
"      The patient should undergo additional evaluation if the test results are discordant or only slightly abnormal.",
"     </li>",
"     <li>",
"      If test results are normal, the patient does not have Cushing's syndrome unless it is extremely mild or cyclic. We do not suggest additional evaluation unless symptoms progress or cyclic Cushing's syndrome is suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;None of these tests have ideal sensitivity or specificity. For example, in one study of 369 overweight and obese patients with two additional features of Cushing&rsquo;s syndrome, the specificity of these tests ranged from 84 percent to 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/26\">",
"     26",
"    </a>",
"    ]. As a result, the choice of test should be individualized to minimize false positive results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Daily urinary cortisol excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty-four hour urinary cortisol excretion provides a direct and reliable practical index of cortisol secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=see_link\">",
"     \"Measurement of urinary excretion of endogenous and exogenous glucocorticoids\"",
"    </a>",
"    .) ACTH and cortisol are secreted in discrete bursts, not only in normal subjects but also in most patients with Cushing's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]; in addition, cortisol is secreted episodically by some adrenal tumors (",
"    <a class=\"graphic graphic_figure graphicRef60086 \" href=\"UTD.htm?2/18/2336\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Twenty-four hour urinary cortisol excretion is an integrated measure of the serum free cortisol concentration (ie, cortisol that is not bound to cortisol-binding globulin [CBG, transcortin] or other serum proteins). The two most important factors in obtaining a valid result are collection of a complete 24-hour specimen and a reliable reference laboratory. The former can usually be obtained by carefully explaining to the patient how to collect the specimen and by measuring urinary creatinine excretion. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .) In adults under the age of 50 years, daily creatinine excretion should be 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (177 to 221",
"    <span class=\"nowrap\">",
"     &micro;mol/kg)",
"    </span>",
"    lean body weight in men and 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (133 to 177",
"    <span class=\"nowrap\">",
"     &micro;mol/kg)",
"    </span>",
"    lean body weight in women. From the ages of 50 to 90, there is a progressive 50 percent decline in creatinine excretion (to about 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in men), due primarily to a decline in muscle mass. Additionally, creatinine excretion is consistent from day to day, with no more than 15 percent variability, allowing comparison of samples.",
"   </p>",
"   <p>",
"    Urinary cortisol may be detected by antibody-based techniques (immunoassays) or by structurally-based techniques (eg, high performance liquid chromatography, mass spectrometry, and combinations thereof). The former assays may be less specific since antibodies may cross-react with steroids that are similar to cortisol, but can be distinguished by the structurally-based techniques. As a result, the normal range is often higher in the immunoassays. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=see_link\">",
"     \"Measurement of urinary excretion of endogenous and exogenous glucocorticoids\"",
"    </a>",
"    .) With respect to laboratory accuracy, some reference laboratories cannot measure urinary cortisol reliably. As a result, it is sometimes more efficient to rely upon a reputable specialized endocrine laboratory for measuring not only urinary cortisol, but also serum cortisol and plasma ACTH.",
"   </p>",
"   <p>",
"    A number of studies have evaluated the utility of urine cortisol as a screening test, using the upper limit of the normal range for different assays as the test criterion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review and meta-analysis of studies of diagnostic tests for Cushing's syndrome was performed in conjunction with the 2008 Endocrine Society Guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/32\">",
"       32",
"      </a>",
"      ]. In their pooled analysis, tests with a high likelihood ratio for a positive (abnormal) test indicated tests that help rule in Cushing's syndrome, while those with a very low likelihood ratio for a negative (normal) test indicated tests that help rule it out. For urinary cortisol, they identified 14 studies including 646 patients with Cushing's syndrome and 5226 patients who did not have Cushing's syndrome. It reported a likelihood ratio of 10.6 (95% CI 5.5-20.5) for an abnormal result and a likelihood ratio for Cushing's syndrome of 0.16 (95% CI 0.08-0.33) for a normal result [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, in another study of 58 patients evaluated prospectively because of mildly abnormal cortisol excretion or response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , 19 had pseudo-Cushing's syndrome, suggesting that the false positive rate may be high in patients evaluated because of clinical suspicion of Cushing's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/33\">",
"       33",
"      </a>",
"      ]. In this study, all patients with pseudo-Cushing's syndrome had urine cortisol excretion equal to or less than three times the upper limit of the normal range.",
"     </li>",
"     <li>",
"      In a study of 105 children with Cushing's syndrome, urine cortisol had a sensitivity of 88 percent (95% CI: 79 to 93 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may be easier for the patient to collect an overnight urine sample from 10 PM to 8 AM, rather than a 24-hour sample, as the initial test. When cortisol excretion is expressed as a function of urinary creatinine excretion, this test appears to give results as reliable as the 24-hour collection. In one series, 30 patients with Cushing's syndrome (21 Cushing's disease, seven adrenal adenoma, two ectopic ACTH syndrome) excreted 44 to 5200 mcg",
"    <span class=\"nowrap\">",
"     cortisol/g",
"    </span>",
"    creatinine (14 to 1639 nmol",
"    <span class=\"nowrap\">",
"     cortisol/mmol",
"    </span>",
"    creatinine) as compared with 4 to 68 mcg",
"    <span class=\"nowrap\">",
"     cortisol/g",
"    </span>",
"    creatinine (1.5 to 21.2 nmol",
"    <span class=\"nowrap\">",
"     cortisol/mmol",
"    </span>",
"    creatinine) in 150 obese control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/35\">",
"     35",
"    </a>",
"    ]. This promising test requires additional confirmation.",
"   </p>",
"   <p>",
"    The patient can be assumed to have Cushing's syndrome if basal urinary cortisol excretion is more than three times the upper limit of normal (which may vary somewhat in different assays) and one other test is abnormal. The patient should then be evaluated for the cause of the hypercortisolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .) On the other hand, patients with equivocally raised values (above normal but less than three times the upper reference value) may have physiologic hypercortisolism and should either be reevaluated after several weeks or be subjected to one or more of the tests described next, depending upon the level of clinical suspicion. In a study of 426 patients with Cushing's syndrome, for example, 47 percent of 288 patients with Cushing's disease, 31 percent of 80 patients with adrenal adenoma, 21 percent of 25 patients with ectopic ACTH or CRH secretion, and 5 percent of 24 patients with adrenal carcinoma had at least one 24-hour urinary cortisol value in this equivocal range [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Up to 40 percent of patients with severe depression or polycystic ovary syndrome may have slightly high 24-hour urinary cortisol excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/8,37\">",
"     8,37",
"    </a>",
"    ]. People who drink very large volumes of liquid also excrete more cortisol (64 percent more cortisol excreted with an intake of five liters per day), while excretion of creatinine and 17-hydroxycorticosteroids remains unaltered [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/38\">",
"     38",
"    </a>",
"    ]. Modest increases of urinary cortisol excretion in patients with urine volumes of more than three liters should be interpreted with caution.",
"   </p>",
"   <p>",
"    When choosing amongst the diagnostic tests, it may be argued that urine cortisol determinations are unnecessary, because late evening serum or salivary cortisol values have similar diagnostic utility and are more convenient. If it is not convenient to collect urine as a second test, then the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test should be used in combination with a late night cortisol test.",
"   </p>",
"   <p>",
"    UFC may not be the ideal test in patients with mild Cushing's syndrome caused by an adrenal incidentaloma, who may have normal urine cortisol values but an elevated evening cortisol concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/25\">",
"     25",
"    </a>",
"    ]. Conversely, if urinary cortisol excretion is indeterminate and the late evening serum cortisol concentrations are normal, the patient does not have Cushing's syndrome unless it is cyclic or mild [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. These examples illustrate the need for complementary tests, and careful consideration of the tests that are chosen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Low-dose dexamethasone suppression tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    substitutes for endogenous cortisol in suppressing ACTH release. The dexamethasone doses used should reliably suppress ACTH secretion by the normal pituitary gland, leading to suppression of cortisol secretion and subsequent reductions in serum cortisol concentrations and urinary excretion of cortisol and cortisol metabolites. There are two forms of the low-dose dexamethasone suppression test: the 1mg &ldquo;overnight&rdquo; and the two-day 2 mg test [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/13\">",
"     13",
"    </a>",
"    ]. The tests are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=see_link\">",
"     \"Dexamethasone suppression tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression tests are standard screening tests to differentiate patients with Cushing's syndrome of any cause from patients who do not have Cushing's syndrome. The high-dose dexamethasone suppression tests were used to distinguish patients with Cushing's disease (Cushing's syndrome caused by pituitary hypersecretion of corticotropin [ACTH]) from most patients with the ectopic ACTH syndrome (Cushing's syndrome caused by nonpituitary ACTH-secreting tumors). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=see_link\">",
"     \"Dexamethasone suppression tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression tests are not a good choice for patients in whom CBG levels may be abnormal or in those taking medications that may alter the metabolism of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/41\">",
"     41",
"    </a>",
"    ]. These patients may have either a falsely positive or negative result.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overnight 1 mg test &mdash; The overnight test consists of administration of 1.0 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      at 11 PM to 12 AM, and measurement of serum cortisol at 8 AM the next morning. Using current specific immunoassays, most normal individuals have an 8 AM serum cortisol value of less than 2",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (55",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"       \"Measurement of cortisol in serum and saliva\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The 2008 Endocrine Society Guidelines suggest a diagnostic cortisol criterion of 1.8",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      recognizing that this choice will optimize sensitivity but decrease specificity. Despite use of this stringent criterion for sensitivity, in one study, 8 percent of patients with Cushing's disease showed suppression to less than 2",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (55",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/42\">",
"       42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The low-dose dexamethasone tests should not be used as the sole criterion for the diagnosis of Cushing's syndrome. At least one additional test should be done to establish or exclude the diagnosis.",
"     </li>",
"     <li>",
"      Standard two-day 2 mg test &mdash; The two-day 2 mg test consists of administering 0.5 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      every six hours for eight doses, and measurement of serum cortisol either two or six hours after the last dose. Because the sensitivity and specificity using urine corticosteroids are low, these endpoints are not recommended. The same criteria for normal suppression (&lt;1.8",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      [&lt;50",
"      <span class=\"nowrap\">",
"       nmol/L])",
"      </span>",
"      used for the 1 mg dexamethasone test are used for the two-day 2 mg test. The two-day 2 mg dexamethasone test is described in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=see_link\">",
"       \"Dexamethasone suppression tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diagnostic accuracy &mdash; In the meta-analysis described above, the 1 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      test and the two-day 2 mg test were both accurate diagnostic tests. [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/32\">",
"       32",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Daily urinary cortisol excretion'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For the 1 mg test, in 14 studies including 249 patients with Cushing's syndrome out of 5305 undergoing testing (using various diagnostic criteria), there was a likelihood ratio of 16.4 (CI 9.3-28.8) for an abnormal result and 0.06 (0.03-0.14) for a normal result.",
"     </li>",
"     <li>",
"      For the two-day 2 mg test, eight studies were identified, including 136 patients with Cushing's syndrome out of 323 who were tested. It found a likelihood ratio of 7.3 (CI 3.6-15.2) for an abnormal result and 0.18 (CI 0.06-0.52) for a normal result.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum collected at the time of cortisol measurement should be retained for measurement of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , to clarify otherwise confusing results caused by noncompliance and individual variability in, and drug effects on, dexamethasone metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The choice of commercial assays for dexamethasone should be based on the availability of a nomogram for expected results. It is possible that some patients with \"normal\" suppressibility to dexamethasone are slow metabolizers of the agent so that the effective dose is larger. This is inferred if the dexamethasone level is above the expected range. It should be possible to measure salivary dexamethasone in conjunction with salivary cortisol to validate suppression of cortisol secretion, but the normal range for salivary dexamethasone during these tests has not been determined.",
"   </p>",
"   <p>",
"    There are some patients in whom an unequivocal conclusion cannot be reached after measurement of two tests. Another first-line test may be useful in identifying patients in this group who have Cushing's syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Late evening salivary cortisol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurements of morning serum or salivary cortisol concentrations in patients suspected of having Cushing's syndrome have no diagnostic value unless they are extremely elevated. Measurement of serum or salivary cortisol in the late evening is based upon the fact that the normal evening nadir in serum cortisol is preserved in obese and depressed patients but not in those with Cushing's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .) Because cortisol levels appear to be entrained to the initiation of sleep, late night salivary cortisol measurement is not a good test for patients with erratic sleep schedules or shift work.",
"   </p>",
"   <p>",
"    A late evening salivary cortisol concentration can be used to establish the diagnosis of Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/45-52\">",
"     45-52",
"    </a>",
"    ]. Saliva is easily collected and cortisol is stable in saliva even at room temperature for several days. Saliva collection has the distinct advantage of being noninvasive, and can be performed by the patient at home. It is especially useful for patients suspected of having cyclical or intermittent Cushing's syndrome, who can collect many samples over an extended period of time and return the accumulated samples to the clinician at one time. As with other cortisol assays, it is useful to evaluate at least three samples from different days.",
"   </p>",
"   <p>",
"    The criteria used to interpret salivary cortisol results differ among studies, perhaps because of assay or collection differences. As a result, published reference ranges are not appropriate for all commercial assays (",
"    <a class=\"graphic graphic_table graphicRef57112 \" href=\"UTD.htm?37/33/38427\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a study of older men (mean age 61 years), some with co-morbidities of diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension, showed poor specificity. Twenty percent of the participants had a late night salivary cortisol value above the upper limit of normal (1.6",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    4.3",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    when measured by enzyme immunoassay [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/54\">",
"     54",
"    </a>",
"    ]. None had Cushing&rsquo;s syndrome.",
"   </p>",
"   <p>",
"    In the meta-analysis described above, midnight salivary cortisol was an accurate diagnostic test. A meta-analysis of six studies included 136 patients with Cushing's syndrome out of 323 tested [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/32\">",
"     32",
"    </a>",
"    ]. It found a likelihood ratio of 9.5 (CI 1.7-54.1) for an abnormal result and a likelihood ratio of 0.09 (CI 0.03-0.28) for a normal result. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Daily urinary cortisol excretion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, while a late evening salivary cortisol measurement is a useful test for the diagnosis of Cushing's syndrome, appropriate assay-specific and perhaps age-specific normative values must be used for its interpretation.",
"   </p>",
"   <p>",
"    In some situations, other second-line tests may be used. These tests may be chosen because of site-specific constraints, lack of access to salivary cortisol assays, or preferences based on experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Late evening serum cortisol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum or salivary cortisol in the late evening is based upon the fact that the normal evening nadir in serum cortisol is preserved in obese and depressed patients but not in those with Cushing's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study achieved 100 percent sensitivity and specificity in 20 normal individuals and 150 patients with Cushing's syndrome using an exclusion criterion of &lt;2",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/55\">",
"       55",
"      </a>",
"      ]. Three of the patients who had Cushing's disease had serum cortisol concentrations below 2",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      after a two-day low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      suppression test.",
"     </li>",
"     <li>",
"      In a subsequent study of 198 patients with Cushing's disease, 27 patients with the ectopic ACTH syndrome, 15 patients with primary adrenal Cushing's syndrome and 23 patients with pseudo-Cushing's syndrome, a single midnight serum cortisol concentration &gt;7.5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (207",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      correctly identified 225 of the patients with Cushing's syndrome and all 23 patients with pseudo-Cushing's (96 percent sensitivity, 100 percent specificity) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/56\">",
"       56",
"      </a>",
"      ]. When the lower criterion (2",
"      <span class=\"nowrap\">",
"       mcg/dL,",
"      </span>",
"      or 50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      was applied to these patients, it resulted in 99.6 percent sensitivity, but only 26 percent specificity, presumably because the earlier comparison group was normal subjects, rather than patients with pseudo-Cushing's syndrome. Thus, the higher criterion is recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study of 105 children with Cushing's syndrome found that a single midnight cortisol level of &ge;4.4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (121",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    gave a sensitivity of 99 percent (95% CI: 94 to 100 percent) while no child without the condition had a higher value [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This test has usually been performed in the hospital, and one group obtains the blood after the patient appears to be asleep [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/55\">",
"     55",
"    </a>",
"    ]. However, sleeping versus awake results have not been evaluated systematically, and our experience is that the test can reliably be performed on an ambulatory basis. This can be done by inserting a heparin-lock earlier in the day to avoid stress-induced cortisol released caused by the anticipation of or pain caused by venipuncture, and asking the patient to return between 11 PM and midnight for blood drawing.",
"   </p>",
"   <p>",
"    We try to obtain samples on at least two evenings. Patients with intermediate values should be reevaluated after several weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     CRH after dexamethasone test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CRH after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    test exploits the greater sensitivity of ACTH secretion to dexamethasone suppression in depressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/57\">",
"     57",
"    </a>",
"    ] and their blunted serum cortisol response to exogenous CRH as compared with patients with Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/17\">",
"     17",
"    </a>",
"    ]. However, neither of these responses alone provides a reliable method for distinguishing depressed patients from those with Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, for example, the serum cortisol concentration was &lt;1.4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (38",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    15 minutes after CRH (given two hours after the last 0.5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    dose in the standard two-day low-dose dexamethasone test) in all 19 patients with pseudo-Cushing's syndrome versus none of 35 patients with Cushing's disease, none of two with ectopic ACTH secretion, and none of two with primary adrenal disease (100 percent sensitivity and 100 percent specificity for Cushing's syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/33\">",
"     33",
"    </a>",
"    ]. However, only the 15-minute sample was accurate, and a serum cortisol concentration &lt;1.4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (38",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    two hours after the last dexamethasone dose had 90 percent sensitivity and 100 percent specificity without the administration of CRH. This test needs further evaluation to confirm its efficacy. It can give false positive results in patients with anorexia nervosa and in endurance-trained men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]; while it is unlikely that patients with anorexia nervosa would be screened for Cushing's syndrome, these results should be considered when testing patients who exercise vigorously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=see_link\">",
"     \"Corticotropin-releasing hormone stimulation test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other studies of patients being evaluated for Cushing's syndrome did not confirm the improved diagnostic accuracy of the CRH after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    test when compared to the low-dose dexamethasone test alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. It is not clear whether these differences reflect differences in dexamethasone metabolism, as dexamethasone levels were not evaluated, or differences in the cortisol assays. In a larger study, 101 patients were divided into two groups according to whether they were taking medications that might alter dexamethasone metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/64\">",
"     64",
"    </a>",
"    ]. They found that the sensitivity and specificity (93 and 92 percent) were higher in those not taking medications compared to those who were. In another study, the test performed as well as repeated examination of routine tests in six patients with appropriate dexamethasone levels in whom the diagnosis was initially unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests have been developed for the diagnosis of Cushing's syndrome, but have not been widely adopted.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      test is based upon the assumption that endogenous CRH secretion is suppressed in patients with Cushing's disease and that the opioid antagonist, naloxone (250",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      body weight intravenously), releases endogenous CRH [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/66\">",
"       66",
"      </a>",
"      ]. Naloxone probably also releases some CRH in patients with Cushing's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/67\">",
"       67",
"      </a>",
"      ], but the increases in plasma ACTH and serum cortisol concentrations are less than those in depressed patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The insulin-induced hypoglycemia test utilizes the fact that the hypercortisolism of depression is usually mild and of short duration and suppression of the hypothalamic-pituitary axis is therefore incomplete. As a result, serum cortisol concentrations increase in response to insulin-induced hypoglycemia in depressed patients with pseudo-Cushing's syndrome, but not in patients with Cushing's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/69\">",
"       69",
"      </a>",
"      ]. This test is not recommended, because it can be unpleasant for the patient and should be avoided in those with a history of seizure disorder or coronary heart disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21830?source=see_link\">",
"       \"Insulin-induced hypoglycemia test\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cortisol production rate &mdash; The twenty-four hour cortisol production rate (CPR), measured by infusion of tracer amounts of nonradioactive cortisol isotopes, is high in patients with Cushing's syndrome. However, in a study of 28 patients with suspected Cushing's syndrome who had equivocal biochemical findings, this measurement did not offer any diagnostic advantage over existing tests such as 24-hour urinary cortisol excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=see_link\">",
"       \"Patient information: Cushing's syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=see_link\">",
"       \"Patient information: Cushing's syndrome (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/47/10994?source=see_link\">",
"       \"Patient information: Cushing's syndrome treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is seldom either clinical or laboratory ambiguity in patients with florid Cushing's disease, the diagnosis can be elusive in patients with early, mild disease. We agree with the 2008 Endocrine Society Guidelines and suggest the following approach [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21913/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that at least two first-line tests should be abnormal to establish the diagnosis of Cushing's syndrome.",
"     </li>",
"     <li>",
"      We suggest late night salivary cortisol, urinary cortisol, and the low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      suppression tests as first-line tests. We suggest using conservative criteria to interpret the tests to maximize sensitivity.",
"     </li>",
"     <li>",
"      Urinary and salivary cortisol measurements should be obtained at least twice.",
"     </li>",
"     <li>",
"      The urinary cortisol excretion should be unequivocally increased (threefold above the upper limit of normal for the assay), or the diagnosis of Cushing's syndrome is uncertain and other tests should be performed.",
"     </li>",
"     <li>",
"      The diagnosis of Cushing's syndrome is confirmed when two tests are unequivocally abnormal.",
"     </li>",
"     <li>",
"      The patient should undergo additional evaluation if the test results are discordant or only slightly abnormal.",
"     </li>",
"     <li>",
"      If test results are normal, the patient does not have Cushing's syndrome unless it is extremely mild or cyclic. We do not suggest additional evaluation unless symptoms progress or cyclic Cushing's syndrome is suspected.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/1\">",
"      Weber SL. Cushing'S syndrome attributable to topical use of lotrisone. Endocr Pract 1997; 3:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/2\">",
"      Nutting CM, Page SR. Iatrogenic Cushing's syndrome due to nasal betamethasone: a problem not to be sniffed at! Postgrad Med J 1995; 71:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/3\">",
"      Hughes JM, Hichens M, Booze GW, Thorner MO. Cushing's syndrome from the therapeutic use of intramuscular dexamethasone acetate. Arch Intern Med 1986; 146:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/4\">",
"      Mann M, Koller E, Murgo A, et al. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997; 157:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/5\">",
"      Samaras K, Pett S, Gowers A, et al. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90:4394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/6\">",
"      Olumide YM, Akinkugbe AO, Altraide D, et al. Complications of chronic use of skin lightening cosmetics. Int J Dermatol 2008; 47:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/7\">",
"      Oldenburg-Ligtenberg PC, van der Westerlaken MM. A woman with Cushing's syndrome after use of an Indonesian herb: a case report. Neth J Med 2007; 65:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/8\">",
"      Cizza G, Nieman LK, Doppman JL, et al. Factitious Cushing syndrome. J Clin Endocrinol Metab 1996; 81:3573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/9\">",
"      Quddusi S, Browne P, Toivola B, Hirsch IB. Cushing syndrome due to surreptitious glucocorticoid administration. Arch Intern Med 1998; 158:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/10\">",
"      Kelly CJ, Ogilvie A, Evans JR, et al. Raised cortisol excretion rate in urine and contamination by topical steroids. BMJ 2001; 322:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/11\">",
"      Lin CL, Wu TJ, Machacek DA, et al. Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/12\">",
"      Workman RJ, Nicholson WE, McCammon DK. Factitious hypercortisoluria. J Clin Endocrinol Metab 1995; 80:3050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/13\">",
"      LIDDLE GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1960; 20:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/14\">",
"      Loosen PT, Chambliss B, DeBold CR, et al. Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry 1992; 25:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/15\">",
"      Pfohl B, Sherman B, Schlechte J, Winokur G. Differences in plasma ACTH and cortisol between depressed patients and normal controls. Biol Psychiatry 1985; 20:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/16\">",
"      Pfohl B, Sherman B, Schlechte J, Stone R. Pituitary-adrenal axis rhythm disturbances in psychiatric depression. Arch Gen Psychiatry 1985; 42:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/17\">",
"      Gold PW, Loriaux DL, Roy A, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986; 314:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/18\">",
"      Amsterdam JD, Maislin G, Winokur A, et al. The oCRH stimulation test before and after clinical recovery from depression. J Affect Disord 1988; 14:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/19\">",
"      Kirkman S, Nelson DH. Alcohol-induced pseudo-Cushing's disease: a study of prevalence with review of the literature. Metabolism 1988; 37:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/20\">",
"      Groote Veldman R, Meinders AE. On the mechanism of alcohol-induced pseudo-Cushing's syndrome. Endocr Rev 1996; 17:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/21\">",
"      Yanovski JA, Nieman LK, Doppman JL, et al. Plasma levels of corticotropin-releasing hormone in the inferior petrosal sinuses of healthy volunteers, patients with Cushing's syndrome, and patients with pseudo-Cushing states. J Clin Endocrinol Metab 1998; 83:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/22\">",
"      Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88:5593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/23\">",
"      Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications. J Endocrinol Invest 2006; 29:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/24\">",
"      Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/25\">",
"      Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/26\">",
"      Baid SK, Rubino D, Sinaii N, et al. Specificity of screening tests for Cushing's syndrome in an overweight and obese population. J Clin Endocrinol Metab 2009; 94:3857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/27\">",
"      Crapo L. Cushing's syndrome: a review of diagnostic tests. Metabolism 1979; 28:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/28\">",
"      Mengden T, Hubmann P, M&uuml;ller J, et al. Urinary free cortisol versus 17-hydroxycorticosteroids: a comparative study of their diagnostic value in Cushing's syndrome. Clin Investig 1992; 70:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/29\">",
"      Hellman L, Weitzman ED, Roffwarg H, et al. Cortisol is secreted episodically in Cushing's syndrome. J Clin Endocrinol Metab 1970; 30:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/30\">",
"      Sederberg-Olsen P, Binder C, Kehlet H, et al. Episodic variation in plasma corticosteroids in subjects with Cushing's syndrome of differing etiology. J Clin Endocrinol Metab 1973; 36:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/31\">",
"      Van Cauter E, Refetoff S. Evidence for two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion. N Engl J Med 1985; 312:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/32\">",
"      Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008; 93:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/33\">",
"      Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 1993; 269:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/34\">",
"      Batista DL, Riar J, Keil M, Stratakis CA. Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 2007; 120:e575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/35\">",
"      Corcuff JB, Tabarin A, Rashedi M, et al. Overnight urinary free cortisol determination: a screening test for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1998; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/36\">",
"      Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/37\">",
"      Carroll BJ, Curtis GC, Davies BM, et al. Urinary free cortisol excretion in depression. Psychol Med 1976; 6:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/38\">",
"      Mericq MV, Cutler GB Jr. High fluid intake increases urine free cortisol excretion in normal subjects. J Clin Endocrinol Metab 1998; 83:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/39\">",
"      Kidambi S, Raff H, Findling JW. Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. Eur J Endocrinol 2007; 157:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/40\">",
"      Meinardi JR, Wolffenbuttel BH, Dullaart RP. Cyclic Cushing's syndrome: a clinical challenge. Eur J Endocrinol 2007; 157:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/41\">",
"      Blethen SL, Chasalow FI. Overnight dexamethasone suppression test: normal responses and the diagnosis of Cushing's syndrome. Steroids 1989; 54:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/42\">",
"      Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab 2004; 89:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/43\">",
"      Meikle AW. Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone. Clin Endocrinol (Oxf) 1982; 16:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/44\">",
"      Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions. II. Arch Intern Med 1992; 152:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/45\">",
"      Castro M, Elias PC, Quidute AR, et al. Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab 1999; 84:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/46\">",
"      Laudat MH, Cerdas S, Fournier C, et al. Salivary cortisol measurement: a practical approach to assess pituitary-adrenal function. J Clin Endocrinol Metab 1988; 66:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/47\">",
"      Bonnin R, Villabona C, Rivera A, et al. Is salivary cortisol a better index than free cortisol in serum or urine for diagnosis of Cushing syndrome? Clin Chem 1993; 39:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/48\">",
"      Raff H, Raff JL, Findling JW. Late-night salivary cortisol as a screening test for Cushing's syndrome. J Clin Endocrinol Metab 1998; 83:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/49\">",
"      Putignano P, Toja P, Dubini A, et al. Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing's syndrome. J Clin Endocrinol Metab 2003; 88:4153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/50\">",
"      Papanicolaou DA, Mullen N, Kyrou I, Nieman LK. Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2002; 87:4515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/51\">",
"      Yaneva M, Mosnier-Pudar H, Dugu&eacute; MA, et al. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab 2004; 89:3345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/52\">",
"      Viardot A, Huber P, Puder JJ, et al. Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. J Clin Endocrinol Metab 2005; 90:5730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/53\">",
"      Raff H, Homar PJ, Burns EA. Comparison of two methods for measuring salivary cortisol. Clin Chem 2002; 48:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/54\">",
"      Liu H, Bravata DM, Cabaccan J, et al. Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol (Oxf) 2005; 63:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/55\">",
"      Newell-Price J, Trainer P, Perry L, et al. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1995; 43:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/56\">",
"      Papanicolaou DA, Yanovski JA, Cutler GB Jr, et al. A single midnight serum cortisol measurement distinguishes Cushing's syndrome from pseudo-Cushing states. J Clin Endocrinol Metab 1998; 83:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/57\">",
"      O'Brien, JT, Ames, D, Schweitzer, I. HPA axis function in depression and dementia: a review. Int J Geriatr Psychiatry 1993; 8:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/58\">",
"      Duclos M, Corcuff JB, Pehourcq F, Tabarin A. Decreased pituitary sensitivity to glucocorticoids in endurance-trained men. Eur J Endocrinol 2001; 144:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/59\">",
"      Duclos M, Corcuff JB, Roger P, Tabarin A. The dexamethasone-suppressed corticotrophin-releasing hormone stimulation test in anorexia nervosa. Clin Endocrinol (Oxf) 1999; 51:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/60\">",
"      Martin NM, Dhillo WS, Banerjee A, et al. Comparison of the dexamethasone-suppressed corticotropin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2006; 91:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/61\">",
"      Gatta B, Chabre O, Cortet C, et al. Reevaluation of the combined dexamethasone suppression-corticotropin-releasing hormone test for differentiation of mild cushing's disease from pseudo-Cushing's syndrome. J Clin Endocrinol Metab 2007; 92:4290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/62\">",
"      Erickson D, Natt N, Nippoldt T, et al. Dexamethasone-suppressed corticotropin-releasing hormone stimulation test for diagnosis of mild hypercortisolism. J Clin Endocrinol Metab 2007; 92:2972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/63\">",
"      Pecori Giraldi F, Pivonello R, Ambrogio AG, et al. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) 2007; 66:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/64\">",
"      Valassi E, Swearingen B, Lee H, et al. Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome. J Clin Endocrinol Metab 2009; 94:4851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/65\">",
"      Reimondo G, Bovio S, Allasino B, et al. The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing's syndrome. Eur J Endocrinol 2008; 159:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/66\">",
"      Jackson RV, Grice JE, Jackson AJ, Hockings GI. Naloxone-induced ACTH release in man is inhibited by clonidine. Clin Exp Pharmacol Physiol 1990; 17:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/67\">",
"      Torpy DJ, Jackson RV, Grice JE, et al. Naloxone stimulation of ACTH secretion during petrosal sinus sampling in Cushing's syndrome. Clin Exp Pharmacol Physiol 1993; 20:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/68\">",
"      Davis, BC, Gaitan, D, Loosen, PT, Orth, DN. Naloxone test distinguishes pituitary ACTH-dependent Cushing's disease (CD) from major depressive disorder (MDD) and chronic alcoholism (ALC). J Invest Med 1995; 43(Suppl):259A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/69\">",
"      Besser, GM, Edwards, CRW. Cushing's syndrome. Clin Endocrinol Metab 1972; 1:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21913/abstract/70\">",
"      Samuels MH, Brandon DD, Isabelle LM, et al. Cortisol production rates in subjects with suspected Cushing's syndrome: assessment by stable isotope dilution methodology and comparison to other diagnostic methods. J Clin Endocrinol Metab 2000; 85:22.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 151 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-0D05C0E861-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21913=[""].join("\n");
var outline_f21_25_21913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXCLUDE EXOGENOUS GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHYSIOLOGIC HYPERCORTISOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ADRENAL INCIDENTALOMAS AND SUBCLINICAL CUSHING'S",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DOES THE PATIENT HAVE CUSHING'S SYNDROME?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Daily urinary cortisol excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Low-dose dexamethasone suppression tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Late evening salivary cortisol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Late evening serum cortisol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - CRH after dexamethasone test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/151\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/151|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/18/2336\" title=\"figure 1\">",
"      Episodic cortisol in Cushings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/151|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/33/38427\" title=\"table 1\">",
"      Normal salivary cortisol",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=related_link\">",
"      Corticotropin-releasing hormone stimulation test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=related_link\">",
"      Dexamethasone suppression tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21830?source=related_link\">",
"      Insulin-induced hypoglycemia test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=related_link\">",
"      Measurement of cortisol in serum and saliva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=related_link\">",
"      Measurement of urinary excretion of endogenous and exogenous glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=related_link\">",
"      Patient information: Cushing's syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=related_link\">",
"      Patient information: Cushing's syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/47/10994?source=related_link\">",
"      Patient information: Cushing's syndrome treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_25_21914="Clinical manifestations and diagnosis of sarcoidosis";
var content_f21_25_21914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of sarcoidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/25/21914/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/25/21914/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/25/21914/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/25/21914/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/25/21914/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/25/21914/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/25/21914/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that affects individuals worldwide and is characterized pathologically by the presence of noncaseating granulomas in involved organs. It typically affects young adults, and initially presents with one or more of the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bilateral hilar adenopathy",
"     </li>",
"     <li>",
"      Pulmonary reticular opacities",
"     </li>",
"     <li>",
"      Skin, joint,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eye lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overview of the clinical manifestations and diagnosis of sarcoidosis is presented here. Issues relating to pathogenesis and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence (estimated at 10 to 20 per 100,000 population) and annual incidence of sarcoidosis are not known with certainty. The disease appears to vary in incidence among geographical regions and can also aggregate in families and specific races, being three to four times more common in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/1\">",
"     1",
"    </a>",
"    ]. It has been estimated that the lifetime risk of sarcoidosis in blacks in the United States is 2.4 percent, compared with a lifetime risk of 0.85 percent in whites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the patient's immunogenetic background may play a role in the clinical manifestations of sarcoidosis, and could underlie the heterogeneity of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Epidemiological studies show significant heterogeneity in disease presentation and severity occurs among different ethnic racial groups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. For example, blacks tend to be affected more acutely and with more severe disease than whites, who tend to present with asymptomatic and chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/5\">",
"     5",
"    </a>",
"    ]. There are numerous reports of familial clustering of sarcoidosis. The most prominent finding is linkage to a section within MHC on the short arm of chromosome 6. It appears that several alleles confer susceptibility to disease (HLA DR 11, 12, 14, 15, 17) and others seem to be protective (eg, HLA DRI, DR4, and possibly DQ*0202) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite an extensive research effort, the exact etiology and pathogenesis of sarcoidosis remain unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. According to one widely held hypothesis, there are multiple causes of sarcoidosis, and different patterns of illness may in part be related to different underlying causes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adolescents and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis presents in patients between 10 and 40 years of age in 70 to 90 percent of cases. In approximately one-half of cases, the disease is detected incidentally by radiographic abnormalities (eg, bilateral hilar adenopathy, reticular opacities) on a routine chest radiograph prior to the development of symptoms.",
"   </p>",
"   <p>",
"    Sarcoidosis most frequently involves the lung; thus, common presenting symptoms include cough, dyspnea, and chest pain. Common extrapulmonary abnormalities on presentation include eye and skin lesions.",
"   </p>",
"   <p>",
"    Other features of sarcoidosis include fatigue, malaise, fever, and weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/10\">",
"     10",
"    </a>",
"    ]. Systemic inflammation may contribute to muscle weakness and exercise intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Patients over the age of 70 years appear to be more likely to present with systemic symptoms, including fatigue and anorexia; however, dyspnea and cough are generally present at the same time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Crackles or rales are not commonly heard on chest examination, though wheezing may be present. Up to 30 percent of patients present with extrathoracic manifestations of sarcoidosis (",
"    <a class=\"graphic graphic_table graphicRef76046 \" href=\"UTD.htm?26/16/26892\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Extrapulmonary sarcoidosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic sarcoidosis is rare in children. Children of African descent appear to have more severe and extensive disease compared to Caucasians and Asians. Children between the ages of 8 and 15 develop multisystem disease similar to that described in adults. Younger children often present with skin rash, arthritis, and uveitis without apparent lung involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/18\">",
"     18",
"    </a>",
"    ]. African American children tend to have higher incidences of lymph node involvement, hyperglobulinemia, and hypercalcemia.",
"   </p>",
"   <p>",
"    In a series of Danish children with sarcoidosis, the most common presenting manifestations were erythema nodosum and iridocyclitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/19\">",
"     19",
"    </a>",
"    ]. Ninety percent of the children had an abnormal chest radiograph. The majority (up to 90 percent) of children recover, with or without glucocorticoid therapy. A few develop permanent ocular damage (blindness) and persistent or progressive lung fibrosis. Deaths are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PULMONARY IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung involvement occurs in over 90 percent of patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/15,20\">",
"     15,20",
"    </a>",
"    ]. The \"classic\" chest roentgenogram reveals bilateral hilar adenopathy. This finding, however, may be absent or, if present, may occur in combination with parenchymal opacities. Parenchymal opacities may be interstitial, alveolar, or both. Pleural involvement is unusual (&lt;5 percent of patients), but can result in lymphocytic exudative effusion, chylothorax, hemothorax, and pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stage of pulmonary involvement is based upon the chest radiograph. Although the chest radiograph provides an anatomical guide to lung involvement, it cannot measure disease activity or assess functional defects. The radiographic stages are as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Stage I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage I is defined by the presence of bilateral hilar adenopathy, which is often accompanied by right paratracheal node enlargement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58018 \" href=\"UTD.htm?24/27/25013\">",
"     image 1",
"    </a>",
"    ). Fifty percent of affected patients exhibit bilateral hilar adenopathy as the first expression of sarcoidosis. Regression of hilar nodes within one to three years occurs in 75 percent of such patients, while 10 percent develop chronic enlargement that can persist for 10 years or more.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Stage II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage II consists of bilateral hilar adenopathy and reticular opacities (the latter occurring in the upper more than the lower lung zones). These findings are present at initial diagnosis in 25 percent of patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78632 \" href=\"UTD.htm?2/4/2118\">",
"     image 2",
"    </a>",
"    ). Two-thirds of such patients undergo spontaneous resolution, while the remainder either have progressive disease or display little change over time. Patients with stage II disease usually have mild to moderate symptoms, most commonly cough, dyspnea, fever,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    easy fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Stage III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage III consists of reticular opacities with shrinking hilar nodes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51488 \" href=\"UTD.htm?4/29/4563\">",
"     image 3",
"    </a>",
"    ). Reticular opacities are predominantly distributed in the upper lung zones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Stage IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage IV disease is characterized by reticular opacities with evidence of volume loss, predominantly distributed in the upper lung zones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68742 \" href=\"UTD.htm?4/8/4229\">",
"     image 4",
"    </a>",
"    ). Conglomerated masses with marked traction bronchiectasis may also be seen. Extensive calcification and cavitation or cyst formation may also be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nodular sarcoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph may show multiple, bilateral lung nodules and minimal hilar adenopathy, findings that may simulate metastatic disease. Nodular consolidation with ill-defined borders is seen by computed tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest computed tomography (CT) can demonstrate a variety of abnormalities in patients with sarcoidosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69424 graphicRef56447 graphicRef79110 graphicRef80035 \" href=\"UTD.htm?39/63/40953\">",
"     image 5A-D",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hilar and mediastinal lymphadenopathy",
"     </li>",
"     <li>",
"      Beaded or irregular thickening of the bronchovascular bundles",
"     </li>",
"     <li>",
"      Nodules along bronchi, vessels, and subpleural regions",
"     </li>",
"     <li>",
"      Bronchial wall thickening",
"     </li>",
"     <li>",
"      Ground glass opacification",
"     </li>",
"     <li>",
"      Parenchymal masses or consolidation",
"     </li>",
"     <li>",
"      Parenchymal bands",
"     </li>",
"     <li>",
"      Cysts",
"     </li>",
"     <li>",
"      Traction bronchiectasis",
"     </li>",
"     <li>",
"      Fibrosis with distortion of the lung architecture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High resolution CT (HRCT) scanning reveals a mid-to-upper zone predominance of these changes. It can also detect parenchymal abnormalities that are not seen on the plain chest radiograph.",
"   </p>",
"   <p>",
"    The HRCT findings may correlate with the histologic abnormalities. Ground-glass opacities, for example, are associated with sarcoid granulomas rather than alveolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/28\">",
"     28",
"    </a>",
"    ]. This finding has raised the question of whether alveolitis is a prominent feature of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/29\">",
"     29",
"    </a>",
"    ]. Although it can occur, alveolitis is rarely identified in those with clinically significant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     PET scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fluorine-18-fluorodeoxyglucose (18F-FDG) PET scan may be helpful to identify occult lesions and possibly reversible granulomatous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. This test does not differentiate sarcoidosis from malignancy, as 18F-FDG PET may be positive in both processes. However, in a small study (24 sarcoid, 17 lung cancer), the combination of 18F-FDG and 18F-FMT (L-[3-18F]-methyltyrosine) PET scanning was able to differentiate sarcoidosis from malignancy; sarcoid lesions were positive on 18F-FDG PET, but negative on 18F-FMT PET (both are positive in patients with cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/32\">",
"     32",
"    </a>",
"    ]. Additional studies are needed for confirmation. This tracer may not be available at all institutions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17080?source=see_link\">",
"     \"Computed tomographic and positron emission tomographic scanning of pulmonary nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Radiotracer scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallium-67 lung scanning is a noninvasive test for staging the \"alveolitis\" found in interstitial lung diseases. This compound localizes in inflammatory foci of the lung, but localizes little, if at all, in normal lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The role of gallium-67 scanning in the diagnosis and management of sarcoidosis is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that there is a direct relationship between a visual index of gallium-67 uptake in the lung and the number of inflammatory cells (particularly macrophages) recovered by bronchoalveolar lavage in patients with sarcoidosis (and idiopathic pulmonary fibrosis). As a result, the uptake of gallium-67 may be useful in determining the degree of alveolar inflammation in such patients, since it is primarily concentrated in alveolar macrophages and less so in neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, an adequate study of whether the level of gallium-67 accumulation correlates with the stage of inflammation or how the level of radionuclide uptake might correspond to the stage of disease has not yet been performed. In addition, studies in normal subjects demonstrate a small but significant amount of gallium-67 in alveolar macrophages obtained by bronchoalveolar lavage despite negative imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, gallium-67 lung scanning is not recommended in the routine evaluation of patients because it is difficult to interpret, it is not specific, and a negative scan does not exclude disease.",
"   </p>",
"   <p>",
"    Other types of radiotracer-based scanning may aid in the diagnosis and clinical assessment of patients with sarcoidosis in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. As an example, one trial enrolled 22 patients with sarcoidosis and obtained scans following administration of technetium-labeled depreotide, which binds to somatostatin receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/39\">",
"     39",
"    </a>",
"    ]. Scan results were positive in 18 patients (81 percent), and all four patients with negative total body scans had normal plain chest radiographs. The full operating characteristics of this test are unknown, and its clinical use remains experimental.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     AIRWAY ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pulmonary sarcoidosis may have abnormalities of the upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower airways that are difficult or impossible to detect with routine imaging, but recognizable with alternative diagnostic modalities (eg, bronchoscopy) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endobronchial disease exists in approximately 40 percent of patients with stage I disease and approximately 70 percent of patients with stages II or III disease.",
"     </li>",
"     <li>",
"      Clinically significant airway stenosis is uncommon, but may be difficult to manage when severe [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"       \"Diagnosis and management of central airway obstruction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     EXTRAPULMONARY SARCOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis can involve all organ systems to a varying extent and degree (",
"    <a class=\"graphic graphic_table graphicRef76046 \" href=\"UTD.htm?26/16/26892\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/15,44\">",
"     15,44",
"    </a>",
"    ]. The most prominent sites of extrapulmonary disease include the skin, eyes, reticuloendothelial system, musculoskeletal system, exocrine glands, heart, kidney, and central nervous system.",
"   </p>",
"   <p>",
"    Extrapulmonary manifestations vary on the basis of sex, age at presentation, and ethnicity (",
"    <a class=\"graphic graphic_figure graphicRef77449 \" href=\"UTD.htm?13/31/13822\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/15\">",
"     15",
"    </a>",
"    ]. As an example, women are more likely to have neurologic or ocular involvement, while men more frequently have abnormalities of calcium homeostasis. Up to 30 percent of patients present with extrapulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/15-17,45\">",
"     15-17,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Dermatologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous involvement is seen in approximately 25 percent of patients with sarcoidosis, and is often an early finding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/20/19786?source=see_link\">",
"     \"Cutaneous manifestations of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16522?source=see_link\">",
"     \"Management of cutaneous sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several types of skin lesions can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A maculopapular eruption is the most common subacute lesion. It usually involves the alae nares, lips, eyelids, forehead, rear of neck at the hairline,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      previous trauma sites (eg, scars and tattoos) (",
"      <a class=\"graphic graphic_picture graphicRef69405 graphicRef56226 \" href=\"UTD.htm?0/1/31\">",
"       picture 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef66626 \" href=\"UTD.htm?13/5/13396\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Waxy, pink nodular lesions are frequently distributed on the face, trunk, and extensor surface of the arms and legs.",
"     </li>",
"     <li>",
"      Plaque-like lesions can occur in chronic sarcoidosis including lupus pernio, a violaceous discoloration of the nose, cheeks, chin, and ears (",
"      <a class=\"graphic graphic_picture graphicRef76184 graphicRef63312 \" href=\"UTD.htm?31/59/32696\">",
"       picture 3A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Erythema nodosum (EN) is a panniculitis. It is a component of Lofgren's syndrome and associated with a good prognosis and spontaneous remission [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Lofgren's syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Atypical lesions may be ulcerative, psoriasiform, hypopigmented, follicular, angiolupoid, rosacea-like, or morpheaform [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ophthalmologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular involvement occurs in up to 20 percent of patients with sarcoidosis and is the presenting symptom in 5 percent. Lesions include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anterior uveitis (iridocyclitis or iritis)",
"     </li>",
"     <li>",
"      Posterior uveitis (chorioretinitis)",
"     </li>",
"     <li>",
"      Retinal vasculitis",
"     </li>",
"     <li>",
"      Keratoconjunctivitis",
"     </li>",
"     <li>",
"      Conjunctival follicles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, secondary glaucoma, cataract formation, and blindness are late complications in untreated patients. The combination of anterior uveitis, parotid gland enlargement, facial palsy, and fever (uveoparotid fever) is referred to as Heerfordt's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=see_link&amp;anchor=H14#H14\">",
"     \"Retinal vasculitis associated with systemic disorders and infections\", section on 'Sarcoidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sarcoidosis also affects extraocular orbital tissues, including the lacrimal glands, extraocular muscles, and optic sheath, and may present as a soft tissue orbital mass [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/52\">",
"     52",
"    </a>",
"    ]. Of these, the most common manifestation is lacrimal gland involvement. The most common symptoms in this series were a palpable mass and orbital swelling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127017283\">",
"    <span class=\"h2\">",
"     Upper respiratory tract disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper respiratory tract sarcoidosis may involve the larynx, pharynx, nares",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sinuses; it should be suspected in all patients with systemic sarcoidosis and upper respiratory tract symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/43,53-59\">",
"     43,53-59",
"    </a>",
"    ]. Among 36 patients with rhinosinusitis due to sarcoidosis, the most common symptoms and signs were nasal obstruction (86 percent), nasal crusting (47 percent), and anosmia (44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/59\">",
"     59",
"    </a>",
"    ]. Epistaxis and nasal polyposis were present in about 25 percent. The co-existence of facial lupus pernio and rhinosinusitis due to sarcoidosis has been variably reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On endoscopic examination, mucosal hypertrophy is common and two main patterns are seen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/59\">",
"     59",
"    </a>",
"    ]. Among patients without crusting and epistaxis, small discrete nodules (sometimes called granulations) were visible on the inferior turbinates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    septum. In contrast, those with epistaxis and crusting had the appearance of atrophic rhinitis with focal areas of hemorrhage and diffuse crusting of dried blood. In other reports, these features have been observed together [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/58\">",
"     58",
"    </a>",
"    ]. Noncaseating granulomata are seen on biopsy of the nasal mucosa. Involvement of the paranasal sinuses is common among patients with intranasal sarcoidosis (13 of 15 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H38#H38\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Consider evaluation for systemic diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Reticuloendothelial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reticuloendothelial system disease is common in sarcoidosis. It can manifest as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral lymphadenopathy &mdash; up to 40 percent of patients",
"     </li>",
"     <li>",
"      Hepatomegaly &mdash; 20 percent",
"     </li>",
"     <li>",
"      Noncaseating granulomas on liver biopsy with or without hepatomegaly &mdash; 75 percent",
"     </li>",
"     <li>",
"      Splenic enlargement &mdash; 25 percent, 80 percent of whom have granulomas. Hypersplenism can lead to anemia, leukopenia, and thrombocytopenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal system involvement may occur in up to 10 percent of patients with sarcoidosis. Manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute polyarthritis (especially the ankle joints), usually in association with erythema nodosum and occasionally with acute uveitis.",
"     </li>",
"     <li>",
"      Chronic arthritis with periosteal bone resorption. Radiographically, this may appear as cysts, which can mimic rheumatoid disease (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70918 \" href=\"UTD.htm?13/1/13343\">",
"       image 6",
"      </a>",
"      ). This form of arthritis is usually associated with a chronic protracted course. No correlation exists between the osseous lesions and the plasma calcium concentration.",
"     </li>",
"     <li>",
"      Diffuse granulomatous myositis. An uncommon complication of sarcoidosis, it indicates progressive disease and is associated with a poor prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Musculoskeletal sarcoidosis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=see_link\">",
"     \"Sarcoid arthropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25752?source=see_link\">",
"     \"Sarcoid: Muscle, bone, and vascular disease manifestations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lofgren's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lofgren's syndrome is the combination of erythema nodosum (EN), hilar adenopathy, migratory polyarthralgias, and fever seen primarily in women. Men with acute sarcoidosis generally present with signs of bilateral ankle arthritis, but without EN [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/61\">",
"     61",
"    </a>",
"    ]. In general, Lofgren's syndrome is associated with a good prognosis and spontaneous remission [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=see_link\">",
"     \"Erythema nodosum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lofgren's syndrome is strongly associated with the presence of HLA-DQB1*0201 and specific polymorphisms of C-C chemokine receptor 2 (CCR2) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In a study of patients from the United Kingdom and the Netherlands, DQB1*0201-positivity was associated with a better outcome and greater likelihood of Lofgren's syndrome, than DQB1*0201-negativity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/62\">",
"     62",
"    </a>",
"    ]. DQB1*0201-negative patients took longer to recover and were more likely to need treatment at an early stage. In a series of 301 Swedish patients with Lofgren's syndrome, DRB1*03 positivity was associated with a better outcome than DRB1*03 negativity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link&amp;anchor=H5#H5\">",
"     \"Human leukocyte antigens (HLA): A roadmap\", section on 'Class II region'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Exocrine glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painless swelling of the salivary glands occurs in approximately 4 percent of patients with sarcoidosis. Xerostomia and keratoconjunctivitis sicca also may be seen, producing manifestations similar to those seen in Sj&ouml;gren's syndrome. Pancreatitis also occurs in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\", section on 'Keratoconjunctivitis sicca'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=see_link&amp;anchor=H10#H10\">",
"     \"Gastrointestinal sarcoidosis\", section on 'Pancreatic'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Renal and electrolyte",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities related to calcium metabolism are the most common renal and electrolyte abnormalities observed among patients with sarcoidosis. The defect in calcium metabolism is due to extrarenal production of calcitriol by activated macrophages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Manifestations include increased intestinal calcium absorption, hypercalciuria (which occurs in up to 50 percent of cases), hypercalcemia (which occurs in 10 to 20 percent), and nephrocalcinosis. If untreated, renal calcium deposition can lead to chronic renal failure and end-stage renal disease.",
"   </p>",
"   <p>",
"    Although granulomatous infiltration of the kidney is not uncommon, it is rarely the sole cause of renal dysfunction. Other renal complications of sarcoidosis include membranous nephropathy, a proliferative or crescentic glomerulonephritis, focal segmental glomerulosclerosis, polyuria (due to nephrogenic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    central diabetes insipidus), hypertension, and a variety of tubular defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link\">",
"     \"Renal disease in sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatous involvement of the ventricular septum and conduction system can lead to a variety of arrhythmias, including complete heart block and sudden death. Such involvement may be heralded by palpitations, syncope, dizziness, or chest pain.",
"   </p>",
"   <p>",
"    In addition, chronic pulmonary hypertension and cor pulmonale can result from severe scarring of the pulmonary parenchyma and vascular obliteration. In this setting, death from sarcoidosis usually results from right ventricular failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"     \"Cardiac sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 percent of patients with sarcoidosis have neurologic involvement, which can occasionally be the presenting symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/66\">",
"     66",
"    </a>",
"    ]. Manifestations of central nervous system (CNS) disease usually occur early, while peripheral nerve and skeletal muscle involvement is characteristically seen in the later stages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"     \"Neurologic sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Granulomatous basal meningitis with infiltration or compression of adjacent structures is responsible for most of the CNS manifestations, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypothalamic hypopituitarism",
"     </li>",
"     <li>",
"      Central diabetes insipidus",
"     </li>",
"     <li>",
"      Hydrocephalus",
"     </li>",
"     <li>",
"      Lymphocytic meningitis",
"     </li>",
"     <li>",
"      Cranial nerve palsies, particularly facial palsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically recognizable gastrointestinal (GI) disease occurs in 0.1 to 0.9 percent of patients with sarcoidosis, although the incidence of subclinical involvement may be much higher. The stomach is the most commonly involved portion of the GI tract, but sarcoidosis of the esophagus, appendix, colon, and rectum has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Sarcoidosis can also involve the liver and pancreas. Small bowel sarcoidosis has been reported, but is very rare [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=see_link\">",
"     \"Gastrointestinal sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Reproductive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis rarely involves the female genital tract. Case reports have described sarcoidosis of the endometrium, ovary, or uterus detected during the evaluation and treatment of menometrorrhagia or pelvic masses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Systemic sarcoidosis, in the absence of significant cardiopulmonary compromise, does not affect fertility and does not increase the incidence of fetal or obstetrical complications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/71\">",
"     71",
"    </a>",
"    ]. It will often improve during pregnancy, possibly due to increases of maternal free cortisol.",
"   </p>",
"   <p>",
"    Sarcoidosis can involve the testes, and must be differentiated from testicular cancer and tuberculosis. Recurrent epididymitis due to sarcoidosis rarely can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/66,72\">",
"     66,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Thyroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis can cause diffuse goiter or, rarely, a solitary thyroid nodule [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Almost all patients are euthyroid, although cases of clinical hypothyroidism caused by diffuse replacement of thyroid tissue have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/66,75\">",
"     66,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/15/43257?source=see_link\">",
"     \"Infiltrative thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is a common symptom in patients with sarcoidosis. One study found higher resting energy expenditure and increased C-reactive protein (CRP) levels in the subset of patients with sarcoidosis who have fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/76\">",
"     76",
"    </a>",
"    ]. Thus, fatigue may reflect a metabolic derangement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     LABORATORY ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of laboratory abnormalities are frequently seen in patients with sarcoidosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia is uncommon. When present, it usually results from the anemia of chronic disease, although hypersplenism, bone marrow involvement, or autoimmune hemolytic anemia can occur in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leukopenia (5 to 10 percent), eosinophilia (approximately 25 percent), and thrombocytopenia (rare) can be seen.",
"     </li>",
"     <li>",
"      The erythrocyte sedimentation rate is frequently elevated, but is not useful in assessing disease activity.",
"     </li>",
"     <li>",
"      Hypercalciuria is more commonly observed than hypercalcemia.",
"     </li>",
"     <li>",
"      Hypergammaglobulinemia (30 to 80 percent), diminished skin test reactivity, and a positive rheumatoid factor can exist.",
"     </li>",
"     <li>",
"      A moderate elevation in the serum alkaline phosphatase concentration implies diffuse granulomatous hepatic involvement.",
"     </li>",
"     <li>",
"      Arterial blood gases may be normal, or may reveal hypoxemia and hypocapnia (hyperventilation). Exercise may accentuate these abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Serum ACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum angiotensin converting enzyme (ACE) level is elevated in 75 percent of untreated patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/78\">",
"     78",
"    </a>",
"    ]. False positive results are unusual (&lt;10 percent), but frequent enough to limit the usefulness of serum ACE as a diagnostic test [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/20,78\">",
"     20,78",
"    </a>",
"    ]. Tissue levels of ACE are typically very high. The value of monitoring the ACE level to assess the course of the disease remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function tests characteristically reveal a restrictive pattern with a reduction in the diffusing capacity for carbon monoxide, although it is not unusual for lung function to be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/79\">",
"     79",
"    </a>",
"    ]. Endobronchial sarcoidosis may lead to impairment of airflow and obstructive respiratory physiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major value of pulmonary function testing is to assess the course of the disease in the individual patient by sequential measurements. It is not a reliable means for detecting parenchymal sarcoidosis, nor does it provide an accurate estimate of the extent of parenchymal disease. In addition, the clinician cannot predict the natural course of lung involvement or the response to therapy solely on the basis of these tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoalveolar lavage (BAL) can be used as an adjunctive measure to support the diagnosis of sarcoidosis by demonstrating a reduced number of CD8 cells, an elevated CD4 to CD8 ratio, and an increased amount of activated T cells, CD4 cells, immunoglobulins, and IgG-secreting cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/80-87\">",
"     80-87",
"    </a>",
"    ]. BAL can also be helpful in excluding infections as an alternative diagnosis.",
"   </p>",
"   <p>",
"    The finding of lymphocytosis in lavage fluid is neither specific nor sensitive for the diagnosis of sarcoidosis. It therefore has the potential for diagnostic misinterpretation. As an example, one study evaluated 128 untreated patients with BAL lymphocytosis due to a variety of causes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/82\">",
"     82",
"    </a>",
"    ]. Although there were limitations to this study, several results were of particular interest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BAL fluid with greater than 2 percent neutrophils or greater than 1 percent eosinophils suggested that sarcoidosis was not the correct diagnosis",
"     </li>",
"     <li>",
"      A CD4 to CD8 ratio less than one had a 100 percent negative predictive value for sarcoidosis. However, this finding should be interpreted with caution in light of case reports of CD8-predominant sarcoidosis.",
"     </li>",
"     <li>",
"      The triad of a CD4 to CD8 ratio greater than four to one, a lymphocyte percentage greater than or equal to 16 percent, and a transbronchial biopsy demonstrating noncaseating granulomas was the most specific test for sarcoidosis. This combination of findings was associated with a 100 percent positive predictive value (PPV) for distinguishing sarcoidosis from other interstitial lung diseases, and an 81 percent PPV for distinguishing sarcoidosis from all other diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    D-dimer in BAL fluid also supports the diagnosis of sarcoidosis. One observational study found that 8 out of 10 patients with sarcoidosis had detectable D-dimer in their BAL fluid (defined as &gt;78 ng D-dimer per mL of concentrated BAL fluid), compared with none of 18 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/86\">",
"     86",
"    </a>",
"    ]. Among patients with sarcoidosis, black patients appear more likely than white patients to have D-dimer in their BAL fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic morphologic feature of sarcoidosis is the noncaseating granuloma of the lung, which are most commonly found in the alveolar septa, the walls of bronchi, and the pulmonary arteries and veins. Sarcoid granuloma formation is probably preceded by an alveolitis that involves the interstitium more than the alveolar spaces and is characterized by the accumulation of inflammatory cells, including monocytes, macrophages, and lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sarcoid granuloma is a focal, chronic inflammatory reaction formed by the accumulation of epithelial cells, monocytes, lymphocytes, macrophages, and fibroblasts. Multinucleated giant cells are frequently found among the epithelioid cells within the granuloma follicle and often have cytoplasmic inclusions, such as asteroid bodies, Schaumann bodies, and birefringent crystalline particles (calcium oxalate and other calcium salts) (",
"    <a class=\"graphic graphic_picture graphicRef83308 \" href=\"UTD.htm?40/12/41159\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef83306 \" href=\"UTD.htm?40/7/41078\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef83307 \" href=\"UTD.htm?31/3/31798\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/90\">",
"     90",
"    </a>",
"    ]. Most sarcoid granulomas gradually resolve and leave few or no residual manifestations of previous inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnostic test for sarcoidosis does not exist. Instead, the diagnosis of sarcoidosis requires three elements:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Compatible clinical and radiographic manifestations",
"     </li>",
"     <li>",
"      Exclusion of other diseases that may present similarly",
"     </li>",
"     <li>",
"      Histopathologic detection of noncaseating granulomas (",
"      <a class=\"graphic graphic_picture graphicRef67837 graphicRef67903 \" href=\"UTD.htm?19/34/20010\">",
"       picture 7A-B",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These elements are achieved by a comprehensive evaluation in all patients with suspected sarcoidosis, followed by a diagnostic procedure in most cases.",
"   </p>",
"   <p>",
"    Diseases that can also present with upper lobe-predominant alveolar, interstitial, nodular, or cystic radiographic abnormalities include hypersensitivity pneumonitis, eosinophilic granuloma, collagen vascular disease, pneumoconiosis, chronic beryllium lung disease (ie, berylliosis), and infections, particularly tuberculosis and histoplasmosis.",
"   </p>",
"   <p>",
"    Fortunately, most cases of sarcoidosis are easily recognized and create minimal diagnostic dilemma. There are, however, several settings that are particularly prone to diagnostic difficulty. As an example, diagnosis may be difficult in the absence of extrapulmonary manifestations, marked hilar lymphadenopathy, or mediastinal lymphadenopathy. Similarly, the presence of HIV infection, an occupational or environmental exposure history to beryllium or infectious agents,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prominent systemic symptoms may make the diagnosis more challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Prominent systemic symptoms (eg, fever, night sweats, weight loss,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fatigue) increase the concern for infection or malignancy.",
"   </p>",
"   <p>",
"    A sarcoid-like disorder with granulomatous infiltration of the liver and lungs and variable elevations in ACE levels is recognized in patients with common variable immunodeficiency (CVID). Therefore, patients with apparent sarcoidosis who are hypogammaglobulinemic and have recurrent infections should be evaluated for CVID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive initial evaluation should be performed in all patients with suspected sarcoidosis. The purpose of this initial evaluation is to obtain additional data supporting the diagnosis of sarcoidosis, while eliminating alternative diagnoses. Suggested elements of the evaluation include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/93\">",
"     93",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History, including occupational and environmental exposure",
"     </li>",
"     <li>",
"      Physical examination",
"     </li>",
"     <li>",
"      Posteroanterior chest radiograph",
"     </li>",
"     <li>",
"      Pulmonary function tests, including spirometry and DLCO",
"     </li>",
"     <li>",
"      Peripheral blood counts",
"     </li>",
"     <li>",
"      Serum chemistries, including creatinine, calcium, and liver enzymes",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"     <li>",
"      Routine ophthalmologic examination",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       Tuberculin skin test",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies that may be considered include a serum angiotensin converting enzyme (ACE) level, serum immunoglobulin levels, and bronchoalveolar lavage (BAL), as discussed above. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Bronchoalveolar lavage'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Diagnostic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with a classical Lofgren's syndrome of fever, erythema nodosum, arthralgias, and bilateral hilar lymphadenopathy may not require biopsy if the abnormalities resolve quickly and spontaneously, and no alternative explanation for the constellation of findings exists. For all other patients with suspected sarcoidosis, biopsy is urged for confirmation of the diagnosis.",
"   </p>",
"   <p>",
"    Biopsies should be performed on accessible lesions, which may include palpable lymph nodes, subcutaneous nodules, cutaneous lesions, an enlarged parotid gland, or an enlarged lacrimal gland. Erythema nodosum lesions should not be biopsied, because the histopathology will demonstrate panniculitis and not granulomas, even if sarcoidosis exists [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fiberoptic bronchoscopy with transbronchial lung biopsy (or biopsy of visible endobronchial lesions) is currently the preferred procedure if there is no easily accessible, peripheral lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/94\">",
"     94",
"    </a>",
"    ]. The specimens obtained should be used for both culture and histologic stains, including stains for acid-fast bacilli and fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transbronchial needle aspiration with ultrasound guidance or endoscopic ultrasound-guided fine-needle aspiration may improve the yield from diagnostic aspiration of mediastinal lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. These techniques may prevent a surgical biopsy in some patients, but require specialized equipment and significant operator experience. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3642?source=see_link\">",
"     \"Transbronchial needle aspiration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=see_link\">",
"     \"Endobronchial ultrasound: Indications, advantages, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Open lung biopsy, thoracoscopic lung biopsy, or mediastinal lymph node biopsy may be required if less invasive tests are unable to provide a diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Assess disease extent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of sarcoidosis is confirmed, the extent of organ involvement should be determined. For patients with biopsy-proven single organ involvement and no evidence of an alternative diagnosis, an instrument exists which can serve as a surrogate for tissue confirmation of sarcoidosis involving other organs (",
"    <a class=\"graphic graphic_table graphicRef65081 graphicRef72769 \" href=\"UTD.htm?5/36/5710\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on the indications for specific tests and optimal frequency of monitoring of disease activity in sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/25/21914/abstract/99\">",
"     99",
"    </a>",
"    ]. Patients with more significant initial symptoms will need more frequent follow up, those who have minimal or no symptoms need less frequent evaluation. For example, patients who are started on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for active disease will need to be reevaluated in 4 to 8 week intervals, but patients who are asymptomatic may be seen in three to four-month intervals for the first year and less frequently (usually yearly) thereafter. A general guideline and list of tests is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef67386 \" href=\"UTD.htm?9/59/10173\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Any new symptoms and on-going medications used to treat active disease will also influence follow up testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Extrapulmonary sarcoidosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=see_link\">",
"       \"Patient information: Sarcoidosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=see_link\">",
"       \"Patient information: Sarcoidosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that affects individuals worldwide and is characterized pathologically by the presence of noncaseating granulomas in involved organs. The cause of sarcoidosis is unknown. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estimated prevalence of sarcoidosis is 10 to 20 per 100,000 population. Sarcoidosis is more common among blacks than whites. Blacks more commonly present with acute, severe disease, while whites more commonly present with mild, chronic disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sarcoidosis typically affects young adults. In approximately one-half of cases, it is detected in asymptomatic individuals due to incidental radiographic abnormalities (eg, bilateral hilar adenopathy, reticular opacities). Common presenting symptoms include cough, dyspnea, chest pain, eye lesions,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      skin lesions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The stage of pulmonary sarcoidosis is based upon the chest radiograph. Stage I is defined by the presence of bilateral hilar adenopathy. Stage II consists of bilateral hilar adenopathy and reticular opacities, while stage III consists of reticular opacities with shrinking hilar nodes. Stage IV is characterized by extensive parenchymal damage including reticular opacities, volume loss, conglomerated masses, traction bronchiectasis, calcification, cavitation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cyst formation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pulmonary imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sarcoidosis can involve all organ systems. The most prominent sites of extrapulmonary disease include the skin, eyes, reticuloendothelial system, musculoskeletal system, exocrine glands, heart, kidney, and central nervous system. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Extrapulmonary sarcoidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with sarcoidosis commonly have an elevated angiotensin converting enzyme (ACE) level and hypercalciuria. Pulmonary function tests characteristically demonstrate a restrictive defect with impaired gas exchange, while an elevated CD4 to CD8 ratio may be detected by bronchoalveolar lavage. Noncaseating granulomas are the characteristic histopathologic abnormality. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Laboratory abnormalities'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Serum ACE'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Pulmonary function'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35\">",
"       'Bronchoalveolar lavage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H36\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A definitive diagnostic test for sarcoidosis does not exist. Instead, the diagnosis of sarcoidosis requires compatible clinical and radiographic manifestations, exclusion of other diseases that may present similarly, and histopathologic detection of noncaseating granulomas. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A comprehensive evaluation should be performed in all patients with suspected sarcoidosis, which consists of history, physical examination, a chest radiograph, pulmonary function tests, peripheral blood counts, serum chemistries, urinalysis, electrocardiogram, ophthalmologic examination, and a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      . The purpose of this evaluation is to obtain additional data supporting the diagnosis of sarcoidosis, while eliminating alternative diagnoses. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who present with a classical Lofgren's syndrome of fever, erythema nodosum, arthralgias, and bilateral hilar lymphadenopathy do not require biopsy if the abnormalities resolve quickly and spontaneously, and no alternative explanation for the constellation of findings exists. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Diagnostic procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsy should be performed in most other cases of suspected sarcoidosis. Biopsy of accessible peripheral lesions is preferred. Fiberoptic bronchoscopy with transbronchial biopsy should be performed if an accessible peripheral lesion cannot be identified. Open lung biopsy, thoracoscopic lung biopsy, or surgical mediastinal lymph node biopsy are options if bronchoscopy cannot be performed or is nondiagnostic. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Diagnostic procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/1\">",
"      Thomas KW, Hunninghake GW. Sarcoidosis. JAMA 2003; 289:3300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/2\">",
"      Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/3\">",
"      Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/4\">",
"      Martinetti M, Tinelli C, Kolek V, et al. \"The sarcoidosis map\": a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995; 152:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/5\">",
"      Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/6\">",
"      Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008; 31:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/7\">",
"      Johnson LA, Edsall JR, Austin JH, Ellis K. Pulmonary sarcoidosis: could mycoplasma-like organisms be a cause? Sarcoidosis Vasc Diffuse Lung Dis 1996; 13:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/8\">",
"      Bocart D, Lecossier D, De Lassence A, et al. A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Am Rev Respir Dis 1992; 145:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/9\">",
"      Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/10\">",
"      Sharma OP. Fatigue and sarcoidosis. Eur Respir J 1999; 13:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/11\">",
"      Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/12\">",
"      Delobbe A, Perrault H, Maitre J, et al. Impaired exercise response in sarcoid patients with normal pulmonary functio. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/13\">",
"      Miller A, Brown LK, Sloane MF, et al. Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. Chest 1995; 107:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/14\">",
"      Chevalet P, Cl&eacute;ment R, Rodat O, et al. Sarcoidosis diagnosed in elderly subjects: retrospective study of 30 cases. Chest 2004; 126:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/15\">",
"      Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/16\">",
"      Rizzato G, Tinelli C. Unusual presentation of sarcoidosis. Respiration 2005; 72:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/17\">",
"      Rizzato G, Palmieri G, Agrati AM, Zanussi C. The organ-specific extrapulmonary presentation of sarcoidosis: a frequent occurrence but a challenge to an early diagnosis. A 3-year-long prospective observational study. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/18\">",
"      Pattishall EN, Kendig EL Jr. Sarcoidosis in children. Pediatr Pulmonol 1996; 22:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/19\">",
"      Milman N, Hoffmann AL. Childhood sarcoidosis: long-term follow-up. Eur Respir J 2008; 31:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/20\">",
"      Baughman RP. Pulmonary sarcoidosis. Clin Chest Med 2004; 25:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/21\">",
"      Soskel NT, Sharma OP. Pleural involvement in sarcoidosis. Curr Opin Pulm Med 2000; 6:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/22\">",
"      Navaneethan SD, Venkatesh S, Shrivastava R, et al. Recurrent pleural and pericardial effusions due to sarcoidosis. PLoS Med 2005; 2:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/23\">",
"      Huggins JT, Doelken P, Sahn SA, et al. Pleural effusions in a series of 181 outpatients with sarcoidosis. Chest 2006; 129:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/24\">",
"      Hours S, Nunes H, Kambouchner M, et al. Pulmonary cavitary sarcoidosis: clinico-radiologic characteristics and natural history of a rare form of sarcoidosis. Medicine (Baltimore) 2008; 87:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/25\">",
"      Koyama T, Ueda H, Togashi K, et al. Radiologic manifestations of sarcoidosis in various organs. Radiographics 2004; 24:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/26\">",
"      M&uuml;ller NL, Kullnig P, Miller RR. The CT findings of pulmonary sarcoidosis: analysis of 25 patients. AJR Am J Roentgenol 1989; 152:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/27\">",
"      M&uuml;ller NL, Mawson JB, Mathieson JR, et al. Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology 1989; 171:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/28\">",
"      Nishimura K, Itoh H, Kitaichi M, et al. Pulmonary sarcoidosis: correlation of CT and histopathologic findings. Radiology 1993; 189:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/29\">",
"      M&uuml;ller NL, Miller RR. Ground-glass attenuation, nodules, alveolitis, and sarcoid granulomas. Radiology 1993; 189:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/30\">",
"      Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/31\">",
"      de Prost N, Kerrou K, Sibony M, et al. Fluorine-18 fluorodeoxyglucose with positron emission tomography revealed bone marrow involvement in sarcoidosis patients with anaemia. Respiration 2010; 79:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/32\">",
"      Kaira K, Oriuchi N, Otani Y, et al. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007; 131:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/33\">",
"      Line BR, Hunninghake GW, Keogh BA, et al. Gallium-67 scanning to stage the alveolitis of sarcoidosis: correlation with clinical studies, pulmonary function studies, and bronchoalveolar lavage. Am Rev Respir Dis 1981; 123:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/34\">",
"      Schoenberger CI, Line BR, Keogh BA, et al. Lung inflammation in sarcoidosis: comparison of serum angiotensin-converting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assessment of the T lymphocyte alveolitis. Thorax 1982; 37:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/35\">",
"      Beaumont D, Herry JY, Sapene M, et al. Gallium-67 in the evaluation of sarcoidosis: correlations with serum angiotensin-converting enzyme and bronchoalveolar lavage. Thorax 1982; 37:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/36\">",
"      Baughman RP, Shipley R, Eisentrout CE. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung 1987; 165:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/37\">",
"      Braude AC, Chamberlain DW, Rebuck AS. Pulmonary disposition of gallium-67 in humans: concise communication. J Nucl Med 1982; 23:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/38\">",
"      Braude AC, Cohen R, Rahmani R, et al. An in vitro gallium-67 lung index for the evaluation of sarcoidosis. Am Rev Respir Dis 1984; 130:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/39\">",
"      Shorr AF, Helman DL, Lettieri CJ, et al. Depreotide scanning in sarcoidosis: a pilot study. Chest 2004; 126:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/40\">",
"      Lebtahi R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med 2001; 42:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/41\">",
"      Polychronopoulos VS, Prakash UB. Airway involvement in sarcoidosis. Chest 2009; 136:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/42\">",
"      James JC, Simpson CB. Treatment of laryngeal sarcoidosis with CO2 laser and mitomycin-C. Otolaryngol Head Neck Surg 2004; 130:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/43\">",
"      Fouty BW, Pomeranz M, Thigpen TP, Martin RJ. Dilatation of bronchial stenoses due to sarcoidosis using a flexible fiberoptic bronchoscope. Chest 1994; 106:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/44\">",
"      Cozier YC, Berman JS, Palmer JR, et al. Sarcoidosis in black women in the United States: data from the Black Women's Health Study. Chest 2011; 139:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/45\">",
"      Judson MA, Thompson BW, Rabin DL, et al. The diagnostic pathway to sarcoidosis. Chest 2003; 123:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/46\">",
"      Roberts SD, Mirowski GW, Wilkes D, et al. Sarcoidosis. Part II: extrapulmonary and systemic manifestations. J Am Acad Dermatol 2004; 51:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/47\">",
"      English JC 3rd, Patel PJ, Greer KE. Sarcoidosis. J Am Acad Dermatol 2001; 44:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/48\">",
"      Lodha S, Sanchez M, Prystowsky S. Sarcoidosis of the skin: a review for the pulmonologist. Chest 2009; 136:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/49\">",
"      Ma&ntilde;&aacute; J, Marcoval J, Graells J, et al. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol 1997; 133:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/50\">",
"      Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 52:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/51\">",
"      Birnbaum AD, Oh FS, Chakrabarti A, et al. Clinical features and diagnostic evaluation of biopsy-proven ocular sarcoidosis. Arch Ophthalmol 2011; 129:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/52\">",
"      Mavrikakis I, Rootman J. Diverse clinical presentations of orbital sarcoid. Am J Ophthalmol 2007; 144:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/53\">",
"      Braun JJ, Gentine A, Pauli G. Sinonasal sarcoidosis: review and report of fifteen cases. Laryngoscope 2004; 114:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/54\">",
"      Long CM, Smith TL, Loehrl TA, et al. Sinonasal disease in patients with sarcoidosis. Am J Rhinol 2001; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/55\">",
"      Kay DJ, Har-El G. The role of endoscopic sinus surgery in chronic sinonasal sarcoidosis. Am J Rhinol 2001; 15:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/56\">",
"      Rottoli P, Bargagli E, Chidichimo C, et al. Sarcoidosis with upper respiratory tract involvement. Respir Med 2006; 100:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/57\">",
"      deShazo RD, O'Brien MM, Justice WK, Pitcock J. Diagnostic criteria for sarcoidosis of the sinuses. J Allergy Clin Immunol 1999; 103:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/58\">",
"      Baughman RP, Lower EE, Tami T. Upper airway. 4: Sarcoidosis of the upper respiratory tract (SURT). Thorax 2010; 65:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/59\">",
"      Reed J, deShazo RD, Houle TT, et al. Clinical features of sarcoid rhinosinusitis. Am J Med 2010; 123:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/60\">",
"      Aubart FC, Ouayoun M, Brauner M, et al. Sinonasal involvement in sarcoidosis: a case-control study of 20 patients. Medicine (Baltimore) 2006; 85:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/61\">",
"      Grunewald J, Eklund A. Sex-specific manifestations of L&ouml;fgren's syndrome. Am J Respir Crit Care Med 2007; 175:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/62\">",
"      Sato H, Grutters JC, Pantelidis P, et al. HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002; 27:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/63\">",
"      Spagnolo P, Renzoni EA, Wells AU, et al. C-C chemokine receptor 2 and sarcoidosis: association with Lofgren's syndrome. Am J Respir Crit Care Med 2003; 168:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/64\">",
"      Grunewald J, Eklund A. L&ouml;fgren's syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med 2009; 179:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/65\">",
"      Garcia C, Kumar V, Sharma OP. Pancreatic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/66\">",
"      Porter N, Beynon HL, Randeva HS. Endocrine and reproductive manifestations of sarcoidosis. QJM 2003; 96:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/67\">",
"      Sprague R, Harper P, McClain S, et al. Disseminated gastrointestinal sarcoidosis. Case report and review of the literature. Gastroenterology 1984; 87:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/68\">",
"      Sharma, A, Kadakia, J, Sharma, O. Gastrointestinal sarcoidosis. Semin Respir Crit Care Med 1992; 6:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/69\">",
"      Menzin AW, You TT, Deger RB, et al. Sarcoidosis in a uterine leiomyoma. Int J Gynaecol Obstet 1995; 48:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/70\">",
"      DiCarlo FJ Jr, DiCarlo JP, Robboy SJ, Lyons MM. Sarcoidosis of the uterus. Arch Pathol Lab Med 1989; 113:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/71\">",
"      Selroos O. Sarcoidosis and pregnancy: a review with results of a retrospective survey. J Intern Med 1990; 227:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/72\">",
"      Haas GP, Badalament R, Wonnell DM, Miles BJ. Testicular sarcoidosis: case report and review of the literature. J Urol 1986; 135:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/73\">",
"      Vailati A, Marena C, Aristia L, et al. Sarcoidosis of the thyroid: report of a case and a review of the literature. Sarcoidosis 1993; 10:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/74\">",
"      Warshawsky ME, Shanies HM, Rozo A. Sarcoidosis involving the thyroid and pleura. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/75\">",
"      Bell NH. Endocrine complications of sarcoidosis. Endocrinol Metab Clin North Am 1991; 20:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/76\">",
"      Drent M, Wirnsberger RM, de Vries J, et al. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999; 13:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/77\">",
"      Karetzky M, McDonough M. Exercise and resting pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/78\">",
"      Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis--its value in present clinical practice. Ann Clin Biochem 1989; 26 ( Pt 1):13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/79\">",
"      Dunn TL, Watters LC, Hendrix C, et al. Gas exchange at a given degree of volume restriction is different in sarcoidosis and idiopathic pulmonary fibrosis. Am J Med 1988; 85:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/80\">",
"      Lin YH, Haslam PL, Turner-Warwick M. Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests. Thorax 1985; 40:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/81\">",
"      Ward K, O'Connor C, Odlum C, Fitzgerald MX. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax 1989; 44:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/82\">",
"      Winterbauer RH, Lammert J, Selland M, et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993; 104:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/83\">",
"      Agostini C, Trentin L, Zambello R, et al. CD8 alveolitis in sarcoidosis: incidence, phenotypic characteristics, and clinical features. Am J Med 1993; 95:466.",
"     </a>",
"    </li>",
"    <li>",
"     Semenzato, G, Agostini, C. Immunologic events in the pathogenesis of interstitial lung disease: the paradigm of sarcoidosis. In: Interstitial Lung Disease, 4th, King, TE Jr, Schwarz, MI (Eds), B.C. Decker, Hamilton, ON 2003. p.300.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/85\">",
"      Kantrow SP, Meyer KC, Kidd P, Raghu G. The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis. Eur Respir J 1997; 10:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/86\">",
"      Perez RL, Duncan A, Hunter RL, Staton GW Jr. Elevated D dimer in the lungs and blood of patients with sarcoidosis. Chest 1993; 103:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/87\">",
"      Perez RL, Kimani AP, King TE Jr, et al. Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis. Respiration 2007; 74:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/88\">",
"      Keogh BA, Hunninghake GW, Line BR, Crystal RG. The alveolitis of pulmonary sarcoidosis. Evaluation of natural history and alveolitis-dependent changes in lung function. Am Rev Respir Dis 1983; 128:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/89\">",
"      Takemura T, Hiraga Y, Oomichi M, et al. Ultrastructural features of alveolitis in sarcoidosis. Am J Respir Crit Care Med 1995; 152:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/90\">",
"      Myers JL, Tazelaar HD. Challenges in pulmonary fibrosis: 6--Problematic granulomatous lung disease. Thorax 2008; 63:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/91\">",
"      Newman TG, Minkowitz S, Hanna A, et al. Coexistent sarcoidosis and HIV infection. A comparison of bronchoalveolar and peripheral blood lymphocytes. Chest 1992; 102:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/92\">",
"      Haramati LB, Lee G, Singh A, et al. Newly diagnosed pulmonary sarcoidosis in HIV-infected patients. Radiology 2001; 218:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/93\">",
"      Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/94\">",
"      de Boer S, Milne DG, Zeng I, Wilsher ML. Does CT scanning predict the likelihood of a positive transbronchial biopsy in sarcoidosis? Thorax 2009; 64:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/95\">",
"      Roethe RA, Fuller PB, Byrd RB, Hafermann DR. Transbronchoscopic lung biopsy in sarcoidosis. Optimal number and sites for diagnosis. Chest 1980; 77:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/96\">",
"      Annema JT, Veseli&ccedil; M, Rabe KF. Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of sarcoidosis. Eur Respir J 2005; 25:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/97\">",
"      Wildi SM, Judson MA, Fraig M, et al. Is endosonography guided fine needle aspiration (EUS-FNA) for sarcoidosis as good as we think? Thorax 2004; 59:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/98\">",
"      Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/25/21914/abstract/99\">",
"      Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357:2153.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4353 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21914=[""].join("\n");
var outline_f21_25_21914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PULMONARY IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Stage I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Stage II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Stage III",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Stage IV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nodular sarcoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PET scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Radiotracer scanning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      AIRWAY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EXTRAPULMONARY SARCOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Dermatologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ophthalmologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H127017283\">",
"      Upper respiratory tract disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Reticuloendothelial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lofgren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Exocrine glands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Renal and electrolyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Reproductive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Thyroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      LABORATORY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Serum ACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Diagnostic procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Assess disease extent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4353\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4353|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/27/25013\" title=\"diagnostic image 1\">",
"      Hilar adenopathy PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/4/2118\" title=\"diagnostic image 2\">",
"      Sarcoidosis stage II PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/29/4563\" title=\"diagnostic image 3\">",
"      Interstitial sarcoidosis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/8/4229\" title=\"diagnostic image 4\">",
"      Advanced sarcoidosis PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/11/16562\" title=\"diagnostic image 5A\">",
"      Stage II sarcoidosis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/56/17295\" title=\"diagnostic image 5B\">",
"      Pseudoalveolar sarcoidosis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/39/22128\" title=\"diagnostic image 5C\">",
"      Scarring in sarcoidosis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/42/29344\" title=\"diagnostic image 5D\">",
"      Miliary sarcoidosis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/1/13343\" title=\"diagnostic image 6\">",
"      Sarcoid arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4353|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/31/13822\" title=\"figure 1\">",
"      Clinical manifestations of sarcoidosis in different groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4353|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/31/32244\" title=\"picture 1A\">",
"      Sarcoidosis - facial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/49/25363\" title=\"picture 1B\">",
"      Sarcoidosis - papules on neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/5/13396\" title=\"picture 2\">",
"      Maculopapular sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/5/34898\" title=\"picture 3A\">",
"      Lupus pernio - nasal tip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/25/32148\" title=\"picture 3B\">",
"      Lupus pernio - nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/12/41159\" title=\"picture 4\">",
"      Sarcoid granuloma with an asteroid body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/7/41078\" title=\"picture 5\">",
"      Sarcoid granuloma with Schaumann body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/3/31798\" title=\"picture 6\">",
"      Sarcoid granuloma with calcium oxalate crystal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/2/28710\" title=\"picture 7A\">",
"      Transbronchial biopsy sarcoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/6/6247\" title=\"picture 7B\">",
"      Nodular sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4353|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/16/26892\" title=\"table 1\">",
"      Sarcoid organ involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/60/4045\" title=\"table 2A\">",
"      ACCESS criteria sarcoid A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/30/36332\" title=\"table 2B\">",
"      ACCESS criteria sarcoid B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/59/10173\" title=\"table 3\">",
"      Sarcoid monitoring",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17080?source=related_link\">",
"      Computed tomographic and positron emission tomographic scanning of pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/20/19786?source=related_link\">",
"      Cutaneous manifestations of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=related_link\">",
"      Endobronchial ultrasound: Indications, advantages, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=related_link\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=related_link\">",
"      Gastrointestinal sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/15/43257?source=related_link\">",
"      Infiltrative thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16522?source=related_link\">",
"      Management of cutaneous sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=related_link\">",
"      Pathogenesis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=related_link\">",
"      Patient information: Sarcoidosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=related_link\">",
"      Patient information: Sarcoidosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=related_link\">",
"      Retinal vasculitis associated with systemic disorders and infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=related_link\">",
"      Sarcoid arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25752?source=related_link\">",
"      Sarcoid: Muscle, bone, and vascular disease manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3642?source=related_link\">",
"      Transbronchial needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_25_21915="Musculoskeletal disease in DM";
var content_f21_25_21915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Musculoskeletal diseases associated with diabetes mellitus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Hand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carpal tunnel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dupuytren's contracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexor tenosynovitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetic sclerodactyly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limited joint mobility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Shoulder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adhesive capsulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcific periarthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limited joint mobility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Lower limb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuropathic arthropathy (foot and ankle)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetic muscle infarction (thigh and calf)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Osteoarthritis (knee)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Spine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diffuse idiopathic skeletal hyperostosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21915=[""].join("\n");
var outline_f21_25_21915=null;
var title_f21_25_21916="Pegintron Rebetol dose mod";
var content_f21_25_21916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for dose modification and discontinuation of PegIntron (peginterferon) or PegIntron/REBETOL (ribavirin) for hematologic toxicity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laboratory values",
"       </td>",
"       <td class=\"subtitle1\">",
"        Peginterferon",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ribavirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Hemoglobin",
"       </td>",
"       <td>",
"        &lt;10 g/dL*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Decrease by 200 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;8.5 g/dL",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        White blood cell count",
"       </td>",
"       <td>",
"        &lt;1.5 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Reduce dose by 50 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;1 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Neutrophil count",
"       </td>",
"       <td>",
"        &lt;0.75 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Reduce dose by 50 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;0.5 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Platelet count",
"       </td>",
"       <td>",
"        &lt;50 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Reduce dose by 50 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;25 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For patients with a history of stable cardiac disease receiving PegIntron in combination with ribavirin, the PegIntron dose should be reduced by half and the ribavirin dose by 200 mg/day if a &gt;2 g/dL decrease in hemoglobin is observed during any 4-week period. Both PegIntron and ribavirin should be permanently discontinued if patients have hemoglobin levels &lt;12 g/dL after this ribavirin dose reduction.",
"    </div>",
"    <div class=\"reference\">",
"     Table adapted from: Product information: Peg Intron&reg; (peginterferon alfa-2b). Schering Corporation, Kenilworth, NJ. Available online at: file://www.spfiles.com/pipeg-intron.pdf (Accessed on September 13, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21916=[""].join("\n");
var outline_f21_25_21916=null;
var title_f21_25_21917="Ataxias due to enzyme defects";
var content_f21_25_21917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of hereditary ataxias due to known enzymatic defects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Gene locus and protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Intermittent ataxias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Hyperammonemias and aminoacidurias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Ornithine transcarbamylase deficiency",
"       </td>",
"       <td>",
"        Xp21.1",
"       </td>",
"       <td>",
"        Ornithine transcarbamylase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Citrullinemia",
"       </td>",
"       <td>",
"        9q34",
"       </td>",
"       <td>",
"        Arginosuccinate synthetase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Arginase deficiency",
"       </td>",
"       <td>",
"        6q23",
"       </td>",
"       <td>",
"        Arginase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Arginosuccinaciduria",
"       </td>",
"       <td>",
"        7cen-q11",
"       </td>",
"       <td>",
"        Arginosuccinate lyase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Hyperornithemia-hyperammonemia- homocitrullinuria syndrome",
"       </td>",
"       <td>",
"        13q14",
"       </td>",
"       <td>",
"        Mitochondrial ornithine transporter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Hartnup disease",
"       </td>",
"       <td>",
"        5p15.33",
"       </td>",
"       <td>",
"        Neutral amino acid transporter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Isovaleric acidemia",
"       </td>",
"       <td>",
"        15q14",
"       </td>",
"       <td>",
"        Isovaleric acid CoA dehydrogenase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Disorders of pyruvate and lactate metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pyruvate dehydrogenase complex",
"       </td>",
"       <td>",
"        Xp22.2 (most common)",
"       </td>",
"       <td>",
"        E1-alpha subunit (most common)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Multiple carboxylase deficiency",
"       </td>",
"       <td>",
"        21q22",
"       </td>",
"       <td>",
"        Holocarboxylase synthetase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Progressive ataxias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tay-Sachs disease",
"       </td>",
"       <td>",
"        15q23-q24",
"       </td>",
"       <td>",
"        Alpha subunit of hexosaminidase A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sandhoff disease",
"       </td>",
"       <td>",
"        15q13",
"       </td>",
"       <td>",
"        Beta subunit of hexosaminidase A and B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Niemann-Pick type A and B",
"       </td>",
"       <td>",
"        11p15.4-p15.1",
"       </td>",
"       <td>",
"        Acid sphingomyelinase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Niemann-Pick type C",
"       </td>",
"       <td>",
"        18q11-q12",
"       </td>",
"       <td>",
"        NPC1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14q24.3",
"       </td>",
"       <td>",
"        NPC2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metachromatic leukodystrophy",
"       </td>",
"       <td>",
"        22q13",
"       </td>",
"       <td>",
"        Arylsulfatase A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adrenomyeloneuropathy",
"       </td>",
"       <td>",
"        Xq28",
"       </td>",
"       <td>",
"        Adrenoleukodystrophy protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abetalipoproteinemia",
"       </td>",
"       <td>",
"        4q22",
"       </td>",
"       <td>",
"        Microsomal triglyceride transfer protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypobetalipoproteinemia",
"       </td>",
"       <td>",
"        2p24",
"       </td>",
"       <td>",
"        Apolipoprotein B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebrotendinous xanthomatosis",
"       </td>",
"       <td>",
"        2q33",
"       </td>",
"       <td>",
"        Mitochondrial sterol 27-hydroxylase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ataxia with vitamin E deficiency",
"       </td>",
"       <td>",
"        8q13",
"       </td>",
"       <td>",
"        Alpha-tocopherol transfer protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lesch-Nyhan syndrome",
"       </td>",
"       <td>",
"        Xq26",
"       </td>",
"       <td>",
"        Hypoxanthine-guanine phosphoribosyl- transferase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wilson disease",
"       </td>",
"       <td>",
"        13q14",
"       </td>",
"       <td>",
"        ATP7B (copper transporting ATPase)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ceroid lipofuscinosis",
"       </td>",
"       <td>",
"        Several variants",
"       </td>",
"       <td>",
"        Multiple gene products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Refsum disease",
"       </td>",
"       <td>",
"        10pter",
"       </td>",
"       <td>",
"        Phytanoyl CoA hydroxylase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        X-linked ataxia, ichthyosis, and taporetinal dystrophy",
"       </td>",
"       <td>",
"        Xpter-p22",
"       </td>",
"       <td>",
"        Arylsulfatase C",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21917=[""].join("\n");
var outline_f21_25_21917=null;
var title_f21_25_21918="Androgen levels in PCOS";
var content_f21_25_21918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Serum androgen concentrations are high in women with the polycystic ovary syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 327px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean serum concentrations of testosterone (pg/mL), androstenedione (pg/mL), and DHEA-sulfate (mcg/mL) in 10 normal women between Day&nbsp;2 to&nbsp;4 of their menstrual cycle and 19 women with polycystic ovary syndrome (PCOS). The mean serum concentration of each androgen was high in the women with PCOS, but there was substantial overlap between the two groups and many women with PCOS had normal values for one or more androgens.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: DeVane GW, Czekala NM, Judd HL, Yen SS. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 1975; 121:496.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21918=[""].join("\n");
var outline_f21_25_21918=null;
var title_f21_25_21919="Valvotomy in mitral stenosis";
var content_f21_25_21919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemodynamic improvement after valvotomy in mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left ventricular (LV) and left atrial (LA) pressures before and after balloon mitral valvotomy. After valvotomy, there is a fall in left atrial pressure and a substantial reduction in the transmitral pressure gradient (arrow). The cardiac output increased from 5.9 to 7.4 L/min.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John D Carroll, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_25_21919=[""].join("\n");
var outline_f21_25_21919=null;
